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Attention-deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder 
that affects children, adolescents and adults. Several adverse outcomes have been 
consistently associated with a diagnosis of ADHD at any point in life. In this thesis, we were 
dedicated to the study of the course of ADHD from childhood to adulthood focusing on three 
perspectives. First, we discuss the age at onset of ADHD. Historically, ADHD has first been 
identified and described in children. Prospective clinical studies of children with ADHD found 
that the disorder might persist throughout adulthood, and the concept of adult ADHD 
remained tied to a childhood-onset disorder. Diagnostic manuals included age at onset in 
childhood as a core criterion for a valid ADHD diagnosis in adolescence and adulthood. 
However, recent studies challenged the validity of this criterion, suggesting that many ADHD 
cases in adulthood might have had a late onset. In this thesis, we present our contribution to 
the field with original data from a longitudinal birth cohort in Brazil and a theoretical 
discussion on the evidence so far available on the matter. Second, our research tried to 
parse out children who are at high risk for either persisting with ADHD throughout 
adolescence (for those already affected) or developing ADHD during their development into 
young adulthood. While many risk factors are already known, the literature is 
heterogeneous, findings are sometimes contradictory, and there is little clinical translation 
from the evidence. We reviewed and meta-analyzed the evidence available on risk factors 
for ADHD persistence, providing summary estimates for several known risk factors. We then 
developed and validated a multivariable risk calculator that aggregated several of these risk 
factors into one accurate individualized risk prediction. This tool is intended for research and 
clinical use, and available on-line. Third, we investigated the relative immaturity effect, by 
which children who are born later in the school calendar year present are more frequently 
diagnosed with ADHD. We did so by reviewing and meta-analyzing the evidence available, 
and by analyzing data from three large community-based cohorts placed in Brazil. The effect 
of relative immaturity is a conceptual demonstration of the importance of developmental 
adaptations in the genesis or worsening of ADHD symptoms, which might influence its 








O Transtorno de Déficit de Atenção/Hiperatividade (TDAH) é um transtorno comum do 
neurodesenvolvimento que afeta crianças, adolescentes e adultos. O diagnóstico de TDAH 
estão consistentemente associados com desfechos adversos em qualquer idade. Nesta tese, 
nós nos dedicamos ao estudo do curso do TDAH da infância até a idade adulta, focando em 
três perspectivas. Primeiro, discutimos a idade de início do TDAH. Historicamente, o TDAH 
foi identificado e descrito pela primeira vez em crianças. Estudos clínicos prospectivos de 
crianças com TDAH descobriram que o transtorno pode persistir até a idade adulta, e o 
conceito de TDAH adulto permaneceu conectado a um transtorno de início na infância. 
Manuais diagnósticos incluíram idade de início na infância como um critério central para um 
diagnóstico válido de TDAH na adolescência e idade adulta. Entretanto, estudos recentes 
desafiaram a validade empírica deste critério, sugerindo que muitos casos de TDAH na idade 
adulta podem ter um início tardio. Nesta tese, apresentamos nossa contribuição nesta área 
com dados originais de uma coorte de nascimento no Brasil, e uma discussão teórica a 
respeito da evidência disponível sobre o assunto. Na segunda perspectiva, nossa pesquisa 
tentou identificar crianças que estão em risco para persistir com TDAH ao longo da 
adolescência (para aquelas já afetadas pelo transtorno) ou desenvolver TDAH ao longo do 
seu desenvolvimento até o início da idade adulta. Embora diversos fatores de risco sejam 
conhecidos, a literatura é heterogênea, os achados são por vezes contraditórios, e existe 
pouca tradução da evidência para a clínica. Nós revisamos e meta-analisamos a evidência 
disponível em fatores de risco para a persistência de TDAH, produzindo assim estimativas 
sumarizadas de risco para diversos fatores conhecidos. Em um segundo estudo, 
desenvolvemos e validamos uma calculadora de risco multivariada que agrega vários destes 
fatores em uma predição de risco individualizada e acurada. Esta ferramenta está disponível 
gratuitamente on-line, e pode ser usada em contextos clínicos e de pesquisa. Na terceira 
perspectiva, investigamos o efeito da imaturidade relativa, pelo qual crianças que nasceram 
mais tarde no ano letivo são mais frequentemente diagnosticadas com TDAH. Nós revisamos 
e meta-analisamos a evidência disponível, e analisando dados de três grandes coortes 
comunitárias no Brasil. O efeito da imaturidade relativa é uma demonstração conceitual da 
importância de adaptações desenvolvimentais na gênese de sintomas de TDAH, que podem 
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Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental syndrome 
characterized by pervasive and impairing symptoms of inattention, hyperactivity, and 
impulsivity1. ADHD commonly affects children, adolescents and adults2,3. Evidence from 
clinical, epidemiological and longitudinal studies have consistently documented strong 
associations between ADHD and adverse life outcomes4-6. Children with ADHD show an 
increased risk of accidental injuries7, poor relationship with peers8 and parents9, worse 
quality of life10, and impaired school performance11. Adolescents with ADHD show more 
school refusal and grade retention11, earlier and more frequent use of marijuana, tobacco 
and other illicit drugs12,13, earlier sexual engagement14  and more frequent teenage 
pregnancy15,16. Adults with ADHD have lower education attainment, reduced job 
performance, and increased emotional problems17-19. At all ages, there is increased mortality 
by external and accidental causes20. Overall, the estimated incremental economic burden 
imposed by ADHD ranges from $143 to $266 billion dollars in the United States alone, most 
of which is a consequence of lost productivity21. 
 
The evidence supporting the scientific knowledge behind the epidemiology, diagnosis, 
neurobiology and treatment has been growing rapidly in the last decades (Figure 1). Despite 
the wealth of data, several unanswered questions remain on all these areas pertaining to 
ADHD and its correlates. One critical area relates to how and when ADHD might emerge 
throughout development, and the factors by which it persists as a chronic life condition in 
some individuals: the developmental course of ADHD. 
 
Figure 1. Number of publications by year containing the words ADHD or “hyperkinectic 







































































































































A historical perspective on the developmental course of ADHD 
 
The ADHD syndrome was first described scientifically in the eighteenth century in children22. 
A Scottish physician named Alexandre Crichton wrote a book series entitled “An inquiry into 
the nature and origin of mental derangement: comprehending a concise system of the 
physiology and pathology of the human mind and a history of the passions and their 
effects’’23. One of its chapters was focused on disorders of attention, in which he described a 
syndrome very much alike to what is nowadays known as the inattentive subtype of ADHD. 
Already at that time, Dr. Chrichton clearly indicated the idea that affected individuals were 
born with this syndrome and that it manifests very early in life: “When born with a person it 
becomes evident at a very early period of life”. Another concept that was reintroduced later 
in the field is the tendency to remission. The author stated that this syndrome of 
distractibility “generally diminished with age”. Both of these historical cornerstones on the 
developmental course of ADHD, the age at onset and the persistence/remission dichotomy, 
will be central in this thesis. 
 
The first systematic case reports of an ADHD-like syndrome in the literature came over a 
century later with the lectures of Sir George Still to the Royal College of Physicians of London 
entitled “On Some Abnormal Psychical Conditions in Children’’24. In these lectures, a specific 
group of children were described with features that resembled ADHD closely. Seven out of 
nine cases had an onset before age 7 – a cut-off which would be adopted decades later by 
the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 
Similarly, Drs. Franz Kramer and Hans Pollnow, in a series of case reports entitled “On a 
hyperkinetic disease of infancy”, observed that the peak onset of this disorder akin to ADHD 
was at age 625. 
 
While the case reports accumulated, and leaned towards a more homogeneous syndrome, 
researchers started to link the early age at onset with presumed mild neurological deficits to 
convey an etiological-based nomenclature for the syndrome. Among the first terms was 
“minimal brain damage”, later updated to “minimal brain dysfunction”, based on the idea 
that the hyperactivity and inattention derived from abnormalities in the frontal lobes26. 




insults, thus the early presentation. This nomenclature was soon abandoned, however, due 
to its broadness and lack of specificity.  
 
Therefore, the DSM-II incorporated ADHD into a more descriptive model, labeling it as 
“Hyperkinetic Reaction of Childhood”27. There were no specific criteria for age at onset, but 
the manual stated that the disorder was found especially in young children and tended to 
remit during adolescence. Years later, the DSM-III was the first diagnostic manual to specific 
require age at onset of symptoms before age 7, based solely on clinical experience28. 
 
Why does the course of ADHD matter? 
 
Precise, evidence-based knowledge on the course of ADHD has several implications for 
research and clinical practice. These implications affect every other related field on ADHD, 
from diagnosis and classification to neurobiology and clinical management. Current 
assumptions on the course of ADHD might be overstated and lacking the support of 
evidence, as we will see further in the current thesis. These assumptions have nevertheless 
been shaping the way science and healthcare in ADHD goes forward in some key areas. 
 
First, there is the issue of diagnosis and classification. Currently, the Diagnosis and Statistical 
Manual for Mental Disorders, 5th edition (DSM-5) classifies mental disorders according to 
their predominant occurrence along the lifetime 1. ADHD is grouped among other 
neurodevelopmental disorders that occur in childhood. Not only the classification is 
important, but the diagnostic criteria as well. The DSM-5 requires the onset of many ADHD 
symptoms to be present in childhood (before age 12) for the diagnosis of the syndrome in an 
individual of any age. The assumption that ADHD is always a childhood-onset disorder, which 
is endorsed by the main diagnostic manuals, implicates that: a) individuals who report a later 
onset of symptoms are excluded from epidemiological, clinical and etiological studies on 
ADHD; b) adult and adolescent patients who do not confirm the required childhood-onset 
are deprived of treatment; c) ADHD is usually grouped with other childhood-onset 
neurodevelopmental disorders such as autism or dyslexia, despite different clinical 





The understanding of the neurobiology of ADHD is affected by the understanding of the 
course of ADHD, not only by the way patients are selected or grouped, but also by the 
intricate conclusions that follow from the assumptions that prevail regarding the longitudinal 
pathways of symptoms across development. For instance, a childhood-onset centered 
framework for ADHD implies that the genetic vulnerability of individuals with ADHD should 
be mostly expressed as a phenotype when these are children – therefore, case-control 
studies in childhood were the most frequent design in the quest for ADHD genes in the last 
decades29. Likewise, longitudinal neuroimaging studies have usually departed from ADHD 
children who outgrow or not their ADHD throughout development assessing which 
structural and functional changes occur in the brain related to these symptom trajectories30-
32. However, emergence of symptoms after childhood is never considered in these studies. 
 
A paramount feature of the clinical management of medical conditions, including mental 
disorders, is the ascertainment of a correct prognosis. Meanwhile, the current 
understanding of ADHD is that of a chronic condition1,30. The available treatments, however, 
have only short-term effects that tend to disappear after discontinuation33. Long-term 
adherence is usually low 34,35. Regardless of treatment, many children will get better and 
remit spontaneously during development. Many others will continue to experience lifelong 
impairing symptoms 36. In the case of ADHD, parsing out children whose ADHD will remit 
from those whose ADHD will persist for many more years could inform clinicians in advance 
about who will benefit from intensive strategies to improve adherence, and who will benefit 
from a scheduled gradual strategy of testing tapering off treatment. 
 
What is known on the course of ADHD? 
 
Since the first reports on the nineteenth century to the first clinical trials, ADHD has always 
been conceptualized as a disorder of childhood, and most of the evidence on ADHD comes 
from studies conducted in school-aged children. Unsurprisingly, the first seminal studies to 
investigate the course of ADHD in a long-term basis departed from clinical samples of 
children with ADHD and their unaffected peers37. These studies were the first to unveil the 
deleterious long-term effects of having ADHD as a kid, a finding that was extensively 




afterwards as adolescents and young adults, lower educational attainment, worse 
professional and financial achievements, and poorer satisfaction with their relationships. 
They also exhibited a range of other psychiatric disorders in young adulthood, such as 
depression and anxiety, more frequently than controls (Table 1). 
 
However, a surprising finding at that time was that many of those young adults with a 
history of childhood ADHD still exhibited impairing symptoms of inattention, hyperactivity 
and impulsivity that were indistinguishable from those that they presented as children. 
Gradually, the field started to recognize the entity of adult ADHD, and epidemiological, 
etiological and clinical studies were conducted in this population. Currently, adult ADHD is 
widely recognized as a valid disorder with impairing features and proper response to 
treatment 6. However, perhaps by the course of these findings, among the scientific 
community, adult ADHD remained tied to the idea of childhood ADHD.  
 
Although these studies leveraged on a sound longitudinal design, there were marked 
methodological differences both within each study (in their multiple follow-up assessments) 
and among the studies. Some of these methodological differences could potentially have an 
impact on the estimation of persistence rates and frequency of adverse outcomes39. For 
instance, the ADHD diagnostic criteria have changed in the last decades. Several clinical 
studies included at baseline children with ADHD as per DSM-II or DSM-III40,41, which had 
stringent criteria.  At follow-up, they assessed adults with the more flexible DSM-IV criteria – 
such studies are likely to estimate higher persistence rates than those who had not changed 
the criteria during follow-up. A study by Margaret Sibley and colleagues investigated this 
specific issue in the 16-year clinical follow-up of the MTA 42. In that study, persistence 
estimates varied widely from 1.9% (requiring DSM-IV criteria, combining parent and self-
report in the Diagnostic Interview Schedule for Children (DISC) with an item-level AND rule) 
to 61.4% (requiring norm-based symptom count, combining parent and self-report in the 
DISC with an item-level OR rule). 
 
While the relevance of the diagnostic criteria is evident, much less attention has been given 





Table 1. Main studies reporting on longitudinal long-term outcomes of childhood ADHD. 












Main findings in young adulthood 
(Cases compared to Controls) 
Barkley, 2004/200643,44 Both 4-12 14 220/225 Clinical DSM-II More criminal acts and drug abuse 
Lower educational achievement 
More social and work problems 




Males 6-17 10/16 169/217 Clinical DSM-III-R Higher rates of psychopathology 
Lower educational achievement 
Lower occupational status 
More substance addiction 
Biederman, 201046 Females 6-17 11 187 Clinical DSM-III-R Higher rates of psychopathology 
More substance addiction 
Dalsgaard, 201520 Both No 
restriction 
32 1922248 Community ICD-9/10 Higher rates of mortality due to external causes 
Galera, 2009/201211,47 Both 4-18 8/18 1264/1103 Community DSM-IV More socioeconomic disadvantage 
Lower academic performance and educational 
achievement 




Both 6-12 9-33 104-189 Clinical DSM-II Higher rates of psychopathology 
Lower educational and occupational achievement 
Higher rates of arrests, convictions and incarceration 
Worse social outcomes 




Both 7-10 12-16 717 Clinical DSM-IV Lower educational achievement 
Worse occupational outcomes 
More neuroticism and emotional liability  





ADHD symptoms from all available sources (for instance, the patient, close relatives, and 
teachers), it is relatively clear that the main source of information changes across 
development from the main caregivers (usually the parents) to the own patient51. In the 
context of research, structured and semi-structured interviews usually consider only one 
report – either the parent report for children and the self-report for older adolescents and 
adults. Almost all longitudinal studies that span several developmental stages are affected 
by the change in the source of information39. This change might impact persistence 
estimates by adding external confounders, that is, the inter-rater agreement, which is known 
to be low to moderate between patients and their informants 51-53.  
 
The nature of these samples also has the potential to impact the study of the ADHD course. 
The first longitudinal reports were clinically based. On one hand, they benefited from a 
thorough and careful clinical assessment; these samples were, in general, very well 
described and resembled the clinical scenario encountered by clinicians in their day-to-day 
practice. However, clinically referred samples often select more severe and impaired cases 
that might not speak to the entire population of ADHD patients. There is a tendency, 
therefore, that clinical samples would overestimate persistence and adverse outcomes 
compared to what are the true rates in the population, and that population-based samples 
underestimate these rates compared to what is actually seen in clinical practice39.  
 
The accumulation of longitudinal follow-up studies of children with ADHD revealed that 
persistence of symptoms throughout adulthood was a frequent outcome, but other possible 
developmental courses were observed. A seminal systematic review and meta-analysis on 
the subject determined that 15% of children with ADHD would still persist with a full 
syndrome (including symptom threshold, impairment and pervasiveness) by adulthood36. 
Another 35% would have remitted completely, regardless of treatment, in a course that 
could be called the “benign ADHD of childhood”. The remaining 50% would be partial 
remitters, still presenting with abnormal levels of symptoms that do not fulfill criteria for a 
formal diagnosis. Notably, the gradual persistence of the syndrome is associated with a 
gradient of functional outcomes: controls have better outcomes than remitters, who in turn 





In accordance with a neurodevelopmental perspective, longitudinal studies with 
neuroimaging data of children with ADHD and their peers have found that the differential 
trajectories of childhood ADHD are linked to the brain development. One of the first 
longitudinal neuroimaging studies with ADHD children was conducted by Professor 
Castellanos and his colleagues at the National Institute of Mental Health54. In this case-
control study, 152 children and adolescents with ADHD had, at baseline, smaller volumes 
across all regions of the brain compared to 139 age- and sex-matched controls. In follow-up 
visits, differences persisted across development in most regions. The studies by Philip Shaw 
and colleagues investigated the developmental trajectories of ADHD cases and controls with 
longitudinal brain imaging 32,55,56. They observed significant developmental abnormalities in 
cortical thinning, especially in the medial and dorsolateral prefrontal cortex – brain regions 
that are central to attention and cognitive control. Along development throughout 
adolescence, there was a general tendency of normalization of the cortex to a point where 
cases and controls were fairly equal in terms of brain development. Those findings matched 
the idea that ADHD frequently remits throughout adolescence. Furthermore, the analyses 
showed that when ADHD persisted, brain normalization did not occur, and the more ADHD 
symptoms in adulthood, the lesser the rate of cortical development in a continuous fashion. 
In general, the literature suggests that the remitted brain has similar functioning than the 
never affected brain in some – prefrontal cortex, default mode network – but not all – 
posterior cortex, thalamus, striatum – structures and networks57. Furthermore, well-
powered case-control studies with a wide range age of participants found brain differences 
between patients and controls to be more pronounced in children and adolescents than in 
adults58. A case control study spanning participants from 8 to 30 years of age found smaller 
brain volumes to be consistent and developmentally stable from childhood to early 
adulthood31. However, the caudate and putamen volumes were found to increase in young 
adulthood in cases, while in controls it had a tendency to decrease. Authors hypothesize that 
overcompensatory mechanisms could be at play in such brain regions. 
 
Another evidence that ADHD is a disorder strongly related to normal development comes 
from observations that equal demands for children of slightly different age (and therefore, 
assumed development) generate symptoms of ADHD. The current school system provides an 




compared to their classmates, who are usually grouped within a one-year range at school. 
Psychiatrists and pediatricians will, most of the times, rely on this comparison in order to set 
the threshold between clinically relevant ADHD symptoms and typical development59. 
Nevertheless, children are not of the exact same age within one classroom: because they 
were born on a 12-month range, there might be up to a 15% difference (at first grade, when 
they are 6 years old) of age between two classmates. 
 
Accordingly, epidemiological and clinical studies found higher rates of ADHD among children 
who are relatively young compared to their classmates (i.e., were born in the last months of 
the school year)60-67. These reports leverage on three types of data: epidemiological samples 
using official records of ADHD diagnosis; epidemiological samples using official records of 
ADHD medication; and clinical samples assessing relative immaturity within diagnosed 
children and adolescents. Regardless of methodological differences, almost all those studies 
agree that being relative immature within the school year is a risk factor for receiving an 
ADHD diagnosis and/or medication. The estimates, however, are variable, with relative risks 
ranging from 1.12 to 2.43 considering only positive and significant associations.  
 
Clearly, there is no plausible reason to assume that these children have a stronger biological 
load for ADHD, either genetic or environmentally. However, their relative immaturity along 
development, paired with untailored demands from school, might “produce” a syndrome 
much alike ADHD. There are two pieces of evidence that further support this notion. First, 
because of different school calendar years over the world, effects based on seasonality can 
be discarded – the effect is always set off along the birthdate for beginning school. Second, 
some studies suggest that the effect of relative immaturity reduces with age60,61,65. This is 
consistent with the idea that the older the children, the less the importance of month of 
birth on total age. 
 
The sum of the evidence presented here provides strong support for the perspective of 
ADHD as a neurodevelopmental, childhood-onset disorder that has a natural tendency to 
ameliorate during development. In this perspective, adult ADHD is always a consequence of 
a failure during an individual’s brain development in recovering to normative levels, resulting 




warrant further studies for either endorsing this prevailing perspective or revealing its 
weaknesses, inciting a necessary debate in the scientific community. 
 
What are the gaps on the evidence-based knowledge about the course of ADHD? 
 
i. The age at onset of ADHD 
 
The age at onset of ADHD is a concept in evolution. The DSM-III and the DSM-IV required 
that the maximum age for a valid diagnosis of ADHD was 7 years based on clinical experience 
together with plausible assumptions derived from a neurodevelopmental perspective of the 
disorder28,68. However, at least at the time when these manuals were conceptualized, there 
was no evidence to support the validity of any proposed cut-offs. Gradually, researchers 
began to underline the implications of setting a threshold that is not evidence-based. 
Professors Joseph Biederman and Russel Burkley were the first to question the validity of the 
age ate onset criterion proposed in the diagnostic manuals at their time69. They reviewed 
the evidence available, concluding that while there was empirical support for the idea that 
ADHD begins early in life, there was no empirical support for selecting the age of 7. They 
recommend further studies, calling attention to the relevance of this topic. If the proposed 
criterion was not operating towards more validity of the disorder, many patients with valid 
symptoms and impairment would have been prevented to receive proper diagnosis and 
treatment.  
 
In fact, many years later, a systematic review by Kieling and colleagues identified several 
clinical and epidemiological studies that failed to find differences between individuals 
affected with ADHD who reported onset of symptoms before compared to those whose 
onset was after 7 years of age70. In the DSM-IV field trials, age at onset depended on the 
subtype of ADHD, with the inattentive subtype showing a later onset than the hyperactive-
impulsive and combined subtypes71. Furthermore, the trials also showed that requiring age 
at onset for impairment – a novel criterion of the DSM-IV – reduced the agreement between 
clinical judgment and operationalized diagnosis. The rates of false negative diagnosis were 
high – clinicians would validate 75% of cases that had all criteria but age at onset for 




review evaluated children with ADHD with and without age at onset criteria on clinical 
settings. Those studies demonstrated that the groups were very similar in a broad range of 
features, such as levels of impairment, patterns of comorbidity, and neuropsychological 
measures72-76. Not only later onsets had the same clinical presentation, but they also 
responded to treatment with stimulant medication with similar effectiveness77,78. Kieling and 
colleagues did not identify any studies documenting significant differences between children 
with ADHD meeting or not the age at onset criterion. 
 
The review also underlines that the concerns with the validity of the age onset criterion 
increase as the patient in question gets older: there is poor accuracy of the retrospective 
recall documented in prospective studies79. Nearly a half of children with ADHD denied 
having symptoms in childhood when asked retrospectively years afterwards. However, 
selecting a broader definition or even eliminating the age at onset criterion might have led 
to a hasty rise in prevalence, with potential undesired reactions of public opinion.  
 
Considering the bulk of evidence in their review, Kieling and colleagues suggested that the 
next version of the DSM should revise the age at onset criterion. Authors’ recommendation 
was to increase the threshold from 7 to 12 years old – at the same time, maintaining the 
childhood-onset nature of the disorder while reducing false negative rates of the later onset 
cases. Russel Barkley and Joseph Biederman recommended abolishing the age at onset 
criterion until enough evidence could support a specific threshold69. However, other 
researchers opposed the change, arguing that entrance in school is an environmental factor 
for an increase in symptoms from age 7 onwards, and that such increase should not be 
considered a true disorder80. Furthermore, they were concerned with the possibility of a 
massive increase in the prevalence of ADHD. 
 
Polanczyk and colleagues went on to evaluate the clinical and epidemiological impact of 
raising the age at onset criterion to 12 years of age80. In the Environmental Risk (E-Risk) 
Longitudinal Study, which tracked 2,232 twins from England and Wales from birth to age 12, 
DSM-IV ADHD assessments were conducted at ages 5, 7, 10 and 12. With this longitudinal 
design, they could observe that a very small minority of children would fulfill full criteria 




evidence that 95% of individuals with adult ADHD from a population survey recalled onset 
before age 12, and that the expected increase in prevalence would be negligible, the DSM-5 
committee opted to maintain the age at onset criterion at the broader level of 12 years of 
age.  
 
After the revision of the DSM-5, new studies tested the impact of the modified criterion in 
prevalence and disorder validity. Contradicting the previous findings of Polanczyk and 
colleagues, these studies identified important rises in the prevalence of ADHD of up to 50% 
in adolescents and adults81,82. Another study on adults failed to find differences in quality of 
life and overall impairment between earlier and later onset of ADHD83. Nevertheless, all 
these studies were based on retrospective recall of age at onset, likely being subject to recall 
bias. In summary, as is the case in any change to less stringent diagnostic criteria, prevalence 
rates are expected to rise. Temporal trends are still lacking to inform on the actual 
magnitude of this increase. 
 
The previous studies provided some insights on the nature and validity of later onset ADHD. 
However, long-term population-based longitudinal studies were at the time lacking to 
further clarify the question. A long follow-up was needed because further thresholds beyond 
adolescence, or even no threshold at all, should be carefully evaluated. Moreover, the long-
term outcomes that conferred validity to the diagnosis of ADHD in childhood derived from 
analyses of children followed until at least young adulthood. To compare the validity of the 
traditional childhood-onset ADHD with later onset ADHD, such long-term outcomes needed 
to be measured. A population-based sample was needed because all the clinical samples so 
far conducted required the age at onset criterion for inclusion, and therefore no comparison 
group can be established. A prospective design was needed because the retrospective recall 
is inaccurate.  
 
The first study to address these needs was derived from the Dunedin cohort, in New 
Zealand84. This study followed a representative cohort of 1037 individuals from birth to age 
38. ADHD was assessed for the first time at ages 11 to 15, but requiring age at onset before 
7. When participants were 38 years old, ADHD was again assessed, but this time without 




adult ADHD cases consisted of essentially non-overlapping sets: almost 90% of adult cases 
lacked a prospectively collected childhood history of ADHD, and less than 10% of the 
childhood cases had persisted with ADHD. Those adults with ADHD, even if their onset was 
after the age of 15, reported more life impairment, less life satisfaction, more involvement in 
car accidents, worse savings behavior, and received government benefits for a longer period 
in life. There are some caveats in the Dunedin study. The gap between ADHD assessments 
was wide, making it hard to ascertain when ADHD symptoms first appeared between 15 and 
38 years old. The source of information changed from parents in childhood to self-reports in 
adulthood. There were high levels comorbid disorders and substance abuse in adulthood, 
and the sample size was too small to adequately assess whether the endorsed ADHD 
symptoms should be attributed to these conditions. Likewise, the few cases with childhood-
onset adult (i.e., persistent) ADHD was too small for adequate comparisons to the more 
numerous late-onset cases with adult ADHD. Despite the methodological soundness of the 
Dunedin study, the novelty of these findings raised questions about whether this would be a 
replicable finding in independent samples85. 
 
Following the New Zealand study, two other large population-based birth cohorts provided 
consistent evidence that many adults did not have childhood ADHD. One of these studies 
reported data from the 1993 Pelotas cohort in Brazil, and is part of this thesis (Article #1)15. 
The other was conducted by Agnew-Blais and colleagues in a British cohort of twins, the 
Environmental Risk (E-Risk) Longtudinal Twin Study86. 
 
The E-Risk cohort followed 2232 twins born in the United Kingdom from birth to age 18 with 
91.3% retention. DSM-IV ADHD was assessed at ages 5, 7, 10 and 12, and then again at age 
1886. Most (67.5%0 of the young adults with ADHD had not met criteria in any of the 
childhood assessments. As in the Dunedin study, there was no difference between late-
onset ADHD and childhood-onset ADHD in terms of impairment and rates of mental health 
disorders in young adulthood. The E-Risk study also has some caveats. The sample size was 
too small to control for comorbid mental disorders in adulthood. While the gap between 
ADHD assessments was much smaller, the last age at assessment was at age 18, limiting 






The Avon Longitudinal Study of Parents and Children (ALSPAC) cohort followed 14701 
children born in the United Kingdom from birth to age 17 with multiple dimensional 
assessments of ADHD using the hyperactivity subscale of the Strengths and Difficulties 
Questionnaire (SDQ-H)87. In a categorical analysis of two time points, 47% of the adult ADHD 
cases had childhood onset, but 53% did not (n=244, representing 2.5% of the cases with 
symptoms above the threshold for high ADHD symptoms at age 17 but were below the 
threshold for borderline symptoms at age 7). The late-onset ADHD group represented the 
majority of adults with ADHD, resembling the evidence from the three previous studies. The 
most important limitation of this study is the reliance on screening instruments at all ages 
without a cut-off point based on internal calibration with a semi-structured instrument in 
the last assessment. This assessment was in late adolescence, and there was no control for 
comorbidities at this point.  
 
Concerned with the differences between her own clinical experience and the findings from 
clinical samples compared to the novel findings from epidemiological samples, Dr. Mary 
Solanto wrote a letter to the JAMA Psychiatry criticizing some of the methods of the 
cohorts88. In our reply (Appendix #1), we acknowledge the limitations and suggest further 
studies to understand the phenomenon in the clinical context89. We then joined the 
Multimodal Treatment Study for ADHD (MTA) team to investigate the issue in the largest 
clinical trial ever conducted for ADHD (Appendix #2)90. 
 
Using a prospective long-term follow-up design, the incidence of late-onset ADHD was 
estimated in the group of children in the Local Normative Comparison Group (LNCG) without 
ADHD (N=258 of n=289 recruited from classmates) of the MTA90. These individuals were 
followed from childhood (ages 9-12) to adulthood (ages 23-26), and over the course of 14 
years, they underwent eight comprehensive assessments, which included psychiatric 
evaluations to measure ADHD symptoms and related impairments. Diagnostic procedures 
utilized parent-, teacher-, and self-reports of ADHD symptoms, as well as for impairment, 
substance use, and other mental disorders. The dense and comprehensive assessments of 
the MTA contrast with the infrequent and limited assessments in the population-based 




context and timing of late-onset of ADHD symptoms was possible. It is informative to note 
that 53% of adolescents and 79% of adults who had late-onset ADHD were excluded because 
symptoms or impairment was better explained by exclusion conditions. Heavy marijuana use 
was the most common reason for exclusion, and the presence of other psychiatry disorders 
was the next most common. Based on the MTA assessment, there was no evidence for 
significant adult-onset ADHD, but there was compelling evidence for adolescent-onset 
ADHD. The comprehensive assessments of the MTA suggested that most adolescent-onset 
cases were adolescent-limited in which there was desistence of symptoms before adulthood. 
 
Two other recent epidemiological investigations also raised doubts about the existence and 
validity of the late onset ADHD trajectory. The first reanalyzed data from the ALSPAC cohort: 
after defining late onset ADHD as those with high SDQ-H scores at age 17 and low SDQ-H 
scores at age 12, authors had looked at previous ADHD assessments91. Most of those with 
apparent late onset ADHD had high scores at least in one moment before age 12. 
Participants with genuine late onset ADHD, however, had a similar profile of 
neurodevelopmental impairments than children without ADHD. A second study was based 
on the High-Risk Cohort in Brazil92. Authors concluded that, while adolescent-onset ADHD 
was as frequent as reported in previous studies, the group had more cognitive impairments 
and a higher load of psychopathology in childhood than controls – late onset ADHD could, 
therefore, be a heterotypic continuity.  
 
Clearly, the late onset ADHD trajectory remains a contradictory and debatable issue. This is 
first gap in the literature for which this thesis is dedicated to. Our aim was to provide new 
data, discuss and integrate the findings on late onset ADHD. 
 
ii. Predicting the course of ADHD 
 
While the novel hypothesis that the ADHD syndrome might emerge during adolescence or 
adulthood remains to be verified, the traditional neurodevelopmental perspective of 
childhood-onset ADHD has yet an unpredictable course. Even though it is well established 
that childhood ADHD may unfold into a lifelong persistent and impairing disorder or into 




persistence30. The ability to identify such individuals in advance could implicate, for clinical 
practice, the need for intense surveillance and a long-term planning, resulting in better care. 
For research, it could provide the opportunity to search for biological underpinnings of a 
persistent disorder and perhaps tailoring interventions targeted at this high-risk group of 
patients. 
 
The first step towards identifying who is at risk for any given outcome is to identify what 
individual factors are associated with this outcome in a longitudinal fashion. ADHD already 
leverages from a series of studies focused on the evaluation of potential risk factors for 
disorder’s persistence79,93-96. Candidates include characteristics of the ADHD syndrome itself 
(severity, pervasiveness, subtypes), other co-occurring psychiatric disorders, gender, and 
intelligence, among others. However, the literature was not yet summarized into a 
comprehensive systematic review, neither had the effect sizes of candidate factors been 
aggregated into a meta-analysis.  
 
Sophisticated approaches have used neuropsychological measures to predict the onset or 
persistence of ADHD during adolescence with inconsistent findings97. Longitudinal studies, 
measuring neuropsychological functioning and ADHD symptoms across development, have 
found associations between baseline and/or trajectories of neuropsychological measures 
and the remission or persistence of ADHD symptoms98-100. Other similar studies found no 
association101-103. Overall, current available evidence seems to be insufficient to support 
routinely clinical use of neuropsychology to inform on the course of ADHD symptoms.  
 
A more advance step towards the identification of high-risk groups and a personalized 
medicine approach relies on the development of risk models that consider all risk factors at 
once to provide one single individualized estimation of risk for each person104. This has been 
already a standard procedure in other areas of medicine, such as Cardiology105. For instance, 
the well-known Framingham risk score for cardiovascular disease calculates, based on easily 
measured clinical characteristics, the individual risk of any given patient of a major 
cardiovascular event in the following 10 years106. This risk model, as many others, has 
drastically changed the medical practice and research in their fields, tailoring specific 





In the field mental health, the adoption of this risk model approach is gradually increasing: 
on a systematic review that searched the literature up to 2014, 43 reports of prediction 
models in Psychiatry were identified – none of those predicting the course of ADHD107. At 
that time, authors called the attention to the lack of large-scale longitudinal studies, and the 
reliance on internal validation, rather than on external validation, of most published studies. 
Internal validation, despite leveraging on statistical techniques to reduce bias, might 
overestimate the measures of performance of the model due to overfitting – the process by 
which the model learns characteristics of that specific sample, which not entirely can be 
translated to other samples. With external validation, the model is tested only on unseen 
data, overcoming the issue of overfitting.  
 
Posterior to the time span of this systematic review, large-scale, well-designed and 
externally validated attempts to predict mental health outcomes were conducted in the 
field. In the North American Prodrome Longitudinal Study, 596 clinical high-risk for psychosis 
participants were followed up for 2 years or up to conversion to a psychotic state108. Clinical 
predictors, such as younger age, lower memory performance, higher levels of suspiciousness 
and unusual though content were combined into a multivariable model with time-to-event 
regression, internally validated with bootstrap resamples. At external validation with 
independent sampling, performance was good with an Area Under the Receiver Operating 
Curve (AUC) of .79109. A much larger study using medical registers in Great Britain also tried 
to predict nonorganic psychotic disorders among 91199 high-risk individuals110. The derived 
model was also quite simple, using only data available from the registers: age, sex, ethnicity, 
and index diagnosis before transitioning to psychosis. However, performance measures were 
good at external validation, with an AUC of .79. A risk calculator for the prediction of Bipolar 
Disorder among 412 offspring of bipolar patients was developed in the Pittsburgh Bipolar 
Offspring Study111. They were followed from a mean age of 12 years old, during a 5-year 
follow-up. A time-to-event regression was modeled using measures of mood and anxiety, 
general psychosocial functioning, age at mood disorder onset in the bipolar parent, and age 
at each visit. This calculator was not externally validated, but internal validation with 






Overall, few large-scale longitudinal studies with proper external validation and 
sophisticated statistical techniques were conducted to predict the course of mental 
disorders through multivariable prediction models. Particularly, no study was ever 
conducted to predict the course of ADHD: either its remission or persistence for childhood 
ADHD, or the emergence of symptoms during adolescence for late onset ADHD. These are 
gaps in the literature that this doctorate thesis also aims to help fulfilling: to synthesize the 
evidence on predictors of ADHD persistence/remission/emergence; and to propose a 
prediction model with state-to-art methodology in the field to predict the course of ADHD 
throughout development. 
 
Notably, the idea of advanced risk models might be associated to sophisticated and complex 
data, such as those obtained through neuroimaging, genetics, and neuropsychological 
measures. However, most of the main risk calculators available in other areas of medicine 
such as Cardiology 105 rely on relatively simple phenotypic information to generate accurate 
predictions. One of the reasons for the simplicity of the array of predictors of these tools is 
the focus on applicability in clinical settings through a wide range of available resources. The 
other might be because phenotypic data are still much more informative to these models, to 
a point where inclusion of other more complex kinds of data is superfluous. For instance, in 
2011, the ADHD-200 Consortium announced a competition where they provided a public 
dataset of functional and structural neuroimaging of 973 ADHD cases and controls. The 
winner would be the research group that could develop the most accurate and 
discriminative model to parse out cases and controls based on the information provided. 
Surprisingly, the most accurate predictive model was the one that completely ignored the 
neuroimaging data, and relied only on simple phenotypic data112. 
 
iii. Relative immaturity and ADHD 
 
A plausible rationale for the existence of so many developmental trajectories of ADHD, 
including remission, persistence, emergence and re-emergence of symptoms, is that 
dynamic environmental demands have a role in the expression of the phenotype113. It is 




might report very different levels of ADHD symptoms if they are exposed to different levels 
of academic and environmental demands. Likewise, if equal demands are imposed to 
children with equal biological vulnerabilities but different levels of developmental 
maturation (i.e., because of different chronological age), there is also a chance of different 
levels of phenotypic expression of ADHD symptoms.  In fact, this effect of relative 
immaturity might be operating in modern societies and their school system. Children and 
adolescents who are born at the end of the school year calendar are up to a year younger 
than their classmates who are born at the beginning of the school year calendar. Their 
attentional demands are, however, mostly equal. 
 
A number of studies show that children who are relatively immature compared to their 
classmates are most often diagnosed with ADHD60-67. For instance, studies leveraging 
cohorts of national medical registers from Sweden, Norway, Finland and Iceland all found 
greater incidences of ADHD diagnosis or medication use among children who were born in 
the last months of the calendar year60-62,64. Case-control studies investigated whether month 
of birth was unbalanced across diagnosed children and their peers66,67. In sum, three types of 
design verified the issue: epidemiological samples gathering registers of ADHD diagnosis; 
epidemiological samples using registers of ADHD medication; and clinical samples assessing 
relative immaturity within diagnosed children and adolescents. With few exceptions, 
independently of the methodological differences, all these studies confirm the association 
between relative immaturity and ADHD. However, this is an overlooked issue in clinical 
guidelines and manuals114,115. On the contrary, there is evidence reporting that this effect 
has increased in recent years, instead of disappearing due to increased awareness60. 
 
One explanation for the lack of awareness is the important gaps in the literature. First, 
representative studies that had actively collected the diagnosis of ADHD in children and 
adolescents in the community are missing, and only these could exclude the effect of 
referral bias. Second, there is not a pooled effect estimate for determining the size of this 
effect in the prevalence rates of ADHD clinical diagnosis. Third, even if month of birth is 
consistently associated with ADHD, other factors could be explaining the association – for 
instance, seasonality and weather issues at birth. Therefore, a more accurate design is 







To contribute for the understanding of possible developmental trajectories of ADHD 
throughout the life cycle and their associated factors.  
 
Specific objectives 
a. Verify the existence and the validity of a late-onset trajectory of ADHD in an independent 
population-based representative sample in Brazil – Article #1.  
b. Systematically review the literature on risk factors for the persistence of ADHD, and 
summarize their effects with meta-analytic techniques – Article #2.  
c. Develop and validate a risk model to predict the persistence, remission and emergence of 
ADHD during adolescence - Article #3. 
d. Systematically review the literature on relative immaturity and ADHD, and summarize its 
effect with meta-analytic techniques – Article #4. 
e. Investigate the issue of the relative immaturity effect and ADHD on three independent 
population-based samples in Brazil – Article #4. 
f. Review the literature on methodological challenges of long-term longitudinal studies on 
ADHD – Article #5. 
g. Review the literature on the debate around the validity of the late-onset trajectory of ADHD 

















Regarding each of the abovementioned specific objectives, we had the following a priori 
hypotheses: 
 
a. We will verify the existence of a substantial number of late-onset ADHD cases in our 
independent population-based sample, replicating the findings of previous epidemiological 
samples from New Zealand and the United Kingdom. These late-onset cases will have similar 
rates of impairment and functional outcomes as childhood-onset adults with ADHD.  
b. We will identify clinical and demographic predictors of ADHD persistence, each of these 
associated with a small independent effect in summarized estimates of meta-analyses. 
c. A multivariable prediction model of the course of ADHD throughout development with good 
prediction performance will prove to be a feasible attempt. Yet, external validation might be 
a challenging process in diverse designs and settings. 
d. We will be able to summarize the effect of relative immaturity in a consistent and precise 
estimate of relative risk. 
e. In the three independent samples, we will identify a dimensional effect of relative 
immaturity on ADHD symptoms, and changing the school calendar year will also change the 
month of risk for ADHD symptoms. 
f. We will identify heterogeneity and methodological differences among longitudinal studies 
with ADHD children with important impact in the evaluation of their outcomes. 
g. Detailed evaluation of methodological differences and theoretical backgrounds among 
studies evaluating late onset ADHD will provide insights into the reasons for discrepancies on 














All the studies included in this thesis have been approved by their respective Institutional 
Review Boards before data collection and analysis. Original studies included samples of 
several cohorts: the 1993 and the 2004 Pelotas Birth Cohorts; the E-Risk cohort; the ALSPAC 
cohort; the National Institute of Developmental Psychiatry High-Risk Cohort; and the MTA 
clinical study. All participants across all these samples provided written informed consent 
before inclusion in the study. Data were de-identified, and only raw data essential for 
analyses were shared with co-authors – therefore, attempts of identification of participants 









With respect to specific objective a. Verify the existence and the validity of a late-onset 
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IMPORTANCE: The requirement of an age-of-onset in childhood has always been a key 
criterion for the diagnosis of Attention-deficit/hyperactivity disorder (ADHD) in adults, but 
recently it has become surrounded by controversy. 
OBJECTIVE: To investigate whether impaired young adults with ADHD symptoms always have 
a childhood-onset disorder in a population-based longitudinal study.  
DESIGN, SETTING AND PARTICIPANTS: Participants belonged to the 1993 Pelotas Birth 
Cohort Study, including 5,249 individuals born in Pelotas, Brazil, in 1993. They were followed up 
to age 18/19 years, with 81.3% retention. 
MAIN OUTCOMES AND MEASURES: ADHD status was first ascertained at age 11 years 
using a screening instrument (Hyperactivity subscale of the Strength and Difficulties 
Questionnaire – SDQ) calibrated for DSM-IV ADHD diagnosis based on clinical interviews with 
parents using the Development and Well-Being Assessment (DAWBA). At age 18-19 years, 
ADHD diagnosis was derived using DSM-5 criteria, except age-of-onset. We estimated the 
overlap between these groups assessed at ages 11 and 18-19 years, respectively, and the 
rates of markers of impairment in these two groups compared to subjects without ADHD. 
RESULTS: We found ADHD prevalence rates of 8.9% in childhood and 12.2% in young 
adulthood (without using the age-of-onset criterion). Both groups had increased levels of 
impairment in adulthood, as measured by traffic accidents, criminal behavior, incarceration, 
suicide attempts, and comorbidities. However, only 17.2% of children with ADHD continued to 
have ADHD as young adults, and only 12.6% of young adults with ADHD had the disorder in 
childhood. 
CONCLUSIONS AND RELEVANCE: Our findings do not support the assumption that adult 
ADHD is necessarily a continuation of childhood ADHD. Rather, they suggest the existence of 




Attention-deficit/hyperactivity disorder (ADHD) has been traditionally conceptualized as a 
neurodevelopmental disorder. Most recently, DSM-5 included ADHD in a specific section under 
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this umbrella.1 Based solely on clinical wisdom, DSM-III introduced ADHD criterion B, requiring 
symptoms to be present before the age of 7 years, and DSM-IV-TR added that impairment must 
also be present by this same age.2,3 A number of studies challenged the utility and validity of 
this criterion B.4 The DSM-5 scientific committee decided to change the criterion to require 
symptoms before age 12, based on evidence that this threshold would capture almost every 
case presented in childhood, without raising the prevalence rate.1,5 Furthermore, DSM-5 
introduced the concept of adult ADHD as a disorder that begins in childhood and requires 
symptoms to be present before age 12.  
A recent report by Moffitt and colleagues presented data that diverge from this traditional 
perspective.6 In a representative birth cohort followed up to age 38, prevalence rates of 
childhood and adulthood disorder were in accordance with estimates from the literature (6% and 
3.1%, respectively). However, the two groups showed only minimal overlap: 87% of those with 
adult ADHD did not have prior childhood ADHD, and 85% of those with childhood ADHD did not 
continue to have adult ADHD. Castellanos, in an editorial about this paper, emphasized the 
urgent need for replications to confirm or challenge these data.7  
In the present study, we report findings from a prospective longitudinal study of a representative 
birth cohort in Brazil. We hypothesize that 1) prevalence rates of ADHD in childhood and young 
adulthood will be similar to that reported in the literature; 2) individuals with both childhood and 
adulthood ADHD will have higher levels of impairment markers than subjects without ADHD, 
and 3) groups will have little overlap. We extended the prior study by examining the effects of 
comorbid disorders on ADHD continuity. 
Methods 
Design and sample 
Subjects enrolled in this study were participants in the 1993 Pelotas Birth Cohort. All children 
born in the year of 1993 in the city of Pelotas (5,249 individuals) were assessed at multiple time 
points and followed until age 18/19 years, with a retention rate of 81.3%. Further information on 
the cohort design can be found elsewhere.8,9 The Institution Review Board of the Federal 




The assessment at age 11 included data on child mental health using the Brazilian Portuguese 
Version of the Strengths and Difficulties Questionnaire (SDQ), parent report and self-report. A 
sub-sample of 280 subjects was interviewed with Development and Well-Being Assessment 
(DAWBA), and the optimal cut-off for ADHD disorder was estimated to be eight or more points 
on the SDQ hyperactivity scale as rated by parents.10 The SDQ instrument accurately predicted 
ADHD diagnosis with an Area Under the Curve of 0.81 (95% CI 0.74 – 0.88) and the cut-off of 
at least 8 points had 85.7% sensitivity and 67.4% specificity for the diagnosis. 
In the last assessment, subjects at age 18/19 years were interviewed by trained psychologists 
using specific modules for Major Depressive Disorder (MDD), Bipolar Disorder (BD), 
Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD) modified from the Mini-
International Neuropsychiatric Interview.11 ADHD assessment was performed with a structured 
interview according to DSM-5 criteria (see  eTable 1 and Matte et al., 2014).12 For the present 
study, we did not require DSM-5 criterion B (age at onset) for diagnosis of young adult ADHD. 
We defined childhood ADHD as present when scores on the SDQ hyperactivity scale – parent 
version – were equal or higher to eight points and associated with impairment, defined by at 
least one point in the impact supplement. 
We also created a secondary category defined as Young Adult ADHD without Comorbidity (YA-
ADHD-WC) excluding from the young adult ADHD group those subjects with comorbidities, 
including MDD, BD, GAD, SAD, and regular use of illicit drugs. This procedure was done for 
secondary analyses to reduce confounding by these comorbidities that is likely to occur later in 
life, and might contribute to inattentive and/or hyperactive-impulsive symptoms. We also 
excluded these comorbidities from comparison groups without ADHD. The comparison groups 
were defined as those without Childhood ADHD (C-ADHD) for childhood comparisons (C-ADHD 
vs. subjects without C-ADHD), and those without YA-ADHD for adulthood comparisons (YA-
ADHD vs. subjects without YA-ADHD and YA-ADHD-WC vs. subjects without YA-ADHD and 
comorbidities).  
Correlates  
Trained interviewers assessed correlates of tobacco use, illicit drug use, pregnancy, sexually 
transmitted diseases and criminal behavior using confidential questionnaires. Suicide attempts 
were evaluated as part of the assessment of MDD. We estimated IQ with an abbreviated 
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version of the Weschler Adult Intelligence Scale-third edition (WAIS-III).13 Further details of 
assessments of correlates can be found in eTable 2. 
Data analyses  
We estimated differences between groups using chi-square tests for the following variables: 
percentage male, ADHD subtype, traffic accidents, illicit drug use, smoking, criminal behavior, 
correctional institution, comorbidities and teenage pregnancy. We used one-way analysis of 
variance for continuous variables: personal income, years of schooling, IQ. Effect sizes for 
continuous variables were estimated with Cohen’s d. All analyses were performed using SPSS 
v20.0. 
Results 
Prevalence and sex distribution 
Childhood ADHD (C-ADHD) was present in 8.9% (393) of the subjects evaluated at age 11. At 
age 18/19, 12.2% (492) of the subjects fulfilled all DSM-5 criteria for YA-ADHD, except age-of-
onset. After excluding comorbidities, the prevalence of YA-ADHD-WC dropped to 6.3% (256 
subjects). Subjects with C-ADHD had a male preponderance not observed among children 
without ADHD (63.9% vs. 47.9% males, χ2 = 36.679, p < 0.001), while YA-ADHD group had a 
female preponderance (39% vs. 50.4% males, χ2 = 22.187, p < 0.001), and this difference 
persisted after excluding comorbidities (YA-ADHD-WC = 44.9% vs. individuals without YA-
ADHD and without comorbidities = 51.5 % males, χ2 = 4.022, p = 0.045) (Table).  
Persistence and overlap 
Among the 393 subjects in the C-ADHD group, 15.3% (60) continued to have YA-ADHD (7.9% 
with at least one comorbidity, and 7.4% with no comorbidity), 73.3% (288) had no YA-ADHD in 
the 18/19 years assessment, and 11.5% (45) were lost to follow up (see Figure 1), resulting in a 
persistence rate of 17.2%. Furthermore, most C-ADHD cases presented very few symptoms in 
young adulthood (Figure 2), making it unlikely that a lower symptom cut-off would substantially 
change this result. 
Among the 492 subjects in the YA-ADHD group, 12.2% (60) had C-ADHD, 84.6% (416) did not 
have C-ADHD, and 3.3% (16) of the subjects were not assessed with the SDQ at age 11, 
resulting in a prevalence of 12.6% of C-ADHD among the YA-ADHD group. Considering the 256 
subjects in the YA-ADHD-WC group without comorbidities, 11.3% (29) had C-ADHD, and 85.9% 
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(220) did not have C-ADHD, and 2.7% (7) had not been assessed with the SDQ at age 11 
(Figure 1), resulting in a prevalence of 11.6% of C-ADHD among the YA-ADHD-WC group. See 
also secondary analyses in eTables 3-5, checking the robustness of our findings.  
ADHD Presentation in Young Adulthood 
Inattentive presentation prevailed in all groups in young adulthood: those with C-ADHD who 
continued to have YA-ADHD (51.7%), YA-ADHD (53.3%) and YA-ADHD-WC (59%). (See Table 
for other ADHD presentations.) 
Comorbidities and suicide attempts 
Subjects with childhood ADHD had significantly higher rates of comorbidities in young 
adulthood compared to subjects without C-ADHD. At age 18/19, rates of MDD (7.2% vs. 3.8%, 
χ2 = 9.087, p = 0.003), BD (4.2% vs. 1.5%, χ2 = 13.369, p < 0.001), GAD (10.8% vs. 7.2%, χ2 = 
5.489, p = 0.019), SAD (10.2% vs. 6.5%, χ2 = 6.6, p = 0.01), illicit drug use (10.8% vs. 6.8%, χ2 
= 7.479, p = 0.006) and tobacco smoking (25.9% vs. 13.3%, χ2 = 37.92, p < 0.001) were all 
higher in the C-ADHD group. The YA-ADHD group had even higher levels of comorbidities, 
which were also significantly different to subjects without YA-ADHD for MDD (13.6% vs. 2.7%, 
χ2 = 132.066, p < 0.001), BD (7.4% vs. 0.9%, χ2 = 106.634, p < 0.001), GAD (24.9% vs. 5.1% 
χ2 = 238.475, p < 0.001) and SAD (20.2% vs.  5%, χ2 = 153.086, p < 0.001), and tobacco 
smoking (19% vs. 13.7%, χ2 = 9.032, p = 0.003). However, we did not find significant 
differences for illicit drug use (9% vs. 7%, χ2 = 2.592, p = 0.107). A self-reported suicide attempt 
in young adulthood was more likely among children with ADHD than in children without ADHD 
(10% vs. 6%, χ2 = 8.889, p = 0.003), and among the YA-ADHD group than young adults without 
ADHD (15.2% vs. 5.1%, χ2 = 75.541, p < 0.001). The difference remained significant even after 
excluding comorbidities (YA-ADHD-WC: 6.6% vs. 3.5% young adults without ADHD and without 
comorbidities; χ2 = 6.333, p = 0.012). (See Table.) 
Criminal behavior and incarceration 
All three ADHD groups had higher levels of violent crimes compared to subjects without ADHD 
(C-ADHD: 28.7% vs. 14.5%, χ2 = 42, p < 0.001; YA-ADHD: 24.4% vs. 14.4%, χ2 = 28., p < 
0.001; YA-ADHD-WC: 18.5% vs. 11.8%, χ2 = 8.72 p = 0.003). Accordingly, the three groups 
had significantly higher levels of incarceration compared to individuals without ADHD (C-ADHD: 
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4% vs. 0.9%, χ2 = 25.582, p < 0.001; YA-ADHD: 2.8% vs. 1%, χ2 = 12.449, p < 0.001; YA-
ADHD-WC: 1.6% vs. 0.5%, χ2 = 4.216 p = 0.04). (See Table.) 
Teenage pregnancy and sexually transmitted diseases. 
More females with C-ADHD had teenage pregnancies compared to girls without ADHD (21.9% 
vs. 13.2%, χ2 = 7.65, p = 0.006). Differences in teenage pregnancy rates were not observed 
comparing YA-ADHD and YA-ADHD-WC groups to subjects without A-ADHD. A history of 
sexually transmitted diseases was more common in the YA-ADHD group than among young 
adults without ADHD (5.3% vs. 2.2, χ2 = 15.756, p < 0.001), even controlling for comorbidities 
(YA-ADHD-WC vs. young adults without ADHD and comorbidities: 4.7% vs. 1.9%, χ2 = 8.297, p 
= 0.004). The C-ADHD group did not have a statistically significant different rate of sexually 
transmitted diseases compared to children without ADHD (2.9% vs. 2.6%, respectively; χ2 = 
0.133, p = 0.715). (Table) 
Traffic accidents 
Suffering a traffic accident was significantly more likely among the ADHD groups than among 
subjects without ADHD (C-ADHD: 21.9% vs. 17.2%, χ2 = 4.874., p = 0.027; YA-ADHD: 23.2% 
vs. 16.7%, χ2 = 12.457, p < 0.001; YA-ADHD-WC: 21.5% vs 16.2 %, χ2 = 4.636, p = 0.031). 
(Table) 
Personal income and years of schooling 
C-ADHD, YA-ADHD and YA-ADHD-WC groups did not differ from subjects without ADHD in 
terms of personal income and completed years of regular schooling.   
Intelligent Quotient 
The C-ADHD and YA-ADHD groups had lower intelligent quotient (IQ) levels than subjects 
without ADHD, and this difference was larger for C-ADHD (97.17 vs. 89.74, ES = 0.61, p < 
0.001) than for YA-ADHD (96.7 vs. 95.28, ES=0.12, p = 0.013) and YA-ADHD-WC (97.68 vs. 
95.59, ES = 0.17, p = 0.008). 
Discussion 
The notion that adult ADHD is necessarily a continuation of childhood ADHD is an established 
assumption in the field. Recently, a population-based birth cohort provided initial evidence 
suggesting the opposite (i.e., 87% of adult ADHD cases without childhood ADHD).6 In the 
current study, we extended the findings of Moffitt and colleagues for young adults using a 
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similar methodology. We identified that, among young adults with ADHD, 87.4% did not have 
childhood ADHD.  
In the current study, young adults with self-reported ADHD symptoms had a consistent pattern 
of higher impairment than subjects without young adult ADHD, as determined by rates of traffic 
accidents, self-reported violent crimes, incarceration in correctional institutions and 
comorbidities, which are analogous with previous findings in the literature.14-17, Children and 
young adults with ADHD had higher rates of suicide attempts than their counterparts without the 
condition, which is also in accordance with the literature.18 Because comorbidities might be 
responsible for the aforementioned differences, we ran the same analyses excluding subjects 
with co-occurring disorders from the ADHD group, and very similar results emerged, suggesting 
that comorbid disorders do not explain the adult-ADHD impairments. 
Although the expected prevalence rate of childhood ADHD is around 5.3%,19 we observed a 
notably inflated rate, around 8.9%. However, our estimate is similar to that reported by a 
prevalence study that also used a screening instrument.20 Likewise, our adult ADHD prevalence 
rate was 12.2%, against a 2.5%-5% prevalence rate suggested by meta-analyses.21,22 It is likely 
that this difference occurred because of the lower symptom cut-off required by the DSM-5 and 
because we did not require a childhood age-of-onset to make the diagnosis. Indeed, a previous 
report in the same population found an ADHD prevalence rate of 3.5% using the age-of-onset 
criterion.12 Our estimate is considerably higher than that observed in the Dunedin cohort,6 where 
they reported a 3.1% prevalence of ADHD in adults, even not requiring childhood age-of-onset. 
Such a difference might be explained by the fact that their sample was composed of subjects 20 
years older, and there is a tendency for prevalence to decline with increased age.23 A lower 
male/female ratio is expected in adult samples compared to child ones, but we found a 
particularly low male-to-female ratio of 0.64 : 1, which may indicate that females are over-
represented in subjects with late-onset ADHD. 
Our observed persistence rate of ADHD was 17.2%. This finding match perfectly the 
persistence rate estimated by a previous meta-analysis.24 Indeed, the Dunedin cohort was the 
first population-based longitudinal sample to report an extremely low persistence rate of ADHD 
into adulthood (5%). Again, the difference with our estimate was expected because the Dunedin 
cohort is composed of older adults. It is important to bear in mind that our C-ADHD group 
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continue to present significant impairments in adult life despite not continuing to qualify for an 
ADHD diagnosis in adulthood. Three alternative hypotheses have been proposed to explain this 
finding: a) impairments are a residual effect of the disorder; b) impairments are due to the 
effects of persistent comorbidities; c) there is an illusionary bias (e.g., adults with ADHD do not 
perceive their ADHD symptoms).  Future studies should try to elucidate these issues.   
The main strengths of our study include a large representative sample not biased by clinical 
referral. Trained interviewers assessed our subjects at ages 11 and 18 with substantial 
retention. Thus, we were able to report estimates of the overlap between ADHD in children and 
in adults, as well as their correlates, with reasonable accuracy. On the other hand, some 
methodological limitations should be taken into account in the interpretation of the results. First, 
diagnosis of ADHD in childhood was made using a screening instrument (SDQ hyperactivity 
scale). However, it is important to bear in mind that psychologists using the DAWBA in a 
subsample of 280 subjects validated the SDQ hyperactivity scale cutoff scores against ADHD 
diagnosis in clinical interviews.10 In addition, we checked a lower cut-off score that continued 
yielding significant lack of C-ADHD in subjects with YA-ADHD. Second, we relied only on parent 
reports for C-ADHD and self-report for YA-ADHD. This might artificially increase diagnostic 
disagreement because of different information sources. However, when using self-reported 
SDQ hyperactivity scores in childhood, both young adult ADHD groups (YA-ADHD and YA-
ADHD-WC) were far below the threshold for childhood ADHD diagnosis according to parent 
reports (score = 8), confirming that the young adult ADHD cases had few ADHD symptoms in 
childhood. In addition, these assessment procedures reflect more accurately what frequently 
occurs in clinical practice, where childhood ADHD diagnosis relies much more on parental 
reports and adult ADHD diagnosis on self-report.25 One could also question whether, if we had 
used parental reports of adult ADHD, a different group of ADHD cases in adulthood would have 
been identified. However, several previous investigations have found high agreement between 
self- and parent- reports for ADHD diagnosis in adults.26 Moreover, our ADHD cases defined by 
self-report have a clinical, comorbidity and impairment profile similar to the one previously 
described for the disorder in adulthood. Finally, a recent report from our group suggests that 
even adult patients fulfilling DSM-5 ADHD diagnosis by self-report, for whom other informants 
did not report ADHD symptoms in childhood, have the same clinical profile and response to 
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treatment as those whose co-informants described ADHD childhood symptoms.27 Third, we did 
not have a formal diagnosis of some psychiatric disorders that could be the primary source of 
inattention and/or hyperactivity-impulsivity in adults, like substance use disorders and 
personality disorders. Along the same line, diagnoses were ascertained with a structured 
interview rather than clinical judgment. Hence, the alternative explanation that another disorder 
might explain symptoms and impairment better than ADHD itself cannot be completely ruled 
out. However, 6.3% of the adult sample had ADHD without four important and frequent 
comorbidities or illicit drug use, and those subjects remained impaired compared to subjects 
without ADHD and comorbidities. A fourth limitation is that our impairment measure was based 
only on the subject’s perspective; a rater-derived score based on functional correlates was not 
used. However, clinicians tend to see young adult patients without parents and to rely on self-
perception about impairment more than on scales. Fifth, our results in a community sample 
cannot be extrapolated to clinical samples where the majority of the cases tend to be ADHD 
combined type with at least moderate severity. A final potential bias in our study, that indeed is 
inherent to the majority of population-based studies in Psychiatry, is the so-called false positive 
paradox that occurs when the rate of false positives based on the instrument used to assess the 
disorder is higher than the incidence of cases in the population.  
In light of these findings, along with the study’s strengths and limitations, we can draw some 
meaningful implications for practice and research. Above all, our findings do not support the 
premise that adult ADHD is always a continuation of childhood ADHD. Rather, they suggest the 
existence of two syndromes that have distinct developmental trajectories, with a late onset far 
more prevalent among adults than a childhood onset. This would not mean that ADHD could not 
be conceptualized as a neurodevelopmental disorder. Neurodevelopmental disorders may have 
a later onset, as is the case for Schizophrenia.28 In both clinical practice and research, it is 
important to differentiate early and late onset disorders, and future investigations should test if 
they have different pathophysiology, treatment response and prognosis. In addition, adult ADHD 
cases with late onset have clear impairments and their clinical profile cannot be accounted for 
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Table. Characteristics and outcomes of childhood ADHD (C-ADHD), young adulthood ADHD (YA-ADHD and YA-ADHD-WC) and non-ADHD 
comparisons in the 1993 Pelotas Birth Cohort Study. 
 Childhood Comparisons Adulthood Comparisons 
 W/o ADHD 
(n = 4033) 
C-ADHD  
(n = 393) 
 W/o ADHD 
(n = 3547) 
YA-ADHD 
(n = 492) 
 W/o YA-ADHD 
w/o Comorbidity 
(n = 2874) 
YA-ADHD-WC b  
(n = 256) 
 
 % % p-value % % p-value % % p-value 
Prevalence rate 91.1 8.9 -- 87.8 12.2 -- 91.8 8.2 -- 
Gender (Male) 47.9 63.9 < 0.001 50.4 39.0 < 0.001 51.5 44.9 0.05 
ADHD presentation in 
adulthood a 
  0.43       
Inattentive 54.1 51.7 -- -- 53.3 -- -- 59.0 -- 
Hyperactive-impulsive 9.1 5.0 -- -- 8.9 -- -- 12.1 -- 
Combined 36.8 43.3 -- -- 37.8  -- 28.9 -- 
OUTCOMES % % p-value % % p-value % % p-value 
Traffic accidents 17.2 21.9 0.03 16.7 23.2 < 0.001 16.2 21.5 0.03 
Criminal behavior - violent 14.5 28.7 < 0.001 14.4 24.4 < 0.001 11.8 18.5 0.003 
Criminal behavior –– any 16.6 30.9 < 0.001 16.5 27.1 < 0.001 13.7 20.7 0.004 
Incarceration 0.9 4.0 < 0.001 1.0 2.8 < 0.001 0.5 1.6 0.04 
Tobacco smoking 13.3 25.9 < 0.001 13.7 19.0 0.003 10.0 11.8 0.39 
Illicit drug use 6.8 10.8 0.006 7.0 9.0 0.11 -- -- -- 
Depression 3.8 7.2 0.003 2.7 13.6 < 0.001 -- -- -- 
Bipolar Disorder 1.5 4.2 < 0.001 0.9 7.4 < 0.001 -- -- -- 
Generalized Anxiety Disorder 7.2 10.8 0.02 5.1 24.9 < 0.001 -- -- -- 
Social Anxiety Disorder 6.5 10.2 0.01 5.0 20.2 < 0.001 -- -- -- 
Suicide attempt 6.0 10.0 0.003 5.1 15.2 < 0.001 3.5 6.6 0.01 
Teenage pregnancy 13.2 21.9 0.006 13.8 12.8 0.64 13.3 9.9 0.26 
Sexually transmitted diseases 2.6 2.9 0.72 2.2 5.3 < 0.001 1.9 4.7 0.004 
 M (SD) M (SD) p-value M (SD) M (SD) p-value M (SD) M (SD) p-value 
Personal income 510.5 (419) 543.5 (315.9) 0.20 516.43 (422.9)  478.86 (263.6) 0.11 517.5 (449.6) 489 (281.7) 0.40 
Years of schooling 8.63 (2.29)  8.45 (2.35) 0.15 8.61 (2.29) 8.57 (2.26) 0.70 8.62 (2.29) 8.56 (2.15) 0.68 
Intelligence Quotient 97.2 (12.4) 89.7 (11.7) < 0.001 96.7 (12.7) 95.3 (11.8) 0.01 97.7 (12.2) 95.6 (11.9) 0.008 
C-ADHD: Childhood ADHD; YA-ADHD: Young Adults with ADHD; YA-ADHD-WC: Young Adults with ADHD without Comorbidity; IQ: Intelligence Quotient; M: Mean; SD: Standard deviation; a 
Comparison with chi-square in a 2x3 table considering young adult ADHD presentation in children with ADHD that continued to have ADHD in young adulthood and those from the non-ADHD 
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Attention-Deficit/Hyperactivity Disorder (ADHD) is traditionally conceptualized as 
a neurodevelopmental disorder that continues into adulthood in up to half of 
diagnosed cases. In light of current evidence, factors associated with the course 
of the disorder remain unknown. We performed a systematic review of the 
literature searching for risk markers from childhood that predicted the persistence 
of ADHD into adulthood. We reviewed 26,168 abstracts, and selected 72 for full-
text review. We identified data from 16 studies, comprising six population-based 
retrospective samples and ten clinical follow-ups. We performed meta-analyses 
of factors evaluated by at least three studies. Severity of ADHD (OR 2.33, 95% 
CI = 1.6-3.39, p < 0.001), treatment for ADHD (OR 2.09, 95% CI = 1.04 -4.18, p = 
0.037), comorbid Conduct Disorder (OR 1.85, 95% CI = 1.06-3.24, p = 0.030), 
and comorbid Major Depressive Disorder (OR 1.8, 95% CI = 1.1-2.95, p = 0.019) 
emerged as predictors already presented in childhood for ADHD persistence into 
adulthood. Further, we suggest that cohort studies be designed in order to clarify 
such an important question for research and clinical practice. 




Attention-Deficit/Hyperactivity Disorder (ADHD) is a common disorder,[1] 
traditionally conceptualized as resulting from abnormalities in 
neurodevelopment. Its course embodies one challenging scenario, since as 
many as half of affected children present a chronic disorder that persists 
beyond adolescence and throughout adulthood,[2] a trajectory that is 
associated with burden in many aspects of life.[3-5] Thus, from the clinical point 
of view, the identification of individuals with increased risk of persistence that 
may benefit from more intensive strategies aiming at long-term adherence is 
without any doubt of great value. 
 The impact imposed by ADHD in childhood and adolescence is highly 
recognized and documented by several studies.[6,7] Nonetheless, its burden in 
adulthood is still not always recognized, despite investigations clearly 
documenting it.[3,5,8,9] For example, behavioral disorders (ADHD and conduct 
disorder, CD) were included for the first time in the 2010 Global Burden of 
Disease Study,[10] but the impact associated with them was mostly restricted to 
the two first decades of life. Whereas ADHD and CD were reported to account 
for almost two million disability-adjusted life years (DALYs) between ages 15 
and 19 years, they were associated with only two hundred thousand DALYs 
between ages 20 and 24 years. However, the developmental trajectory of these 
disorders does not suggest that they disappear or decrease their impact as 
sharply as suggested.[4] One explanation for the reduced burden of ADHD in 
older ages is the scarcity of follow-up studies. 
The first studies to follow hyperactive children beyond the school years 
reported a tendency towards syndrome remission during adolescence.[11-13] 
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However, this is certainly not the case for every child affected with ADHD. 
Faraone and colleagues[2] pooled ADHD persistence rates from 10 samples in 
a systematic review and meta-analysis, reporting an estimate of 15% when a 
full syndrome in adulthood according to the DSM-IV criteria was required (using 
a 6 symptom cut-off). Moreover, this review also indicated that a higher 
proportion of individuals (up to 65%) remain presenting some level of the 
original symptoms and associated impairment.[2] A recent report by Moffitt and 
colleagues confirmed to a large extent these figures of persistence and further 
extended the knowledge on distinct developmental presentations of ADHD.[14] 
Even in light of the best available evidence, it is impossible for a clinician 
to determine whether a child presenting with ADHD will sustain the condition 
through adolescence and adulthood, therefore preventing carefully planned 
long-term follow-up and treatment. Once available, prevention strategies could 
also play an important role in this group of patients. On the other hand, those 
with a naturally remitting course might benefit from a less intensive approach 
and counseling. 
Although clinical prospective and retrospective studies might be 
informative for clinicians dealing with patients with the same characteristics of 
those from clinical samples, markers of ADHD persistence or remission coming 
from population-based studies are essential to understand the natural history of 
the disorder. Our objective is to identify the current knowledge in terms of 
factors associated with ADHD persistence or remission from childhood until 
adulthood through a systematic review of the literature. We hypothesize that no 
isolated marker will be homogeneously presented in different studies and the 
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heterogeneity of the methods in studies will prevent a complete understanding 
of the predictors of different ADHD trajectories from childhood to adulthood.    
 
Methods 
 The search intended to find prospective or retrospective studies that had 
an assessment of ADHD status in childhood (operationalized as before age 12) 
and adulthood (operationalized as after age 18), and information (clinical, 
demographic, genetic, neurobiological) from childhood. The assessment of 
ADHD status in childhood should be based on interviews in clinical studies and 
on interviews or retrospective self-report in population-based studies. In order to 
address the question of which variable is associated with persistence of ADHD, 
it was required that the study reported the information both for the subjects who 
persisted as well as for those who remitted. We also included review articles 
about the course of ADHD to perform handsearch of reference lists. Our only 
exclusion criterion was if data came from intervention (pharmacological or 
psychosocial) studies, but no study was excluded by this criterion. 
 We searched three major literature databases: Medline, Web of Science 
and PsycINFO. We designed the algorithm in a composed structure with three 
sets of terms: one to capture different writings for ADHD; a second to address 
the longitudinal design required by the inclusion criteria; and a third comprising 
the vocabulary of risk markers. The final search expression was as follows: 
("ADHD" OR "ADD" OR "attention deficit" OR "attention-deficit/hyperactivity" OR 
hyperactiv* OR overactiv* OR inattent* OR "hyperkinetic disorder") AND ("adult" 
OR "adults" OR "adulthood" OR "course" OR "lifetime" OR persist* OR 
"remission" OR "remits" OR declin* OR "lifespan" OR "stable" OR "stability") 
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AND ("risk factor" OR "risk factors" OR predictive factor* OR "risk marker" OR 
"risk markers" OR "protective factors" OR "protective factor" OR prognos* OR 
"follow" OR "longitudinal" OR "long term" OR "prospective" OR "predictor" OR 
"predictors" OR outcome* OR "later"). Two authors (A.C. and A.V.S.) 
independently reviewed the abstracts, and discussed disagreements with a third 
author (C.K.) (Figure 1). We searched genetic studies with the search terms 
described above with an additional set of terms: 
AND ("gene" OR "genetics" OR "gene-gene interaction" OR "epistasis" OR 
"pathway analysis" OR "genome-wide association 
study" OR "GWAS" OR "candidate gene study" OR "cross-disorder"), and a 
different date range: from June 1st, 2011 until April 20, 2015. Franke and 
colleagues[15] had already reviewed the literature prior to that date. One author 
(D.L.R.) reviewed the reference list of this review and additional abstracts using 
the database search strategy, and discussed findings with C.H.D.B. 
Studies that were in accordance with the inclusion criteria or that could 
not be included based only in the content of the abstract were selected for a full-
text review, and the references of these studies were also reviewed. Finally, we 
contacted experts in the area with the final list attached to ask for important 
publications that could have been missed. Two authors (A.C. and A.V.S.) 
independently extracted the following data from selected studies: sample 
setting, number of subjects enrolled, study design, age of first and last 
assessment, diagnostic instruments and disorder definition. They assessed 
predictors on persistence, including factors from childhood that were compared 
between those who persisted and those who outgrew the disorder. They also 
collected data on the magnitude of association, such as odds ratio (OR), risk 
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ratio (RR), or hazard ratio (HR), as presented in the studies. When no OR/RR 
was reported, but the frequency of persistence in two risk groups was available, 
we calculated OR in retrospective studies and RR in prospective studies, and 
95% confidence intervals (95% CI) with standard procedure of 2x2 table. For 
continuous variables, authors extracted means and standard deviations and 
calculated Standardized Mean Difference (SMD) between the groups. When 
factors were assessed by at least three studies that provided sufficient data, we 
used meta-analytic techniques with random-effects model to estimate overall 
effect size using computed OR and 95% CI for all the studies included, using 
Comprehensive Meta-Analysis Software.[16] This study was approved by the 




 Of the initial 32,375 abstracts (26,168 after exclusion of duplicates), we 
selected 72 original studies for full-text review, of which 12 were included in the 
final list. The handsearch of reference lists did not include new references. The 
expert consult retrieved two other studies (one book and one doctoral thesis). 
The search for genetic studies retrieved 862 new abstracts on the topic, 
included 36 articles for full-text review and selected two studies. The final list 
consisted of 16 studies (Table 1). We did not perform publication bias analyses 
due to the small number of studies included for each risk factor. 
Sociodemographic features 
Ten studies evaluated gender as a predictor of the course of ADHD, 
eight of them finding no difference in persistence between males and females 
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[17-25]. Two prospective studies had different results: Breyer and colleagues 
[26] observed a lower persistence for males (RR 0.68, 95% CI=0.5-0.91, p < 
0.001), similarly to Cheung [27]  (RR 0.76, 95% CI=0.68-0.85, p < 0.001). Eight 
samples were included in the meta-analysis (Figure 2A), resulting in a pooled 
OR of 1.23 (95% CI = 0.84-1.81, p = 0.295). Regarding socioeconomic status 
(SES) at childhood, three [19,26,28] reported no difference between persisters 
and remitters. Cheung et al. [27], however, observed a lower SES at baseline in 
the group that persisted compared to those who remitted (3.38 ± 1.01 vs. 4.41 ± 
0.88, p = 0.01). Three studies were included in the meta-analyses (Figure 2H), 
resulting in a pooled SDM of 0.18 (95% CI = -0.23-0.59, p = 0.39). Four studies 
that evaluated intelligent quotient (IQ) at baseline were unanimous not finding 
any influence of this factor in persistence of ADHD [21,22,26,28]. We meta-
analyzed data from three studies (Figure 2I), resulting in a pooled SDM of 0.03 
(95% CI = -0.18-0.23, p = 0.8). Only one study [22] evaluated gestational age 
and birth weight and it did not find difference between the groups. 
 
ADHD characteristics 
Six studies evaluated severity of ADHD as a predictor of the course of 
the disorder. Four of these [17,19,23,24] reported significantly higher levels of 
persistence for individuals with severe impairment, with OR and RRs ranging 
from 1.31 to 3.37. Biederman and colleagues [20] and Chang and colleagues 
[21] found no significant difference in persistence related to severity. We 
included four studies in the meta-analysis (Figure 2C), resulting in a pooled OR 
of 2.33 (95% CI = 1.6-3.39, p < 0.001). Individuals who were treated for ADHD 
were more likely to continue to have the disorder at follow up according to 
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Kessler et al. [23] (OR 4.5, 95% CI = 1.7-11.8, p = 0.002), in a study that 
defined positive treatment history if the individual had any professional 
treatment before age 15, as well as to Chang et al. [21] (OR 9.56, 95% CI = 
2.09-43.67, p = 0.004), that defined positive treatment if the individual used 
standard medication (i.e., any form of methylphenidate to an optimum dosage) 
for at least six months. This effect remained significant even after controlling for 
ADHD severity. However, this was not observed in four other 
studies.[19,20,24,26] We included five studies in the meta-analysis (Figure 2B), 
resulting in a pooled OR of 2.09 (95% CI = 1.04 -4.18, p = 0.037). Three 
investigations assessed age at onset. None of them found significant 
differences between persisters and remitters [17,19,20]. We could not perform 
meta-analysis due to insufficient data (table 2). Four studies evaluated the 
effect of diagnostic subtypes in the course of ADHD. Kessler and colleagues 
[23] reported that individuals with combined type, compared to those with either 
predominantly inattentive or hyperactive types, were at a significant higher risk 
for the persistence of ADHD into adulthood (OR 2.4, 95% CI = 1.3-4.2, p = 
0.003). Yang and colleagues [29] reported that adults with combined subtype of 
ADHD in childhood had the most severe adult ADHD (p < 0.001). Lara and 
colleagues [24] found a greater persistence in individuals who reported only 
inattentive problems (OR 2.7, 95% CI = 1.3-5.6, p = 0.008), inattentive and sub-
threshold impulsive-hyperactive (OR 5.1, 95% CI = 1.8-14.5, p = 0.002), and 
combined subtype (OR 12.4, 95% CI = 4.5 - 34.5, p < 0.001) when compared to 
those who reported only impulsive-hyperactive symptoms at childhood. Further, 
Cheung et al. [27] observed that persisters had higher scores of inattention, but 
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not of hyperactivity, in childhood (as rated by parents). We could not perform 
meta-analysis due to insufficient and incompatible data (table 2).  
 
Comorbidities 
Chang and colleagues [21] observed a higher persistence in individuals 
with comorbid oppositional defiant disorder (ODD) (RR 1.42, 95% CI = 1.14 - 
1.76, p = 0.002). Barkley and Fischer [30] had similar results (RR 2.2, 95% CI = 
1.51 - 3.22, p < 0.001). Two other studies [20,28] found no association between 
ODD and persistence. We included these four studies in the meta-analysis 
(Figure 2D), resulting in a pooled OR of 1.65 (95% CI = 0.75-3.65, p = 0.213). 
Comorbid conduct disorder (CD) was evaluated as a predictor of persistence by 
five studies [17,19-21,28], but only Biederman et al. [20] found a significant 
association. We included four studies in the meta-analysis (Figure 2E), resulting 
in a pooled OR of 1.85 (95% CI = 1.06-3.24, p = 0.03). Major depressive 
disorder (MDD) was a risk marker for the persistence of ADHD in the sample 
studied by Lara et al. [24] (OR 2.2, 95% CI = 1.1-4.3, p = 0.023), but not in three 
other studies [19-21]. We included three studies in the meta-analysis (Figure 
2F), resulting in a pooled OR of 1.8 (95% CI = 1.1-2.95, p = 0.019). Biederman 
and colleagues [19] reported a higher persistence of ADHD in boys with multiple 
(two or more) anxiety disorders (p < 0.05), but this finding was not consistent 
with two other studies [20,21]. We could not perform meta-analysis due to 
insufficient data (table 2). The presence of three or more comorbidities 
increased the odds of persistence by 1.7 (95% CI = 1.1-2.6, p = 0.016) in the 
study by Lara et al. [24], while Chang et al. [21] found no such an association 




Exposure to adversities and trauma 
Lara and colleagues [24] found no association between trauma exposure and 
persistence (OR 1.3, 95% CI = 0.8 -2.3, p = 0.33), a finding consistent with that 
reported by Kessler et al. [23] (p = 0.71). Parental psychopathology increased 
the odds of persistence in two contexts, according to Lara et al. [24]: paternal 
anxiety-mood disorder (OR 2.4, 95% CI = 1.1-5.5, p = 0.033) and parental 
(mother or father) antisocial personality disorder (OR 2.2, 95% CI = 1.2-4.2, p = 
0.014). In regard to exposure to adversities, Biederman and colleagues [20] 
reported higher persistence in girls with a first-degree relative affected with 
multiple (two or more) anxiety disorders (p < 0.05). The same study also found 
that children that lived with only one parent were at higher risk for persistence 
(RR 1.29, 95% CI = 1.07-1.55, p = 0.007), but this finding was not replicated in 
two other samples [19,26]. We included three studies that evaluated single 
parent family as risk marker of persistence in the meta-analysis (Figure 2G), 
resulting in a pooled OR of 1.08 (95% CI =0.36-3.25, p = 0.892).  
 
Neuropsychological measures 
Roizen [28] studied the performance in neuropsychological tests, 
including working memory, visual motor integration, visual sequential memory, 
omission-commission performance test, among others, as a risk factor for 
persistence of ADHD. The author has also created a neuropsychological factor, 
developed with the average of the z-scores of all the tests. None of the 
variables were associated with persistence, including the neuropsychological 
factor (OR 0.70, 95% CI = 0.25-1.95, p = 0.496). Cheung et al. [27] also 
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evaluated neuropsychological measures, including reaction time variability, 
commission errors, omission errors, choice impulsivity, digit span forward, digit 




Clarke and colleagues [31] investigated thirty-eight boys diagnosed with 
ADHD and 38 controls, performing EEG assessments at a mean age of 9.8. 
They found that the ADHD group had a higher theta activity and decreased beta 
and delta activity compared to controls, and a higher theta/beta ratio, which was 
consistent with previous reports in the literature. The authors followed the 
individuals for 11 years until adulthood and had their ADHD status reassessed. 
Interestingly, those who outgrew the disorder had a baseline EEG pattern that 
was the most divergent from that of the control group, being responsible for 
most of the difference between ADHD and control groups reported at baseline. 
This could possibly mean that those whose symptoms are due to brain 
abnormalities that result in an altered electrical activity detected by the EEG 




Li and colleagues [32] evaluated the effect of two single nucleotide 
polymorphisms (SNPs) in the dopamine receptor D4 (DRD4) gene (rs1800955, 
rs916455) on ADHD persistence in a small Chinese sample of adults (n = 193). 
Although there was no evidence of association with the rs1800955 
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polymorphism, they found a significant effect of the rs916455 on ADHD 
persistence. After 11 years of follow-up, 56% of individuals carrying the T allele 
were considered remitters, compared to only 26.6 % of individuals not carrying 
this allele (HR = 1.03, 95% CI = 1.00-1.05, p = 0.018). Biederman and 
colleagues [33] examined the role of three candidates genes (DRD4, dopamine 
transporter - DAT1, and serotonin transporter - 5HTT), which had been 
previously associated with ADHD, on the course of this disorder. Authors 
aggregated data from three samples, encompassing 563 individuals. Survival 
analyses revealed no significant effects of polymorphisms in DAT1 (HR = 1.02, 
95 % CI = 0.68 -1.52, p = 0.923) and 5HTT (HR = 1.13, 95 % CI= 0.67-1.89, p = 
0.644) genes. However, a variable number of tandem repeats (VNTR) 
polymorphism in exon 3 of the DRD4 gene (DRD4 48bp-VNTR) was 
significantly associated with the course of ADHD (HR = 1.66, 95 % CI = 1.02-
2.69, p = 0.040). At the age of 25 years, 76% of the individuals carrying the 
DRD4 7-repeat allele still had the diagnosis of ADHD, while this same estimate 
was 66% in individuals not carrying this allele. 
 
Discussion 
 In many areas of medicine, the advance in the establishment of accurate 
prognosis for chronic disorders has led to meaningful improvements in the 
development of target intervention and personalized care.[34] ADHD, despite 
being one of the most studied health conditions[35], lacks such relevant clinical 
data. This is, to our knowledge, the first systematic review assessing risk 
markers for the persistence of ADHD from childhood into adulthood. We 
searched the literature in three databases reviewing more than 26,000 
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abstracts, searched the references of pre-selected studies, and contacted 
experts in the area of ADHD and follow-up studies to evaluate our final list and 
suggest missing references. Nonetheless, the literature proved to be scarce and 
asymmetric in the field: out of more than 20,000 articles published on ADHD 
only in Medline until April 20, 2015, we found only 16 studies that looked into 
the course of ADHD from childhood into adulthood focusing on risk factors – 
what represents 0.08% of the literature on the disorder. 
 Furthermore, the studies evaluated assorted factors that, in many cases, 
do not enable enough comparisons or meaningful conclusions. The role of 
comorbid ODD, for example, was investigated by four studies with divergent 
results. Other important issues, such as exposure to trauma, lifetime 
adversities, genetic factors, and perinatal factors, were evaluated by even fewer 
studies. However, meta-analytic techniques enabled some more solid and 
interesting conclusions. A severe presentation of ADHD, treatment for ADHD, 
and comorbid conduct disorder and major depressive disorder in childhood 
were significantly associated with persistence of symptoms into adulthood 
(Figure 2). These findings have important implications for clinical practice and 
research. Children with this profile could receive specialized care as they have 
a known tendency to persist with an impairing disorder throughout development. 
Meanwhile, researchers willing to develop preventive interventions could benefit 
from the present review to select children at risk for persistence.  
 The fact that ADHD treatment emerged as a risk marker of persistence 
was a surprising result. However, there are important issues involving this 
particular finding. For example,  it is self-evident that a child is more likely to 
receive treatment if presenting with a severe disorder, which was the most 
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consistent marker of persistence in our meta-analysis. On the other hand, two 
of the five studies included have found a significant association with treatment, 
which led them to run the analysis controlling for severity, and the effect did not 
disappear.[21,23] In this case, an alternative explanation for the observed 
phenomenon is that the instruments used to measure severity in those studies 
may not be so sensitive, neglecting some of the manifestations that makes a 
clinician inclined to start treatment. In addition, the overall effect has a high 
inconsistency index, which reflects the heterogeneity of the studies, especially 
in terms of design and factor definition.  
 According to our and meta-analysis, female gender was not associated 
with ADHD persistence into adulthood. Based on theoretical models of ADHD, 
we expected that female gender would emerge as a significant risk factor, since 
the male-to-female ratio in clinical samples goes from 3:1 in childhood to around 
1:1 in adulthood[36,37], suggesting that males had a tendency to outgrow the 
disorder, while females had a tendency to persist. Our results do not support 
this hypothesis. However, gender differences in externalizing disorders are 
influenced by treatment referral bias and are a good example of an analysis that 
would benefit from prospective, population-based designs. 
 Our findings should be interpreted under the light of limitations. The 
results of any systematic review and meta-analyses hinge on the 
methodological quality of included studies. Six of the studies included were 
retrospective and vulnerable to an increased recall bias. The other ten derived 
from clinical samples, making them subject to a higher selection bias. We have 
not found any prospective, population-based study that addresses the topic. 
Long-term follow-up studies are faced with issues of diagnosis definition: 
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children and adult evaluation made use of different criteria, challenging the 
interpretation of persistence. Furthermore, reports were limited by the set of 
factors available for assessment, as most studies were clearly not designed 
with the primary purpose of evaluating risk markers for the persistence of 
ADHD. Finally, we assessed risk marker for one possible trajectory of ADHD 
(i.e., from childhood to adulthood). Clinical cohorts of individuals with ADHD 
firstly diagnosed in adulthood and followed for several years also suggest that 
different risk factors might operate in determining persistence during this age 
range or that these patients represent a different subset in ADHD clinical 
samples [38]. 
 The present review identified an overlooked question of research in the 
ADHD literature. The current knowledge about risk markers of the course of 
ADHD is still unsatisfactory to guide clinical practice. We recommend that 
prospective, population-based cohort studies should address this issue. Such 
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Figure 2. Meta-analyses of selected* risk markers of ADHD persistence. 
 
 
ADHD Attention-deficit/hyperactivity disorder ODD Oppositional defiant disorder CD Conduct Disorder MDD Major 
depressive disorder. 
Note: All analysis used random-effects model to estimate weights of individual studies. Values of association of 
each study may differ of those reported in the text because of transformation to odds ratio even in prospective 
studies. 
* We selected markers when data from at least three studies were available to include in the meta-analysis. 
# For this analysis, we estimated odds ratios including two parallel samples by Biederman [19,20] that had similar 
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AIM: Few personalized medicine investigations have been conducted for mental health. We aimed to generate and 
validate a risk tool that predicts adult Attention-Deficit/Hyperactivity Disorder (ADHD). 
 
METHODS: Using logistic regression models, we generated a risk tool in a representative population cohort 
(ALSPAC – UK, 5113 participants, followed from birth to age 17) using childhood clinical and sociodemographic 
data with internal validation. Predictors included sex, socioeconomic status, single-parent family, ADHD symptoms, 
comorbid disruptive disorders, childhood maltreatment, ADHD symptoms, depressive symptoms, mother's 
Depression, and intelligence quotient. The outcome was defined as a categorical diagnosis of ADHD in young 
adulthood without requiring age at onset criteria. We also tested Machine Learning approaches for developing the 
risk models: Random Forest, Stochastic Gradient Boosting, and Artificial Neural Network. The risk tool was 
externally validated in the E-Risk cohort (UK, 2040 participants, birth to age 18), the 1993 Pelotas Birth Cohort 
(Brazil, 3911 participants, birth to age 18), and the MTA clinical sample (US, 476 children with ADHD and 241 
controls followed for 16 years from a minimum of 8 and a maximum of 26 years old).  
 
RESULTS: The overall prevalence of adult ADHD ranged from 8.1% to 12% in the population-based samples, and 
was 28.6% in the clinical sample. The internal performance of the model in the generating sample was good, with an 
Area Under the Curve (AUC) for predicting adult ADHD of .82 (95% confidence interval [CI], .79 to .83). 
Calibration plots showed good agreement between predicted and observed event frequencies from 0 to 60% 
probability. In the UK birth cohort test sample, the AUC was .75 (95% CI, .71 to .78). In the Brazilian birth cohort 
test sample, the AUC was significantly lower – 57 (95% CI, .54 to .60). In the clinical trial test sample, the AUC 
was .76 (95% CI, .73 to .80). The risk model did not predict adult Anxiety or Major Depressive Disorder. Machine 
learning approaches did not outperform logistic regression models. An open-source and free risk calculator was 
generated for clinical use and is available on-line at https://ufrgs.br/prodah/adhd-calculator/. 
 
CONCLUSIONS: The risk tool based on childhood characteristics specifically predicts adult ADHD in European 
and North-American population-based and clinical samples with comparable discrimination to commonly used 
clinical tools in internal medicine and higher than most previous attempts for mental and neurological disorders. 


















Attention-deficit/hyperactivity disorder (ADHD) is consistently associated with an increased risk of several adverse 
health and social outcomes, including poor education achievement, risky sexual behaviors and premature mortality  
(Cortese et al., 2013, Chang et al., 2014, Dalsgaard et al., 2015, Faraone et al., 2015). ADHD might begin in 
childhood and persist throughout adulthood, or it may remit spontaneously in around half of the cases (Caye et al., 
2016b). Recent evidence suggested that subthreshold symptoms can get worse over time, causing the emergence of a 
full-blown syndrome only in adulthood (Caye et al., 2017), although the topic is still under debate in the literature 
(Cooper et al., 2018, Manfro et al., 2018). Although some risk factors for the persistence or emergence of adult 
ADHD are known (Caye et al., 2016b, Caye et al., 2016c), the attending psychiatrist is currently unable to correctly 
predict the course of the disorder based on clinical assessments of children or to propose a preventive intervention 
for those at risk. 
One issue might be the inability to combine what is already known about risk factors. Although mental disorders 
arise from multiple risk factors, previous studies frequently define risk for targeted preventive interventions on the 
basis of a single risk factor, for instance, an affected first-degree relative or presence of subthreshold symptoms 
(Brent et al., 2015, Taylor et al., 2015, Buntrock et al., 2016). Meanwhile, multivariable risk scores such as the 
Framingham risk score for cardiovascular disease have been one of the main frameworks for the study of preventive 
strategies in other areas of medicine. 
Our aim was to develop and validate a multivariable risk calculator that estimates the individual risk of ADHD in 
late adolescence/young adulthood based on childhood characteristics. ADHD lends itself easily to the development 
of a risk calculator for the following reasons: First, its adverse health and social consequences are well established 
(Asherson et al., 2016). Second, it is widely accepted that its roots are in early childhood, although some argue the 
full syndrome might develop later in some individuals (Moffitt et al., 2015, Agnew-Blais et al., 2016, Caye et al., 
2016a). Third, being a neurodevelopmental disorder, early intervention has the potential to change brain 
development and improve later clinical outcomes (Shaw et al., 2006). Fourth, there is substantive evidence to 
support a priori hypotheses about specific childhood risk factors (Caye et al., 2016b). 
Method 
Our methods follow well-established probability models in medicine and recommendations of the Transparent 
Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement (Collins 
et al., 2015). We developed the predictive model in one a priori selected sample and validated it independently in 
three external samples (TRIPOD analysis type 3). We selected the Avon Longitudinal Study of Parents and Children 
(ALSPAC) cohort as the generating sample based on the following a priori defined criteria: population-based 
sample, largest sample.  
Samples and participants  
ALSPAC 
The (ALSPAC) is a prospective birth cohort study in the UK. Pregnant women with expected delivery dates 
between April 1st, 1991 and December 31st, 1992, were invited to participate. Ethical approval for the study was 
obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Further details 
on assessments can be found elsewhere (Boyd et al., 2013). Please note that the study website contains details of all 
the data that is available through a fully searchable data dictionary (http://www.bris.ac.uk/alspac/researchers/data-
access/data-dictionary/). For the current study, we included 5113 subjects that were assessed for ADHD in 
childhood (age 7 or 10) and in the last available assessment (age 17).  
E-Risk 
The Environmental Risk (E-Risk) Longitudinal Twin Study is a prospective birth cohort study designed to represent 
the UK population. In 1999-2000, investigators enrolled 1116 families with same-sex 5-year-old twins (N=2232) 
born from January 1st, 1994 to December 4th,1995 (Moffitt and Team, 2002). The study was approved by the Joint 
South London and Maudsley and the Institute of Psychiatry Research Ethics Committee, and parents gave informed 
written consent. Further details can be found elsewhere (Moffitt and Team, 2002). For the analyses, we included 




The 1993 Pelotas Birth Cohort is a prospective longitudinal birth cohort set in Brazil. In 1993, mothers of all 
children born in the city of Pelotas were contacted and 5249 children were enrolled. The study was approved by the 
institutional review board of the Federal University of Pelotas, and participants provided written informed consent. 
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Further information on the cohort design can be found elsewhere (Goncalves et al., 2014). For the current study, we 




The Multimodal Treatment Study of Children with ADHD (MTA) is the largest clinical trial and observational 
follow up conducted with children with ADHD. In the first phase of the study, investigators enrolled 579 children 
aged 7 to 10 years old with ADHD and assigned them to 14 months of one of four groups of management. Two 
years after baseline, 515 consented to enter an observational follow-up and a local normative comparison group of 
289 classmates (258 without ADHD) was added. Assessments were conducted at 12, 14, and 16 years after baseline. 
Informed consent (parental permission and child assent) was obtained for all participating families, using forms 
approved by both local institutional review boards and the NIH. Detailed design and methods have been presented in 
previous publications (1999). We included 717 subjects with any complete ADHD assessment in young adulthood 
(mean age 24). 
 
Assessment and definition of the outcome variable 
In each sample, the outcome was a dichotomous ADHD definition in late adolescence or young adulthood. In 
ALSPAC, participants’ parents completed the hyperactive subscale of the Strengths and Difficulties Questionnaire 
(SDQ-HS) at 17 years of age. The scale showed excellent discrimination against a DSM-IV diagnosis derived from 
the Development and Well-Being Assessment (DAWBA) conducted in a subsample of 1673 participants (AUC = 
89, 95% CI 81 to 96). The best cut-off score to define diagnosis was at least 6 points on the SDQ-HS (sensitivity = 
833%, and specificity = 833%). In the E-Risk, ADHD was ascertained at age 18 years using structured interviews 
based on full DSM-5 criteria (Agnew-Blais et al., 2016). In the MTA sample, ADHD symptoms were derived from 
the parents´ Conners Adult ADHD Rating Scale (CAARS). At least five DSM-5 symptoms of inattention and/or 
hyperactivity were required for the symptom criteria. Impairment was evaluated with the Impairment Rating Scale 
(IRS), which has strong psychometrics and accurately identifies impairment in adults with ADHD (Sibley et al., 
2012). This diagnostic approach was chosen because it has better diagnostic accuracy than a semi-structured 
interview in this sample (Sibley et al., 2017b). In the Pelotas cohort, trained psychologists interviewed the 
participants at 18 to 19 years old with a structured interview for ADHD based on DSM-5 criteria (Caye et al., 
2016a). A strict age-at-onset criterion was not required to define ADHD in young adulthood to take into account 
recent evidence suggesting a significant prevalence of late onset ADHD presentation (Moffitt et al., 2015, Agnew-
Blais et al., 2016, Caye et al., 2016a). 
Assessment and definition of predictor variables 
We selected the following predictor variables assessed in childhood: female sex, socioeconomic status (SES), 
mother’s depression, intelligence quotient, maltreatment, ADHD symptoms, depressive symptoms, oppositional 
defiant behavior and conduct disorders, and single parent family. All predictors were collected before age 12, with 
the exception of intelligence in Pelotas, which was measured at age 18. Their selection was based on extensive 
review of previous reports in the literature and a meta-analysis conducted by our group (Moffitt et al., 2015, Agnew-
Blais et al., 2016, Caye et al., 2016a, Caye et al., 2016b). We have included all variables that were available across 
the four samples with some level of comparability, without performing univariate analysis or stepwise techniques 
for variable selection. Definition of predictors was defined a priori according to relevant literature in the field. 




When developing a predictive model in multiple samples, a recommended approach consists in selecting and tuning 
the best model in one a priori selected sample and assessing its performance fo in the remaining independent 
samples for external validity. Because the evaluation of internal performance within the same sample where the 
model was derived is affected by overfitting, internal validation optimism correction should be performed. Among 
the most accepted techniques for internal validation is bootstrap resampling. 
We have developed the predictive model in the ALSPAC cohort. We ran a logistic regression including outcome 
(ADHD at last assessment) as the dependent variable and all eligible predictor variables as covariates. We inspected 
linearity assumptions of continuous variables by plotting the predictor and the logit of the outcome, and trough Box-
Tidwell regressions. We derived the model using linear splines of equal sample sizes (with knots at 25th, 50th, and 
75th percentiles) in the ADHD symptoms variable, and this model had better fit indexes (AIC, BIC). Multiple 
imputation with chained equations (10 imputations) using the remaining predictors was used to deal with missing 
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values in the predictor variables. We used a fixed number of 10 iterations and assessed convergence with trace plots. 
In the ALSPAC cohort, for each of the 1000 bootstrap resamples, we have performed pooled regression coefficient 
estimates and variance across imputations with the command mi estimate in Stata (Rubin, 1987). We evaluated the 
predictive discrimination of the probability model calculating the area under the receiver operating characteristic 
curve (c statistic) of the estimated probability against the actual outcome as an index of model performance. We 
have assessed optimism of internal validation with bootstrap inference using 1000 replications with the R package 
rms (Harrell et al., 1996). We have assessed internal and external model calibration with calibration curves, plotting 
predicted probabilities against observed frequencies. Extreme predictions at the right end of the distribution (highest 
risk) including less than 1% of the sample at risk were excluded of the calibration analyses to avoid instability of the 
estimates, and these ranges are not shown in each graph. Multiple imputation and model generation were conducted 
in Stata MP 13.0. Finally, we tested the predictive discrimination of the same predictors using Machine Learning 
approaches with the R package caret (see eMethods).  
We performed several sensitivity analyses to assess the robustness of our findings. We analyzed the performance 
(measured by the c-statistic) of the model among individuals who endorsed a very low number of ADHD symptoms 
at baseline (operationalized as equal or below the median of each population) in ALSPAC, E-Risk and Pelotas 
samples. We had also analyzed the performance (measured by the c-statistic) of the model excluding one variable at 
each time. Finally, we present the variation of the predicted probability within fixed levels of ADHD symptoms to 
assess the contribution of the remaining variables to the model. 
Results 
The number of participants with a dichotomous definition of adult ADHD and the frequency of childhood predictors 
in each sample can be found in Table 1.   
Performance of the predictive model in the generating sample 
All variables entered in the probabilistic model were used for the calculation of the estimated risk of the individual 
(Table 2). Only ADHD symptoms were corrected with splines. The predictive model discriminated between adult 
ADHD vs. no adult ADHD with an AUC of 82 (Bootstrap-corrected 95% CI, 80 to 83, p < .001), which indicates 
very good discrimination (Figure 1). Correction for optimism with bootstrapping yielded an AUC of 81. The 
calibration plot showed that predicted probability and observed frequency of adult ADHD closely agreed throughout 
the entire range of risk (0 to around 50% - Figure 2). The bias-corrected calibration curve was nearly identical 
(eFigure 1). The AUC varied within a range of 74 to 82 in sensitivity analyses taking out one predictor at a time 
(eTable 2 in Supplemental material). Proposed probability cut-offs are presented with sensitivity, specificity, 
positive predictive value and negative predictive value in eTable 3 in Supplemental material. 
Performance of the predictive model in a validating cohort sample in the same country 
In the E-Risk study, the predictive model discriminated between adult ADHD vs. no adult ADHD with an AUC of 
75 (Bootstrap-corrected 95% CI, 71 to 78, p < .001), which indicates fair discrimination (Figure 1). The 
calibration plot showed reasonable agreement between predicted and observed event frequencies, especially in the 
lower range of risk (Figure 2). The discrimination was the same when restricting the sample to randomly selected 
non-siblings (eTable 4 in Supplemental material).  
Performance of the predictive model in a validating sample in a middle-income country 
In the Pelotas cohort, the predictive model discriminated between adult ADHD vs. no adult ADHD with an AUC of 
57 (Bootstrap-corrected 95% CI, 55  to 60, p < .001), which indicates poor discrimination (Figure 1). There was 
low agreement between estimated probability and observed frequency of the outcome (Figure 2). 
Performance of the predictive model in a validating clinical sample in a country with similar income 
In the MTA, the predictive model discriminated between adult ADHD vs. no adult ADHD with an AUC of 76 
(Bootstrap-corrected 95% CI, 73 to 80, p < .001) (Figure 1). The calibration plot showed that predicted probability 
and observed frequency of adult ADHD closely agreed throughout the entire range of risk (0 to around 70% - Figure 
2), although the model had underestimated event frequency consistently. 
Performance of the predictive model within participants with very low endorsement of ADHD symptoms in 
childhood 
We tested the performance of the model for predicting late-onset ADHD in population samples, among only 
participants that endorsed few ADHD symptoms in childhood – the median or lower number of symptoms in their 
respective populations. The model had fair discrimination in these subgroups, except for the Pelotas sample in which 
the model already had poor discrimination (Table 3).  
Performance of the predictive model removing one predictor at a time 
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We tested the model taking out one predictor at a time (eTable 2). The most relevant individual predictor was the 
level of ADHD symptoms in childhood. However, the model still had fair performance in the model without ADHD 
symptoms in childhood, with an AUC of 74 (95% CI, 72 to 76, p < .001).  
Variation of the predicted probability within fixed levels of ADHD symptoms 
We assessed the predicted probabilities of an adult ADHD diagnosis at any fixed level of ADHD symptoms, 
considering maximum variation of the remaining factors (see eFigure 2). The observed variance indicates that 
ADHD symptoms are not the only relevant predictive factor in the model. These findings analyzed together clearly 
indicate that this is not a model based on just one variable.     
Specificity of the predictive model in predicting ADHD 
Considering that E-risk is the population cohort with the most comprehensive assessment of comorbid mental 
disorders, we tested model’s discrimination predicting adult Anxiety and Major Depressive Disorder. The 
performance was significantly lower than for ADHD, showing specificity for ADHD compared to other forms of 
adult psychopathology (eTable 5 in Supplemental material). 
Risk calculator and robustness of findings  
Predictive discrimination estimates using three different machine-learning approaches were almost the same (see 
eTable 6 in Supplemental material). In a secondary analysis, we also have developed one comprehensive predictive 
model with all samples at once, using site as one more predictor variable (see eTable 7; eFigure 3). A risk calculator 
can be found at http://www.ufrgs.br/prodah/adhd-calculator/.  
Discussion 
The widespread use of tools that predict clinical outcomes in medical practice has promoted development and 
testing of preventive interventions, but this approach has been rarely attempted for mental health (Bitton and 
Gaziano, 2010). We generated a probability model to predict adult ADHD in a large birth cohort in the UK, with 
very good discrimination – AUC of 81 after optimism correction – and calibration. This performance compares to 
the most used clinical tools in Medicine (Morrow et al., 2000). Recent attempts for mental health reported risk 
scores with good calibration (Fusar-Poli et al., 2017, Hafeman et al., 2017). These studies lacked, however, a 
consistent external validation with completely independent samples.  
Our next step was to validate the score in independent samples. First, we tested the score in another UK birth cohort, 
the E-Risk. Its performance for predicting adult ADHD was similar. This is an important finding because several 
risk models in mental health did not replicate well even in samples from similar settings (Kivipelto et al., 2006, 
Anstey et al., 2014). Since data generated in population samples frequently do not translate to clinical samples 
(Weissman et al., 2011), we tested the performance of the score in the MTA study, the largest clinical trial ever 
conducted for ADHD. As for ALSPAC and E-risk, the score worked well with good discrimination and calibration.  
We then tested the score in a third birth cohort from Brazil. We observed that the score was much less accurate with 
an AUC of 57. This finding is not surprising, since previous evidence suggests that the predictive discrimination of 
risk tools is lower in diverse sociocultural and ethnic populations (Chia et al., 2015). However, since predictor 
factors assessment in Pelotas was the most heterogeneous, observed low discrimination might have been an effect of 
measurement error.  
Models that predict a diagnosis of chronic disorders often include premorbid signs and symptoms of the disease as 
predictive factors. For example, the factor that increased discrimination the most in the recently published calculator 
for psychosis was the index diagnosis when presenting to secondary care, where Psychotic disorders had the greatest 
weight compared to other disorders such as mood disorders (Fusar-Poli et al., 2017). Although this is a valid 
approach, other variables must also add to prediction, otherwise models would be tautological. Therefore, we also 
validated the score in subjects with low endorsement of ADHD symptoms in childhood. The performance was good 
even in this sensitivity analysis. In addition, we assessed probabilities of an adult ADHD diagnosis at any fixed level 
of ADHD symptoms, allowing maximum variation of the remaining factors. Finally, we checked discrimination of 
the model removing each factor at once. Findings suggested that although ADHD symptoms are the most important 
overall predictor, the complete model works as a necessary refinement and a model without ADHD symptoms has 
good discrimination as well.  
We also conducted other secondary analyses to assess robustness of our findings. We tested the impact of using 
other statistical methods on our results. We observed that the discrimination of the prediction models remained 
stable regardless of chosen statistical methods. Finally, we tested the hypothesis of whether the score was specific 
for the prediction of ADHD. This is an important proof-of-concept: personalized medicine has always been a 
challenge for the area of psychiatry, as it has been shown consistently that most identified biomarkers and risk 
factors associated with one mental disorder are also associated with several others (Cross-Disorder Group of the 
Psychiatric Genomics et al., 2013). We observed that the score was specific for ADHD, not predicting Major 
Depressive Disorder or Anxiety Disorders.  
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Previous cohort investigations included in the present study did not find significant childhood DSM dichotomous 
ADHD diagnosis in the trajectory of late onset ADHD (Agnew-Blais et al., 2016, Caye et al., 2016a). Thus, it might 
seem surprising that childhood ADHD symptoms predict adult ADHD. The MTA report also highlighted the 
importance of child ADHD subthreshold symptoms in adult ADHD in cases where formal DSM diagnosis were not 
found in childhood (Sibley et al., 2017a). Since this approach was not the main focus of previous cohort studies 
(ADHD subthreshold symptoms), this might explain why childhood ADHD symptoms predict adult ADHD even in 
cohorts where childhood dichotomous diagnosis was not relevant for adult ADHD.  
Our findings should be interpreted considering a set of limitations. First, the design and assessments of different 
samples were not uniform, limiting the discrimination of the score in the validating samples. Adult ADHD, for 
instance, was measured with a scale rather than with a structured interview in the generating sample, but not in the 
validating samples. It is possible, therefore, that the proposed estimated predictive discrimination in validating 
samples might actually be an underestimation. Further validating efforts with assessments that more closely 
resemble those of the generating sample might observe higher AUCs. However, this could also be seen as strength 
of the study, since observed discrimination indices are considered good, even with different methodologies 
implemented in individual studies. Second, there was attrition in the generating sample’s assessments. Nevertheless, 
potential selection bias does not appear to affect the prediction of outcomes in this cohort, as shown in previous 
publications (Boyd et al., 2013). Also, we have used multiple imputation techniques to deal with missing values. 
Third, the observed positive predictive value in selected cut-offs reaches a maximum of 618%, while the negative 
predictive value is much higher throughout prediction. Although this might be considered insufficient, we ought to 
remember that the positive predictive value depends much on the prevalence of the studied condition, and we are 
working with population-based samples where the base rate of the condition is low. As a comparison, the 
Framingham risk score, that is also a tool developed in the general population, yields a positive predictive value of 
up to 30-40%. The risk score for Bipolar Disorder reports a positive predictive value of up to 32%, even among 
offspring of Bipolar patients (a high-risk sample). Fifth, it is important to note that other variables that are related to 
ADHD could have been part of the risk score like prematurity and ADHD in first degree relatives. However, they 
were not available for testing in the 4 data sets and our guide for risk factors was evidence-based guided by a 
previous meta-analysis (Caye et al., 2016b). Accordingly, the predicted probability provided by the model should be 
considered an estimate probability obtained with a pre-specified set of variables. 
What is the clinical utility of this score, provided that previous literature already has shown that most variables 
included in our model that are non-specific risk factors for mental disorders and ADHD symptoms in childhood, as 
expected, are key predicted risk factor for adult ADHD? No previous effort combined all these variables in a single 
risk calculator. Therefore, the only information that clinicians could offer was that some variables, like comorbidity 
with CD/ODD in childhood, increase the risk of persistence of ADHD. By using this calculator, attending clinicians 
can identify high-risk individuals to inform parents and guide decisions.  
Thus, we propose a multivariable risk model to predict ADHD in young adulthood based on childhood factors that 
has good discrimination in both population and clinical settings. Clinicians can use the model to guide long-term 
decisions based on identification of children at high risk for future adult ADHD diagnosis. Also, it provides a 
framework for testing the effectiveness of preventive interventions focused on high-risk individuals. Furthermore, 
the score might be used to identify at-risk individuals for investigating neurobiological features including brain 
development. The lower discrimination observed in a middle-income country urges the discussion of how globally 
generalizable are the risk models that are currently being widely used in clinical practice.  Indeed, even the well-
established Framingham cardiovascular risk model is being subjected to criticism for its wide variation in 
performance across different populations. Therefore, future attempts to improve the current model should include 
setting-specific recalibration analyses that should then be translated to specific risk calculators to be used across 
different settings. Also, we suggest that cohorts use more standardized methods of collection of predictors and 
outcomes in Psychiatry for the study of risk factors, so that we can disentangle whether failure to replicate is due to 
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Table 1. Frequency of young adulthood ADHD and of childhood predictors across the four samples 
 ALSPAC 
(n = 5113) 
E-Risk 
(n = 2040) 
MTA  
(n = 717) 
Pelotas 
(n = 4039) 
Adult ADHD 486 (95%) 166 (81%) 205 (286%) 492 (122%) 
Female sex 2619 (512%) 1071 (525%) 153 (213%) 2061 (510%) 
Socioeconomic status     
Upper 868 (186%) 401 (197%) 136 (189%) 763 (196%) 
Middle 2172 (464%) 966 (475%) 356 (507%) 1775 (456%) 
Lower 1637 (350%) 665 (327%) 210 (299%) 1358 (349%) 
Single parent 519 (118%) 450 (226%) 190 (265%) 882 (227%) 
ODD or CD 157 (34%) 602 (295%) 304 (436%) 275 (70%) 
Maltreatment     
Not detected 2084 (410%) 1609 (789%) 384 (553%) 2475 (670%) 
Probable 2568 (505%) 312 (153%) 279 (401%) 672 (183%) 
Severe 430 (85%) 119 (58%) 32 (46%) 548 (148%) 
Lifetime Depression of 
the mothera 
1850 (363%) 990 (485%) 326 (482%) 1881 (484%) 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) 
IQ 1069 (163) 989 (156) 1031 (195) 965 (125) 
 Median (IQR) Median (IQR) Median (IQR) Median (IQR) 
Depressive Symptomsb 0 (1) 1 (2.5) 54 (67) 4 (4) 
Number of ADHD 
symptomsc 
2 (6) 15 (33) 83 (96) 4 (5) 
 
 
ADHD Attention-deficit hyperactivity disorder ODD Oppositional Defiant Disorder CD Conduct disorder 
SD Standard deviation IQR Interquartile range IQ Intelligence quotient 
a. Definition of lifetime depression of the mother was designed to be very sensitive, either by multiple 
assessments and/or by applying a very low threshold (further details on Table S1 of Supplementary 
material). 
b. ALSPAC: Number of DSM-IV depressive items endorsed. E-Risk, MTA: Children’s Depressive Inventory 
(CDI) score. Pelotas: Emotional subscale score of the SDQ. 
c. ALSPAC, E-Risk, MTA: number of DSM-IV ADHD items endorsed. Pelotas: Hyperactivity subscale score 
of the SDQ. 
Note: reported values before multiple imputation. Because each factor may have missing values, we report total 
number of participants and a proportion where the denominator is the total number of valid subjects. 
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Table 2. The probability model in the generating sample (n = 5113) 
Predictors OR (BC 95% CI) BC p-value 
Female sex 72 (58 - 89) 003 
Socioeconomic status - - 
Upper social class reference - 
Middle social class 158 (115 – 216) 004 
Lower social class 155 (111 – 215) 010 
Single parent family 119 (90 – 158) 215 
ADHD symptoms – 0-25th  377 (209 – 679) < 001 
ADHD symptoms – 25-50th 119 (102 – 140) 031 
ADHD symptoms – 50-75th 113 (105 – 122) 001 
ADHD symptoms – 75-100th  118 (112 – 125) < 001 
ODD or CD 181 (121 – 271) 004 
Childhood maltreatment - - 
No detected maltreatment reference - 
Probable maltreatment 128 (101 – 164) 045 
Severe maltreatment 135 (93 – 195) 115 
Depression of the mother 141 (113 – 175) 002 
Intelligence quotienta  89 (85 -  95) < 001 
Depressive symptoms (z-score)b 100 (92 – 110) 940 
 
OR Odds Ratio; ODD Oppositional Defiant Disorder; CD Conduct Disorder; ADHD 
Attention-deficit hyperactivity disorder 
BC Bootstrap-corrected 
a. We report the OR for a 10-point change in the intelligence quotient scale. 






Table 3. Performance of the score for individuals with very low ADHD childhood symptoms. 
 AUC BC 95% CI BC p-value 
ALSPAC (n = 2688) 77 72 – 82 < 001 
E-Risk (n = 1099) 78 71 - 86 < 001 
Pelotas (n = 2135) 56 52 - 60 < 001 
 
BC Bootstrap-corrected  
ROC analyses were done only in participants with low endorsement of ADHD symptoms in childhood. Low 
endorsement was defined as median number of symptoms or below the median of their respective population 
(ALSPAC: 2 or less ADHD symptoms; E-Risk: 1 or 0 ADHD symptoms; Pelotas: the median or less than 
median (4) in the hyperactivity subscale of the SDQ). 
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a. With respect to specific objectives d. Systematically review the literature on relative 
immaturity and ADHD, and summarize its effect with meta-analytic techniques and e. 
Investigate the issue of the relative immaturity effect and ADHD on three independent 































As páginas seguintes desta tese foram suprimidas, pois o artigo de número 4 ainda 






























h. With respect to specific objective f. Review the literature on methodological challenges 
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ABSTRACT:  
There is a renewed interest in better conceptualizing trajectories of Attention-
Deficit/Hyperactivity Disorder (ADHD) from childhood to adulthood, driven by an 
increased recognition of long-term impairment and potential persistence beyond 
childhood and adolescence. This review addresses the following major issues 
relevant to the course of ADHD in light of current evidence from longitudinal 
studies: 1) conceptual and methodological issues related to measurement of 
persistence of ADHD; 2) estimates of persistence rate from childhood to 
adulthood and its predictors; 3) long-term negative outcomes of childhood 
ADHD and their early predictors, and 4) the recently proposed new adult-onset 
ADHD. Estimates of persistence vary widely in the literature, and diagnostic 
criteria, sample characteristics and information source are the most important 
factors explaining variability among studies. Evidence indicates that ADHD 
severity, comorbid conduct disorder and major depressive disorder, and 
treatment for ADHD are the main predictors of ADHD persistence from 
childhood to adulthood.  Comorbid conduct disorder and ADHD severity in 
childhood are the most important predictors of adverse outcomes in adulthood 
among children with ADHD. Three recent population studies suggested the 
existence of a significant proportion of individuals who report onset of ADHD 
symptoms and impairments after childhood. Finally, we highlight areas for 
improvement to increase our understanding of ADHD across the life span. 
 




Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurobiological disorder 
characterized by a persistent and impairing pattern of inattentive, hyperactive, 
and/or impulsive symptoms [1]. Meta-analyses suggest prevalence rates around 
5 to 7.1% in childhood and 2.5 to 5% in adulthood [2-4]. The disorder is 
associated with adverse outcomes for affected individuals, their families and 
society in general [5]. 
There is recent interest in better conceptualized adult ADHD [6] and its 
trajectories from childhood to adulthood [5]. A previous meta-analysis found that 
only 15% of diagnosed children continued presenting full ADHD diagnosis in 
adulthood, although 65% presented with a subsyndromal phenotype [7]. This 
figure would suggest a much lower adult ADHD prevalence rate (15% of 5-7% = 
0.8-1.1%) than what has been detected both in meta-analyses (2.5%-5%) [3, 4] 
and in a multi-national study on ADHD prevalence in adults (3.4%) [8]. There is 
a current debate about reasons for this discrepancy. Some investigators 
suggest that the 15% persistence rate is a clear underestimation due to change 
of informants between adult and child assessments and inadequacy of the 
ADHD diagnostic criteria for adults. Major aspects of both the ADHD phenotype 
and its impairments might be different in adults, and other approaches to define 
persistence, like cognitive and social dysfunction, are lacking in the literature.[6] 
In addition, controversies also exist surrounding new findings suggesting an 
unexpected ADHD trajectory. Three recent population studies found a 
substantial number of individuals with onset of clinically significant ADHD 
symptoms and impairments after childhood, challenging the established notion 
of ADHD as exclusively a childhood-onset neurodevelopmental disorder. [9-11] 
This narrative review of the literature addresses the following topics that might 
increase our understanding about these discrepant findings: a) conceptual and 
methodological issues inherent to the study of ADHD trajectories; b) data on 
persistence rates from longitudinal ADHD studies; c) predictors of ADHD 
persistence from childhood to adulthood; d) child and adolescent predictors of 
adult ADHD negative outcome; e) new adult-onset cases and their predictors.  
 
CONCEPTUAL AND METHODOLOGICAL ISSUES INHERENT TO THE 
STUDY OF ADHD TRAJECTORIES 
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a) ADHD Diagnosis 
In the last 50 years, the diagnostic criteria for ADHD from DSM-II to DSM-5 
have been modified [1, 12, 13]. Previous work has demonstrated that use of 
different diagnostic criteria is one of the major factors influencing variability in 
ADHD prevalence rates worldwide over the last three decades [2, 14]. ADHD 
persistence is the proportion affected by the diagnostic definitions in childhood 
(denominator) who also meet the definition in  adult life (numerator) [6,9]. A birth 
cohort study with assessments of the disorder from childhood to adulthood (15) 
provided different ADHD persistence rates depending on the diagnostic system 
used on multiple follow-up waves [15]. An adult norm-based diagnostic 
approach yielded the highest persistence rate compared to any other 
approaches (29.3% against 11.2% to 13.8% for strict criteria definitions). While 
some studies assessed individuals at baseline in childhood for ADHD using 
previous classifications (DSM-II, DSM-III) [16-21], others used more 
contemporary systems such as DSM-IV [11, 22, 23]. Assessments at follow up 
are likewise a source of heterogeneity in persistence estimates: studies have 
used DSM-III [17, 24], DSM-IV [15, 20, 21, 25], and DSM-5 [9, 11] criteria to 
determine ADHD diagnosis in adulthood. Differences of criteria may occur even 
in a same study in longitudinal assessments.  
 
One study evaluated how differences in case definition might impact 
persistence estimates in the 16-year clinical follow-up of the Multimodal 
Treatment Study of ADHD (MTA) [26]. Persistence estimates varied widely from 
1.9% (requiring DSM-IV criteria, combining parent and self-report in the 
Diagnostic Interview Schedule for Children (DISC) with an item-level AND rule) 
to 61.4% (requiring norm-based symptom count, combining parent and self-
report in the DISC with an item-level OR rule). Based on findings from a ROC 
analysis of impairment, the authors concluded that the best combination of 
sensitivity and specificity was achieved using a norm-based threshold of four 
symptoms from either list (more than two standard deviations above the mean 
of the local normative comparison group) assessed with rating scales and 
combining parental and self-report information with an item-level OR rule. This 
approach yielded a persistence rate of 60% for symptoms and 41% for 
symptoms with impairment.  
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Although the presence of impairment has been required by the successive 
revisions of diagnostic criteria for ADHD, the level of impairment required is not 
unanimous. The level of impairment substantially affects variability in ADHD 
prevalence rates worldwide and across the last three decades [2, 14]. Using full 
DSM-5 criteria, a recent population study assessing ADHD prevalence in adults 
[27] found a rate of 3.55% (95%CI 2.98–4.12%) for at least moderate 
impairment, but only 1.4% for severe clinical impairment. Thus, diagnostic rates 
vary substantially from one study to another depending on the level of 
impairment required for diagnosing the disorder at baseline and endpoint, [28].  
 
Another conceptual issue is the source of impairment, which has varied 
across studies. Some studies used general measures of impairment, such as 
the Clinical Global Assessment Scale [29], Clinical Global Impression Scale 
[30], or the Global Assessment of Functioning [31], while others used measures 
that specifically assess impairment derived from ADHD symptoms, such as 
questions included in ADHD modules of structured or semi-structured 
diagnostic instruments [11, 20, 21]. Instruments created to assess impairment 
specifically related to ADHD, as the Barkley Functional Impairment Scale (BFIS) 
were also used [22]. Two paramount clinical follow-ups, the multimodal 
treatment Study of children with ADHD (MTA) [26] and the Pittsburgh ADHD 
Longitudinal Study (PALS) [32], used the Impairment Rating Scale (IRS) 
proposed by Fabiano et al for children with ADHD. [33] Although it is 
questionable whether the source of impairment can be clearly specified when 
comorbidity is the rule, persistence rates ascertained by different instruments, 
even for the same level of impairment, may be substantially different. 
              
b) Sample characteristics 
The origin of the sample (community or clinical) affects prevalence rates and 
clinical correlates of psychiatric disorders [34]. Clinical samples of individuals 
with ADHD in general include more severe cases than population samples and 
thus, report increased comorbidity [35]. Part of this increased morbidity is 
expected according to the “Berkson’s Bias”, a mathematical bias due to 
restricting the sample to those individuals seeking clinical treatment and 
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showing greater levels of severity and comorbidity [34, 36]. Thus, it is not 
surprising that ADHD persistence rates appear to be higher in clinical samples 
[18, 22, 23, 28] than in population-based samples [9-11]. Barriers to health 
services across countries also affect persistence rates. It is expected that 
clinical samples will select more severe and socially deprived cases in countries 
with accessible health care like the UK or Scandinavian countries. [37] 
 
Additionally, retention rate is related to selection bias [38] affecting the 
representativeness of the sample, especially in population-based samples.  A 
population-based sample with a substantial amount of participants lost to follow-
up might underestimate persistence rates, since severe cases may have a 
higher risk of persistence and a higher risk of not attending several longitudinal 
assessments. [39].  
         
c) Demographic aspects 
Longitudinal ADHD studies assess individuals at different ages both at 
baseline in childhood and end point during adulthood [11, 40]. Considering the 
general trend that prevalence rates of ADHD decrease across the life cycle, 
regardless of the criteria used (see Faraone, Biederman, and Mick, [7]), age at 
assessment might be another factor influencing persistence rates. The literature 
shows that ADHD prevalence in adolescence is about half of that in childhood 
[2], and prevalence estimates continue to decrease in adulthood. This has been 
illustrated most clearly by a long ADHD follow-up study that assessed 
participants with childhood-onset ADHD at different time points in adulthood. 
The prevalence of ADHD declined to 43% at 18 years of age and 22% at 41 
years (Mannuzza et al. [17]; Klein et al. [41]). In addition to attrition, these 
studies used different informants and diagnostic criteria classifications at 
different assessment points in adulthood, making it unclear whether the 
decrease in rate was mainly due to age or methodology. Regardless, age at 
entry into the study and age at endpoint clearly affect reported persistence 
rates. 
  
The literature in general also suggests that females might have a higher 
persistence rate than males, as well as more negative outcomes in adulthood 
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[42], although this could not be confirmed in the MTA sample. This sex 
difference might be responsible in part for the lower, in some studies absent, 
male/female preponderance during adulthood (see Matte et al. [27]; Vitola et al., 
personal communication). Thus, the proportion of females in the study may 
affect the observed persistence rate. This might be even more important in 
studies reporting persistence rates based on samples composed exclusively of 
males or females [17, 20, 21]. However, these differences might also be due to 
higher severity, comorbidity or adverse social background of girls diagnosed 
with ADHD compared to boys, instead of being only determined by gender.  
 
d) Informants  
Who is reporting the information is a major factor explaining heterogeneity in 
worldwide ADHD prevalence in childhood and adolescence [2]. The agreement 
between parents and teachers on ADHD symptoms is low in childhood, and the 
literature indicates that children tend to underreport their ADHD symptoms [5]. 
Consequently, the choice of the informant in childhood impacts the estimate of 
prevalence, and changing sources may impact estimates of persistence. As a 
complication, this informant effect may differentially influence various aspects of 
ADHD diagnostic criteria (e.g., either symptoms or impairment).  
Although some reports suggest good inter-rater reliability between adult self-
report and parent reports of childhood and adulthood symptoms [43], others 
documented that neither are reliable for retrospectively reporting ADHD 
symptoms in childhood [9, 44]. In adult clinical studies, parents or relatives that 
knew the individual during childhood tend to report retrospectively fewer 
childhood ADHD symptoms than adult retrospective self-reports [32, 45], the 
opposite of adult current report on symptoms and impairments [26, 42].  
Thus, persistence rates will depend heavily on which information source was 
selected during childhood and adulthood. This is especially important because 
some studies change information source from the parent source in childhood to 
affected individual (self) source in adulthood, potentially artificially deflating 
persistence rates [9-11]. 
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DATA ON PERSISTENCE RATES FROM LONGITUDINAL ADHD STUDIES 
FROM CHILDHOOD TO ADULTHOOD 
Based on the issues discussed above, it is not surprising that ADHD 
persistence rates from childhood to adulthood vary substantially among studies 
(Figure 1). The figure shows estimates of full ADHD diagnostic persistence 
reported by longitudinal studies that followed children to a mean age of at least 
18 years. A comparison of the extremes is informative. The lowest rate detected 
was 4% in a clinical study in the US [17]. This study followed referred boys 
diagnosed with DSM-II hyperkinetic disorder at ages 5 to 11 years and 
reassessed their ADHD status 17 years later with DSM-III-R criteria. Potential 
factors responsible for this low rate include: 1) The sample was composed 
exclusively of males (see below); 2) Patients with comorbid conduct disorder at 
baseline were excluded; 3) Change of diagnostic system and assessment 
approach: DSM-II with clinical interview at baseline and DSM-III-R with 
structured interview at follow up; 4) Requirement of endorsement of childhood 
ADHD symptoms and impairment at follow up to diagnose adult ADHD; 5) The 
strict use of a DSM threshold instead of a norm-based approach. The authors 
emphasize that recall bias might have constrained the persistence rate (see 
Klein et al. [41]). The highest ADHD persistence rate found was 76% in the UK 
study by Cheung and colleagues [22]. Authors followed children and 
adolescents (mean age 11.8, 87% males) with ADHD combined type (DSM-IV) 
criteria for 6.6 years. Factors that might be responsible for this very high rate 
include: 1) A short follow-up time; 2) Similarity of assessment in the two time 
points, using DSM-IV and a structured interview and no change of information 
source (parent report); 3) A clinical sample composed of only ADHD combined 
type (see below); 4) relatively young age at follow up .  
 
PREDICTORS OF ADHD PERSISTENCE FROM CHILDHOOD TO 
ADULTHOOD 
The comprehensive review of persistence rates found few studies that report 
factors in childhood related to the course of symptoms into adulthood. A recent 
systematic review and meta-analysis summarizing the findings thus far 
concluded that available reports are heterogeneous and hard to combine [46]. 
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However, a meta-analysis of predictors assessed and reported by at least three 
studies is summarized in Table 1. 
Characteristics of the clinical syndrome were the most consistent risk factor for 
persistence: comorbid conditions like Conduct Disorder (CD) and Major 
Depressive Disorder (MDD), severe ADHD, and treatment for ADHD are 
associated with ADHD persistence. The finding that ADHD treatment is a risk 
factor for persistence is not surprising, since the most severe cases are 
selected for treatment. Barriers to health care may influence this finding; lack of 
access to treatment might be a marker of environmental or socioeconomic risk 
factors (e.g, ethnic minorities or living in an area with limited resources [47, 48]. 
Importantly the two studies that found the effect of ADHD treatment adjusted 
their findings for disorder severity, but possibly the treatment-severity 
relationship was not fully captured by the instruments used. A clinical study that 
followed individuals for 5 years after a 12-month randomized clinical trial found 
that medication adherence was related to greater improvement but higher end-
point symptoms, while symptom severity at baseline was the most important 
single predictor of persistent symptoms at follow-up [49]. Disentangling this bias 
adequately would require a randomized clinical trial with good adherence and 
retention for several years comparing outcome between allocated groups at 
baseline. However, maintaining adherence to assigned treatment over long 
periods may not be possible. 
An analysis of the MTA evaluated childhood factors influencing persistence of 
ADHD into adulthood at a mean age of 24.7 years [50]. ADHD symptom 
severity, comorbidities, and parental mental health problems were the most 
important risk factors for persistence, while childhood IQ, socioeconomic status, 
parental education and parent-child relationships showed no association with 
persistence. These findings are, in general, similar to what was reported in the 
meta-analysis (see Table 1). However, treatment assignment was not evaluated 
as a risk factor, having been found in previous reports to have lost significant 
association with symptom severity by 3 years [51, 52].  
 
EVALUATION AND PREDICTION OF TRAJECTORIES OF ADHD 
SYMPTOMS 
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Another possible approach to evaluate persistence and remission is to 
investigate trajectories of symptoms rather than categorical diagnosis. Since 
few studies using this approach followed subjects from childhood to adulthood, 
we also included studies where the last assessment was in late adolescence in 
this section.  
One study evaluated baseline differences between trajectories of ADHD 
symptoms (persistently high compared to declining) through grades 3 to 12, 
when participants are expected to be 17 or 18 years old [53]. Participants with a 
more chronic trajectory were more aggressive and more hyperactive at school, 
and more emotionally dysregulated at home than their peers with a declining 
trajectory of ADHD symptoms. The investigators also reported a more stable 
pattern of inattentive symptoms compared to hyperactive symptoms, a finding 
that was reported in previous studies [54].  In a different study, 8395 twin pairs 
were assessed for ADHD at ages 8, 12, 14 and 16 with a DSM-IV ADHD 
symptom subscale. [55] Consistent with population-based and clinical studies, 
there was a general decline of symptoms across ages, and inattentive 
symptoms persisted more than hyperactive/impulsive symptoms. Authors 
reported important inter-individual differences in the developmental course of 
symptoms, mostly explained by genetic influences independently of baseline 
severity. Another study (Howard et al, 2016) showed protective effects related 
to parenting and attendance in college that were manifested in the transition 
from adolescence to adulthood [56]. In the adult assessment of the MTA, a 
dimensional outcome based on symptom-severity showed a large difference 
between the overall ADHD group and comparison group. However, neither 
initial random allocation to treatment with medication nor self-selected, 
extended use of medication significantly predicted adult outcomes on this 
variable within the ADHD group (Swanson et al., personal communication).  
The Avon Longitudinal Study of Parents and Children, a large birth cohort in the 
UK, analyzed factors associated with latent-class trajectories of ADHD 
symptoms  age 4 to 17 years. The persistent class (3.9% of the sample and 
40.2% of participants with high childhood scores ) had mostly males (72.9%) 
and higher conduct problems, language impairments, and social-communication 
problems and lower IQs. Also, the persistent group had higher ADHD genetic 
liability as indexed by ADHD polygenic risk scores, whereas other psychiatric 
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genetic risk scores (schizophrenia, bipolar disorder and depression) were not 
associated with trajectories (Riglin et al, personal communication). 
  
PREDICTORS OF ADULT ADHD DELETERIOUS OUTCOMES THAT CAN 
BE DETECTED IN CHILDHOOD AND ADOLESCENCE 
There is substantial evidence documenting adverse outcomes for those affected 
by ADHD compared to those without the disorder [5, 6]. ADHD affects a wide 
range of functional domains including academic, social, and occupational 
contexts. Studies have documented lower academic achievement [57, 58], 
higher unemployment, and lower income for probands with ADHD followed into 
adulthood [28, 59, 60]. The risk of substance use disorders (SUD) and 
antisocial personality disorder is higher in patients with ADHD than in non-
affected individuals [61-65]. Individuals with ADHD are more likely to have traffic 
accidents than the general population [66-68]. Other documented outcomes 
include obesity [69, 70], dysfunctional family relationships [28, 71] and 
emotional dysregulation [72]. These functional impairments may result in 
reduced perception of well-being [73] and be related to adverse outcomes like 
higher overall mortality rates in individuals with current or past ADHD diagnosis 
[74]. A comprehensive meta-analysis has confirmed a longitudinal association 
of childhood ADHD with adverse outcomes, the most relevant being mental 
disorders and substance abuse, academic and professional underachievement, 
criminality, and risky driving behaviors [75]. The 16-year follow-up of the MTA 
showed that adverse outcomes in education, work, and risky sexual behavior 
were associated with ADHD and symptom persistence; the risk increases in a 
progressive fashion: the local normative comparison group (LNCG) had the 
lowest risk, symptom-persistent ADHD the highest, with symptom-desistent 
ADHD in between. For emotional outcomes, like anxiety and depression, there 
difference was not significant between those whose symptoms remitted and the 
LNCG, while both were doing better than ADHD persisters. Alcohol use and jail 
time did not differ significantly across any of the groups assessed, probably 
because alcohol use was so common and jail time so rare [76].  
Although these adverse adult outcomes associated with ADHD are 
unquestionable, much less clear are their childhood predictors. Several factors 
have been suggested as influencing the outcome in ADHD subjects, like the 
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clinical profile (ADHD severity and comorbidities), pre-natal factors [77], genetic 
and family loading, gene-environment interactions, and protective factors like 
exercise and cognitive ability [5, 78].  
A recent systematic review and meta-analysis on ADHD and criminality 
consistently identified these risk factors for arrests, convictions and 
incarcerations [79]: male sex, low intelligence quotient, severe ADHD, and 
comorbid conduct disorder. Low socioeconomic status was associated in 
univariate analysis but the effect faded in multivariate analysis. A study of 
unimodal (medication only) and multimodal treatments initiated in the 1970s 
evaluated long-term effects and showed an initial protective effect in the 
multimodal treatment group that dissipated in the adult follow up [80, 81]. 
ADHD severity, comorbid conduct disorder and oppositional defiant disorder, 
sexual abuse, school suspension, family history of SUD or ADHD and male 
gender were associated with SUD development in ADHD, whereas ADHD 
inattentive subtype and a fearful temperament were inversely associated [82]. 
One study found that the development of SUD in adulthood was predicted by 
age of treatment initiation in childhood (the later, the higher the risk for SUD) 
and that the relation was moderated by antisocial personality disorder [83]. The 
MTA found no residual effect of initial assignment to 14 months’ treatment with 
medication  and no effect of current treatment with medication in the 
development of SUD in adolescence [84]. The PALS, a clinical follow-up, found 
medication to be a risk factor that lost significance when controlling for other 
factors at baseline [85]. 
A cross-sectional analysis of data from nationwide registers found the overall 
mortality rate higher among ADHD patients than in the general population, and 
the risk was especially higher in females, and with comorbid oppositional defiant 
disorder, conduct disorder, and SUD. The mortality rate ratio was 4.25 (95% 
confidence interval: 3.05-5.78) for individuals diagnosed with ADHD at ages 18 
or older, compared to 1.86 for 5 or younger and 1.58 for those diagnosed 
between 6 and 17 years of age [74]. 
In the Milkauwee follow-up study, higher ADHD scores in childhood predicted a 
wide range of worse outcomes like educational, occupational, financial and 
driving problems, whereas lower IQ was associated only with worse educational 
and occupational outcomes [28]. 
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NEW ADULT-ONSET CASES AND THEIR PREDICTORS 
Historically, ADHD has been conceptualized as a child-onset 
neurodevelopmental disorder [86]. The last DSM version (DSM-5) launched in 
2013 [1] included the disorder in the neurodevelopmental disorders section. 
Three recent population studies from diverse cultures challenged the notion that 
ADHD has its onset only in childhood by suggesting the existence of a 
significant large proportion of individuals who report onset of ADHD symptoms 
and impairments after childhood [9-11]. The most surprising finding among the 
three studies is the similarity in the rates of these new adult-onset cases in the 
three studies: 87% of the adults with ADHD presented new adult-onset in the 
New-Zealand study [9], 87.4% in the Brazilian study [10], and 67.5% in the UK 
investigation [11]. However, issues have been raised about the meaning of 
these findings. One hypothesis is that the new onset cases are the result of the 
false positive paradox. Another explanation is that in all three samples there 
was a shift from parent-report or teacher report in childhood to self-report in 
adulthood. However, the British study has controlled for this potential bias in 
secondary analyses[11]. A recent analysis in the ALSPAC cohort relying on the 
same source information for assessments, and using a screening instrument for 
ADHD (hyperactive SDQ scale) at ages 7 and 17 years old (parental 
assessment), found that 54% of the adult cases were new-onset cases. In 
addition, the persistence rate was only 22%. (Riglin et al, personal 
communication).  
In an analysis of predictors in childhood for the adult-onset ADHD cases, the 
British study [11] found that higher IQ, and lower externalizing and internalizing 
scores differentiated the adult-onset individuals from the ADHD persistent 
group. One possible explanation for this would be that high intelligence and lack 
of comorbidity allow the disorder to go undetected during childhood and 
adolescence.  In the Dunedin study, the following childhood factors differentiate 
the adult ADHD group from non-ADHD adult group: higher ADHD scores by 
teachers’ report, conduct disorder and lower reading ability scores [9]. Future 
investigations need to clarify which factors predict adult-onset cases compared 
to individuals without ADHD. An international effort comparing data sets from 




Several methodological factors intrinsically related to the ADHD diagnosis (e.g., 
diagnostic criteria), demographic and sample characteristics (e.g., clinical or 
population origin and age), and information source (self or other) seem to be 
responsible for different persistence rates from childhood to adulthood among 
studies. Since evidence from longitudinal studies on ADHD is scarce and 
extremely heterogeneous in methodology, it is difficult to disentangle with 
statistical methods the role of each of these factors in explaining the 
heterogeneity of ADHD persistence rate. This scenario results in a wide range 
of observed persistence rates among studies, from as low as 4% [17] to as high 
as 76% [22]. 
The available literature indicates that ADHD severity, comorbid conduct 
disorder and major depressive disorder and treatment for ADHD are the main 
predictors of ADHD persistence from childhood to adulthood [46]. Comorbid 
conduct disorder in childhood is ubiquitous as a predictor of multiple adverse 
outcomes like premature mortality, SUD, and criminality, whereas other factors 
have controversial effects depending on the study. Male sex is a risk factor for 
SUD and criminality but is protective in terms of the overall mortality rate. 
Stimulant medication use may protect against the development of SUD 
(although the MTA, the largest prospective study, failed to find such an effect). 
Severity of ADHD appears to be positively associated with criminality and SUD, 
but its relationship with mortality could not be assessed due to lack of data.  
Finally, innovative investigations like those suggesting the possibility of an 
adult-onset ADHD trajectory predicted by higher cognitive reserve and lower 
symptomatology in childhood are important to expand our knowledge about 





Figure 1. Estimates of ADHD persistence rates into adulthood in longitudinal studies. 
 
All reported studies are longitudinal studies with mean age at follow up of at least 18 years old and a 

















































Table 1. Summary of risk factors reported in the systematic review and meta-analysis by Caye 
and colleagues (2016). 
Factors meta-analyzed and significantly associated with persistence 
































1.06 – 3.24 
 
0.03 
Factors meta-analyzed nonsignificantly associated with persistencea 




Female gender 1.23 0.84 – 1.81 0.295 
Comorbid ODD 1.65 0.75 – 3.65 0.213 
Factors meta-analyzed and consistently not associated with persistence 
PREDICTOR ODDS RATIO 95% CONFIDENCE 
INTERVAL 
P-VALUE 
Single parent family 1.08 0.25 – 1.29 0.179 
PREDICTOR SMDb 95% CONFIDENCE 
INTERVAL 
P-VALUE 
Intelligence quotient 0.03 -0.18 - -0.23 0.8 
Factors not meta-analyzed but associated with persistence in individual studies 
Combined ADHD Subtype • Comorbid Bipolar Disorder • Parental ASPDc 
 
a. Authors note that sensitive analysis or the adoption of less conservative meta-analysis techniques (fixed-
effects models) would result in a positive and significant association for Comorbid ODD and female gender, 
whereas single parent family and intelligence quotient have consistent small and not significant effects on 
persistence across included studies.  
b. Standardized Mean Difference 







REFERENCES OF IMPORTANCE 
Reference How it adds to the literature 
             REFERENCES OF MAJOR IMPORTANCE 
● ● Hechtman et al (2016) A report on long-term outcomes of ADHD children and controls 
within the larger clinical trial on the field and its relationship with 
symptom persistence and desistance. 
● ● Caye et al (2016) First systematic review of childhood predictors of ADHD 
persistence. Provides summarized estimates of risk with meta-
analytic techniques. 
● ● Moffitt et al (2015) The first time that the late-onset ADHD was reported in an 
analysis of a four-decade longitudinal cohort. 
● ● Dalsgaard et al (2015) An analysis of health records found a significant association 
between ADHD and overall mortality.  
● ● Erskine et al (2016) A comprehensive systematic review of long-term outcomes of 
ADHD and conduct disorder. Provides summarized estimates of 
risk with meta-analytic techniques. 
             REFERENCES OF IMPORTANCE 
● Sibley et al (2016) This was the first study to analyze a wide range of ADHD 
persistence definitions and test for the accuracy of those 
definitions within one clinical sample. 
● Agnew-Blais et al (2016) An UK longitudinal cohort found similar results in regard to the 
late-onset ADHD and reported factors from childhood related to 
this trajectory.  
● Caye et al (2016) A Brazilian longitudinal cohort found similar results in regard to 
the late-onset ADHD and tested for multiple confounding factors 
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Purpose of review: The traditional definition of Attention-Deficit/Hyperactivity Disorder (ADHD), 
assuming onset in childhood, has been challenged by evidence from four recent birth-cohort studies that 
reported most adults with ADHD lacked a childhood categorical ADHD diagnosis.  
 
Recent findings: Late-onset of symptoms was evaluated in the long-term follow-up of the Multimodal 
Treatment study of ADHD (MTA). In most cases, other factors were present that discounted the late onset 
of ADHD symptoms and excluded the diagnosis of ADHD.  
 
Summary: We offer two theoretical frameworks for understanding the ADHD trajectory throughout the life 
cycle: 1) the complex phenotype model; and 2) the restricted phenotype model. We conclude that (a) late-
onset (after age 12) is a valid trajectory for ADHD symptoms, (b) the percentage of these cases with 
onset after adolescence is yet uncertain, and (c) the percentage meeting exclusion criteria for diagnosis 
of ADHD is influenced by the rigor of the methodology used to obtain evidence and whether or not DSM 
exclusionary criteria are applied.  
 























Attention-deficit/hyperactivity disorder (ADHD) is characterized by an impairing and chronic pattern of 
symptoms with onset in childhood [1, 2]. By the traditional definition, adults with ADHD are individuals 
with child-onset who did not experience desistence of symptoms. In accordance with this assumption, the 
DSM-5 ADHD committee placed ADHD in the Neurodevelopmental disorders section, along with Autism 
Spectrum Disorders and Intellectual Disability. The criterion of onset of symptoms in childhood was 
modified from 7 to 12 years of age, but this definition of ADHD still excludes the diagnosis for patients 
who report late onset of symptoms in adolescence and adulthood [1]. 
 
Despite consistent evidence from clinical follow up studies that childhood ADHD persists into adulthood in 
approximately half of cases [3-5], epidemiological studies indicate a far smaller proportion of adult cases 
with this developmental pathway (i.e., childhood onset and persistent ADHD) [6, 7].  
 
In the last two years, four reports on population-based studies suggested symptoms of ADHD emerging 
during or after adolescence in most cases of adult ADHD [8-11]. The literature is currently referring to this 
condition as late-onset or adolescent/adult-onset ADHD. Previously, investigators have challenged 
categorical thresholds for the age of onset criteria for ADHD [12-14], and others have described adult 
ADHD and its treatment [15, 16]. The novelty introduced by the recent studies is the possibility that the 
late-onset trajectory might be the rule rather than the exception. Here, we review and discuss the 
available evidence, and propose theoretical models to explain the phenotype of late-onset ADHD and 
discrepancies between epidemiological, community, and clinical samples. 
 
FINDINGS FROM FOUR BIRTH COHORTS SUPPORTING LATE-ONSET ADHD  
 
The Dunedin Study 
 
This study followed a representative cohort of 1037 individuals from birth to age 38 with 95% retention [8]. 
DSM-III ADHD (requiring age of onset before age 7) was assessed at ages 11, 13 and 15. When 
participants were 38, DSM-5 ADHD was assessed without applying the age of onset criterion. 
Reasonable estimates of prevalence were obtained at each age, but the ADHD cases at age 11 (6% of 
the cohort in childhood) and age 38 (3% of the cohort in adulthood) consisted of essentially non-
overlapping sets: 90% of adult cases (28 of 31) lacked a childhood history of ADHD, and only 5% of the 
childhood cases (3 of 61) showed persistence of ADHD. 
 
There are some relevant criticisms of this study. The follow-up covered a very long time span, and the 
gap between ADHD assessments was wide (especially since adult ADHD was not anticipated and thus 
was not assessed at follow-up at age 20), making it hard to ascertain when ADHD symptoms first 
appeared. Furthermore, the source of information was from informants (parents) in childhood and from 
self-reports in adulthood (although informant reports were obtained and showed persistence of symptoms 
in childhood ADHD cases that self-report did not). Although high levels of comorbid disorders and 
substance abuse in adulthood were reported, it was not possible to adequately assess whether the 
endorsed ADHD symptoms should be attributed to these conditions.  
 
Given the unexpected findings from the Dunedin cohort, the field was initially skeptical and recognized 
the need of replication [17]. Two independent birth cohorts, the E-Risk study and the 1993 Pelotas Birth-
cohort study, were used to investigate whether the late-onset ADHD hypothesis would be confirmed or 
rejected in other samples [9, 10, 18]. 
 
 
The E-Risk Study 
 
The E-Risk cohort followed 2232 twins born in the United Kingdom from birth to age 18 with 91.3% 
retention. DSM-IV ADHD (without the criterion of onset before age 7) was assessed at ages 5, 7, 10 and 
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12, and then again at age 18. Among the young adults diagnosed with ADHD, 67.5% failed to meet 
criteria in any of the childhood assessments. But, as in the Moffitt et al (2015) study, there was no 
difference between late-onset ADHD and childhood-onset ADHD in terms of impairment and rates of 
mental health disorders in young adulthood [9]. 
 
Similar to the Dunedin study, there were some weakness of this study. The study design and protocol did 
not allow for adequate control for comorbid mental disorders in adulthood. While the gap between ADHD 
assessments was much smaller, the last age at assessment was at age 18, limiting conclusions about the 
stability of the late onset ADHD or the possibility of onset in older adults. 
 
The 1993 Pelotas Study 
 
The 1993 Pelotas cohort followed 5249 individuals born in Brazil from birth to age 18 and 19, with 81% 
retention. The cohort was evaluated for ADHD with the hyperactivity subscale of the Strengths and 
Difficulties Questionnaire (SDQ-H) calibrated for DSM-IV ADHD diagnosis using the Development and 
Well-Being Assessment (DAWBA) at age 11. At age 18 and 19, ADHD was assessed with a structured 
diagnostic instrument according to the DSM-5 criteria in clinical interviews with psychologists (without the 
age of onset criterion). In this sample, most (87.4%) of the adult ADHD cases lacked history of childhood 
ADHD. This rate was not changed when considering only individuals without current psychiatric 
comorbidities that could mimic ADHD symptoms, like Major Depression, Bipolar Disorder, Anxiety 
Disorder and Substance Abuse Disorders [10].  
 
The major criticism to the Pelotas study is that the childhood assessment of ADHD was with a screening 
questionnaire. Another limitation is that the last age of assessment was in young adulthood. Furthermore, 
there was a change in source of information from childhood (parent-report) to young adulthood (self-
report).  
 
The ALSPAC study 
 
The ALSPAC cohort followed 14701 children born in the United Kingdom from birth to age 17 with 
multiple dimensional assessments of ADHD using the SDQ-H. Data from 9757 individuals (those with at 
least two assessments) were evaluated with latent class analysis. The best-fit model did not include a 
trajectory of rising ADHD symptoms. However, in secondary analysis of two-time points, of the 460 cases 
with symptoms above the cutoff suggesting ADHD at age 17, 47% (n=261) had childhood onset, and 53% 
did not (n=244), defined by being above the symptom threshold at age 17 but below it at age 7 [11].  
 
The most important limitation of this study is the reliance on screening instruments at all ages without a 
cut-off point based on internal calibration with a semi-structured instrument in the last assessment. This 
assessment was in late adolescence, and there was no consideration of comorbidities or substance use 
when making diagnoses.  
 
Critical appraisal of the strengths and limitations of the population-based samples  
 
These four studies taken together present a strong empirical case for the presence of ADHD-like 
symptoms that first emerge in adolescence or young adulthood, and that most of the adults with ADHD 
symptoms do not report onset in childhood. What are some strengths of the 4 studies? The samples 
ascertained were representative of their populations. The longitudinal design put aside the question of 
recall bias that hampers conclusions of retrospective case-control studies [19]. In general, assessment 
methods were those used in the majority of population studies in the mental health arena. In doubtful 
cases, like in the childhood assessment of the Brazilian study, sensitivity analyses were conducted 
systematically.  
 
What are some conclusions from the 4 studies? It is clear that some individuals report late-onset, 
impairing ADHD symptoms. However, the interpretation of these symptoms remains unclear without 
comprehensive longitudinal assessments across development. It is possible that endorsed symptoms 
represent neurocognitive effects of many other conditions that were not considered when making adult 
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diagnoses, including heavy substance use, medication side effects, overlapping symptoms with disorders 
such as depression or anxiety, or the results of a physical illness, and head trauma among others. In 
addition to the age of onset criterion, the DSM-5 criteria state that the diagnosis of ADHD should not be 
made if the symptoms can be attributed to or better explained by these factors. Also, the impact of 
differences in the source of information used for diagnosis (i.e., informant-report in child-onset cases and 
self-report in adult-onset cases) cannot be discounted. Reliance on self-report may result in opposite 
biases for cases referred for treatment at different ages -- under-reporting in cases referred by others in 
childhood (more false negatives) and over-reporting in cases self-referred in adulthood (and more false 
positives) [20]. 
 
FINDINGS FROM THE MTA STUDY 
 
An alternative design was used for the Multimodal Treatment of ADHD Study (MTA), and it provided data 
to address some of the limitations of the population-based cohort studies. Using a prospective long-term 
follow-up design, the incidence of late-onset ADHD was estimated in the group of children in the Local 
Normative Comparison Group (LNCG) without ADHD (N=239 of 289 recruited from classmates) followed 
from childhood (ages 9-12) to adulthood (ages 23-26). They underwent eight comprehensive 
assessments, which included psychiatric evaluations to measure ADHD symptoms and related 
impairments. Diagnostic procedures utilized parent-, teacher-, and self-reports of ADHD symptoms, as 
well as assessment for impairment, substance use, and other mental disorders [21].  
 
The dense and comprehensive assessments of the MTA allow evaluation of context and timing of late-
onset of ADHD symptoms in the potential cases of late onset ADHD. Starting with lenient criteria using 
symptom ratings only (to guard against false negatives), almost half of the LNCG cases were considered 
as potential cases. After applying the DSM-5 exclusion criteria, only 8 cases remained with late-onset 
ADHD (see Table 1), suggesting that 3.3% of the LNCG subjects had a late onset trajectory. But it is 
informative to note that 73% of the adolescents and 92% of the adults who were classified as late-onset 
based on symptom cutoff, impairment and pervasiveness criteria in the MTA protocol (table 1, line 3) 
were eventually excluded from an ADHD diagnosis because symptoms or impairment were better 
explained by other conditions -- or were considered late-identified rather than late-onset (i.e., the case 
met childhood ADHD criteria after baseline but before age 12 or the case had full threshold ADHD 
symptoms reported by teachers but not parents at baseline). Regarding comorbid conditions, heavy 
marijuana use was the most common reason for exclusion, and the presence of other psychiatry 
disorders was the next most common. Based on the MTA assessments, the majority of late-onset cases 
were adolescent-onset cases time-limited presentation indicated by desistence of symptoms prior to 
adulthood. In addition, the majority of adult-onset cases occurred only in conjunction with a complex 
psychiatric history of other disorders.  
 
The MTA also has limitations. For example, it did not obtain comprehensive data on many other factors 
(e.g., physical illnesses, personality disorders, injuries, and medical treatments) that also may have 
contributed to the emergence of late-onset symptoms, and despite the 16-year follow-up, the final 
assessment of the participants was in early adulthood (i.e., ages 23-26).  
 
UNDERSTANDING THE EVIDENCE 
 
Four population-based cohorts comprising more than ten thousand individuals estimated that most cases 
with adult ADHD (53% to 90% across the studies) had an age-of-onset after childhood. Those adult-onset 
cases had similar patterns of impairment and negative outcomes as the childhood-onset cases. In 
contrast, the MTA follow-up of the LNCG group (with ADHD excluded in childhood) evaluated how 
methodological differences in assessment of symptoms affected estimates of persistence [22]. In the 
childhood-onset ADHD cases, the persistence rate in adulthood varied from 1.9% to 61.4% (depending 
on the source, method, and criteria used to define persistence), and because of this, the rate of adult-
onset ADHD varied from 0% to 17% (depending on the diagnostic methodology applied).  
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An additional evaluation [21] noted the proportion of late-onset cases was concentrated in adolescence 
rather than in adulthood, and the manifestation of symptoms later desisted, suggesting an episodic rather 
than consistent profile during adolescence. Major questions exist about how to understand and integrate 
the findings from population-based and samples. 
 
Estimating rates with comparable definitions 
 
In the comprehensive assessment of the LNCG of the MTA, Sibley et al [21] used a sequential 
evaluation. The starting point was a broad definition of symptom presence (i.e., the “or-rule” for high 
symptom ratings by either parent or self-report), chosen intentionally to avoid false negatives. This 
resulted in a high rate of cases with de novo symptom presence with late- onset (n=112, 46.9%), which 
was expected to be implausibly high. Based on sequential application of additional criteria to exclude 
cases based on lack of impairment, lack of cross-situational manifestation, late onset, substance abuse, 
and other mental disorder, almost all late-onset cases (n=104, or 92.9%) met some exclusion criteria that 
overruled the symptom-based diagnosis (see Table 1).  
 
Three population-based studies also considered the two criteria responsible for most (67.9%) of the 
exclusions in the MTA study (impairment and pervasiveness of symptoms – see Table 1). If the MTA 
method stopped at this point, the estimated prevalence of late-onset ADHD among the LNCG would be 
15.1%, exceeding the rate reported based on the methods used for the population-based studies, 
probably because of the inclusion of both self and parent report. This comparison of the clinical MTA 
study and population-based studies focuses our discussion on the way and purpose of applying further 
criteria responsible for the remaining exclusions in the MTA: definition of late onset and symptoms due to 
substance abuse or other mental disorders.  
 
 
Definition of late onset 
 
The population-based samples had different approaches to consider the definition of childhood ADHD: 
positive DSM-III criteria at ages 9, 13 or 15 [8]; positive DSM-IV criteria at ages 5, 7, 10, or 12 [9]; above 
threshold score in the SDQ-H (calibrated by DSM-IV criteria) at age 7 [11] and at age 11 [10]. Any 
individual was deemed late-onset ADHD if full categorical criteria was met in adulthood but not in 
childhood. The methods for the population-based studies assumed that full threshold ADHD in childhood 
should be required to define ADHD as childhood-onset. 
 
In the MTA, individuals in the LNCG with ADHD at baseline were excluded. However, in a further step, 
individuals that had fulfilled DSM-IV criterion A (ADHD symptoms) by at least one source using ratings on 
the SNAP-IV scale from any assessment before age 12 were also excluded. Thus, the MTA methods 
were more rigorous in including subjects as potential late-onset cases with ADHD than the population-
based studies, since individuals only above the symptomatic threshold without any other ADHD criteria 
(pervasiveness and impairment) in childhood were excluded.   
 
If subthreshold or situationally dependent cases in childhood are not excluded, this may add noise to the 
conceptual question: can ADHD really emerge in adulthood in individuals with very few or no symptoms in 
childhood? It is important to note that scores just above a normative cut-off in the SDQ-H was also 
required to define childhood-onset ADHD in secondary analyses in two of the population-based samples, 
reducing the numbers of late onset ADHD cases. However, these analyses retained a substantial group 
of individuals in the late-onset group and they continue to have marked impairment in adulthood. 
 
Symptoms due to substance abuse and other mental health disorders 
 
The comprehensive evaluation in the MTA allowed for assessment of timing of symptom manifestation on 
a case-by-case basis to determine whether late-onset ADHD preceded or was secondary to substance 
use and other mental health disorders. Two of the population-based samples also tried to account for 
comorbid conditions that commonly arise during adolescence and can mimic ADHD symptoms. Removing 
individuals with comorbid mental health conditions excluded many late onset cases (from one half to two 
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thirds in the population-based samples), which is similar to the observations in the clinical MTA sample. 
However, it is important to note that in the MTA, cases of late-onset ADHD were permitted to display 
comorbidities as long as those comorbidities were not considered the cause of the reported ADHD 
symptoms. 
 
The similarities in comorbid rates suggest that the important issue is not the differences in the samples or 
their assessments of comorbidities, but rather it is about how to use this information -- whether to 
consider concurrent or previous psychiatric disorders as exclusions when determining the nature of late-
onset ADHD symptoms. In a disorder like ADHD where, independently of the trajectory, the pattern of 
comorbidities is high [23-25], this is a difficult clinical question.  
 
Additional Relevant Issues: Sample differences between epidemiological and clinical studies and change 
in information source 
 
A recent investigation in a clinical sample from an adult clinic for ADHD showed a very low rate of adult-
onset subjects (6.9%). Even though this single site study might suffer from referral bias, the pattern 
seems to resemble those from other ADHD clinics. Classical studies document that epidemiological and 
clinical investigations select different samples in Medicine in general and particularly in Psychiatry [26, 
27]. For example, clinical samples of ADHD tend to present a higher proportion of ADHD with a combined 
presentation while epidemiological samples tend to have higher prevalence rates of a predominantly 
inattentive type. In addition, the profile of comorbidities might be different between these two types of 
studies [26]. Lopez et al found that adult-onset-cases had a higher educational level, a more frequent 
inattentive ADHD presentation, a less severe ADHD, but similar rates of comorbid psychiatric disorders 
than persistent ADHD cases from childhood to adulthood [28]. It is reasonable to speculate that in ADHD 
epidemiological samples, there might be an overrepresentation, compared to adult clinical samples, of 
ADHD cases with a predominantly inattentive presentation, less severity, lower rates of comorbidities, 
higher cognitive resources, and more family supportive environments in childhood. These protective 
factors may increase rates of late-onset cases in epidemiological samples compared to clinical samples, 
as demonstrated in Figure 1.  
 
On the other hand, epidemiological samples might be more prone to a phenomenon called “the false 
positive paradox.” As extensively documented, the reliability of the ADHD diagnosis based on subjective 
information acquired by interviews or rating scales for documenting symptoms is far from perfect. If the 
false positive rates were very low, the differential impact of reliability would not be great when comparing 
findings from population-based and clinic-based studies. But if these rates are high, the impact on the 
population-based samples may be exaggerated, due to the large number of non-ADHD cases that would 
be multiplied by the false positive rate. When the false positive rate for adult assessments is higher than 
the prevalence, the number of false positive cases may be higher than the number of true positive cases. 
This issue assumes more relevance in epidemiological studies using screening instrument to assess 
adult ADHD, like the ALSPAC study, but tend to produce less impact in studies (like the Dunedin cohort) 
that used the same gold-standard diagnostic procedures as the clinical studies.   
Finally, one of the most important differences in the studies’ designs concerns change of information 
source. Three population-based samples relied on parental report in childhood and on self-report in 
adulthood. Relying on different informants for ascertaining psychiatric diagnosis may generate non-
overlapping groups, since agreement between informants is known to be low [29]. There are two main 
arguments that mitigate the effect of the change of information source in those studies. 
 
The first argument is conceptual. The external validity of the choice of methods in the population-based 
studies is clear, since in the real-world scenario, clinicians will ascertain psychiatric diagnosis in adulthood 
in most cases with self-report only. According to this view, changing the source of information is the lesser 
of two evils, because relying on parent report to make the diagnosis in adulthood will impede translation 
to clinical practice. 
 
The second argument is data-driven. The Dunedin and the E-Risk studies had more than just self-report 
of symptoms: these population-based studies showed that late-onset ADHD individuals had higher ADHD 
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symptoms in adulthood than control individuals according to co-informant reports (but the informant-report 
was also high in childhood onset cases with low self-report of symptoms in adulthood). The ALSPAC 
study relied on parent reports in all time points. What these analyses suggest is that the self-reported 
symptoms in adulthood are confirmed by other sources of information, and that there seems to be an 
undeniable trajectory of late-onset ADHD in some cases even when the source of information is not 
changed.  
 
The MTA study dealt with the change of information source quite differently [see Sibley et al [21]]. Self 
and parent reports were aggregated with specific rules for each DSM criterion during adolescent and 
adulthood.  For symptom criterion, the “or rule” was used for item level (each symptom). For impairment 
criterion, only parent report was used in adolescence and the “or rule”/item level (each impairment) was 
used in adulthood. For pervasiveness criterion, the “and rule” was used. Ratings of adult ADHD 
symptoms by the two sources did show large differences by source (see Swanson et al [30]) suggesting 
lower self- ratings than parent-ratings.   
 
In conclusion, the data from the MTA study do not necessarily conflict with the data from the four 
population-based samples, but the interpretation differs. To facilitate a consensus on the interpretation of 
the data from these studies, we present below two theoretical models offering accounts of the data on 
late-onset ADHD. 
 
THE COMPLEX PHENOTYPE OF CHRONIC DISEASES HYPOTHESIS 
 
The current understanding of most chronic conditions in medicine is that a clinical phenotype arises out of 
intricate and complex interactions between biological and environmental factors [31]. For example, type 2 
diabetes syndrome is clearly affected by environmental pressure, especially obesogenic factors. 
However, we know that obesity is not necessary nor sufficient to cause type 2 diabetes, because 
biological pressures, like genetic predisposition, are essential in the equation [32]. 
 
The complex phenotype model can be easily applied to ADHD (Figure 1). There is substantial evidence 
that inattention and hyperactivity-impulsivity symptoms behave as traits to which an arbitrary cut-off 
applies [33-35]. Neurobiological pressures - for example, the level of brain cortical maturation and 
integrity of the white matter tracts - might affect these traits [36, 37]. But environmental pressures also 
affect traits, for instance, the level of demand and supportiveness of the family or peers. Importantly, none 
of those pressures are expected to be stable over lifetime. How does this explain the traditional course of 
childhood-onset ADHD? In Figure 1, 8 examples are presented. Some individuals who are at the extreme 
of the trait in childhood may experience a maturation of neurodevelopment during adolescence [2] - if 
everything else remains stable, this could result in remission or desistence of symptoms (1A). Others 
could experience some level of initial normalization of the symptomatic profile due to neurobiological 
maturation, but later an age-related increase in environmental demands (e.g., when entering university) 
occur and the symptoms reemerge (1B). In a different group, behavior may not normalize at all, and this 
would be manifested as persistence of symptoms (1C). Individuals with moderate neurobiological 
pressure but environmental conditions that allow for early compensation (e.g., very supportive families) 
that is not present later (e.g., after moving out and accepting a demanding job), may manifest late onset 
of symptoms (1D). Another group may encounter environmental pressure in late adolescence that 
dissipates later, resulting in transient symptoms (1E). Brain injuries [38] and substance abuse [39, 40] can 
increase neurobiological pressure in the long-term, resulting in late onset and persistent symptoms (1F). 
And these factors can operate concurrently, bringing individuals from one extreme to the other, with late 
onset and persistent symptoms (1G) or early onset and desistent symptoms (1H).  
 
In this application of the complex phenotype model, the evaluation is empirical and focused on 
manifestation of symptoms and trajectories over time. The causes (that usually are unobserved) are not 
assumed or used to distinguish the trajectories over time. 
 
The model of unstable complex biological and environmental pressures not only explains the finding of 
late-onset ADHD, it predicts it, as well as every other possible ADHD trajectory. To deny the late onset of 
ADHD would ignore half of the possible trajectories of ADHD symptoms (see panels 1D, 1E, 1F, and 1G).  
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As an analogy, we could imagine how physicians in the second half of the nineteenth century, already 
aware of the typical type 1 diabetes syndrome, came to learn of the existence of a similar syndrome of 
polyuria and polydipsia that arises later in life and is preceded by other clinical conditions. Considering 
the complex phenotype model, type 1 diabetes would arise from a very high biological pressure, 
depending very little of the environmental pressure to reach a diagnostic threshold on blood glucose 
levels. Type 2 diabetes, on the other hand, arises much later in life due to the fact that it depends 
moderately of biological and environmental pressures. Likewise, diabetes is usually preceded or occurs 
concurrently with many comorbidities [41]. This comorbid profile does not mean that type 2 diabetes does 
not exist! 
 
THE RESTRICTED PHENOTYPE HYPOTHESIS 
 
As in the complex phenotype model, behaviors that underlie ADHD symptoms are assumed to be 
influenced by multiple biological and environmental factors in the restricted phenotype model. However, 
the restricted phenotype model places limits on these factors, accepting that some but not all are 
associated with ADHD (e.g., as specified by the DSM criteria). The diagnosis of ADHD is excluded when 
symptom manifestation is preceded by (or is concurrent with) the appearance of environmental factors 
(i.e., trauma, deprivation), physical disorders (i.e., hypothyroidism, dementia), injury (i.e., concussion), or 
side effects of medication or illicit substances (i.e., chemotherapy, marijuana, pharmacological side 
effects), which may plausibly elicit symptoms of inattention, impulsivity, or hyperactivity. The restricted 
phenotype model does not question whether the multiple trajectories of ADHD symptoms occur, but 
instead asks whether likely underlying causes (even though typically unobserved) of these trajectories 
should be invoked to exclude the diagnosis of ADHD in some individuals. 
 
The restricted phenotype model was applied to the late onset ADHD cases in the MTA by comparing 
diagnosis at multiple assessments points over time when the participants are in different stages of 
development (childhood, adolescence, and adulthood). Figure 2 shows an initial assessment (in 
childhood) and a later assessment (e.g., in adolescence or adulthood). Only 4 alternative are presented: 
(2A) high levels in childhood and later in development (childhood-onset and persistent ADHD symptoms), 
(2B) low levels in childhood and high levels later (bona fide adult onset ADHD that is due to multiple 
biological and environmental factors and their interaction), (2C) low levels in childhood and high levels 
later due to other factors (adult-onset ADHD excluded due to other disorders or conditions), and (2D) high 
levels in childhood but not later in development (childhood-onset but desistent ADHD symptoms). 
 
Figure 2 emphasizes that a critical clinical focus of assessment of late onset ADHD is to assign cases 
with the same trajectories to different groups (i.e., to 2B or 2C). This requires attributing possible reasons 
for increasing symptoms over time (i.e., from childhood to adolescence or adulthood) to classify late onset 
ADHD as a bona fide diagnosis (2B) or to exclude the diagnosis (2C).  
 
The restricted phenotype model suggests late onset ADHD may be a separate disorder in some cases, 
but it does not necessarily exclude all cases with late onset of ADHD symptoms. For example, bona fide 
late-onset ADHD is shown in Figure 1D for cases in which the manifestation of ADHD symptoms in 
childhood is overcome by compensation that reduces the severity of ADHD symptoms (and thus 
childhood-onset is not recognized), but the symptoms emerge later in adolescence or in adulthood, when 





The clinical message suggested by these two alternative models of late-onset ADHD is that it may be 
important to compare symptoms at multiple points over time instead of just evaluating symptoms at just 
one point in time, and concurrently to evaluate other factors that may be the underlying cause of 
symptoms. The difference between the models may be merely a difference in emphasis on how to use 
unobservable factors (i.e., possible causes rather than just manifestation of symptoms). Thus, a major 
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question for the field is “Which of these factors are permissible as legitimate causes of late onset ADHD 
symptoms and which should be considered exclusionary”? A critical theoretical issue is the degree to 
which ADHD symptoms are associated with a limited number of specific possible causes (the narrow-
restricted phenotype model), or whether ADHD symptoms are considered to be non-specific 
manifestations of an unlimited number of causes (the broad complex phenotype model). 
 
It is important to recognize that in the literature reviewed here, late-onset of ADHD symptoms occurred in 
all assessed samples (2.7% in the Dunedin sample, 5.4% in the E-risk study, 6.3% in the Pelotas sample 
after excluding assessed comorbidities, 2.5% in the ALSPAC investigation and 3.3% in the MTA). Also, it 
is important to recognize that the prevalence of adult DSM ADHD (i.e., including several symptoms in 
childhood) ranges between 2.5 to 4.4% [42, 43]. In the studies reviewed here, the lowest estimate for 
late-onset ADHD (2.1% for the most restrictive definition in the MTA – see table 1, last line) represents 
48% of the highest prevalence rate estimated for adult ADHD (4.4%). So, late onset ADHD does not 
seem to be a negligible condition.  
 
Many questions remain about late-onset ADHD, and we end this review with a list of some of these that 
we believe should direct research on this important topic: (a) what defines a bona fide late-onset ADHD? 
(b) what is its prevalence? (c) Is there a developmental limit to onset of the symptoms (only in 
adolescence or also in adulthood)? (d) Are there more neurobiological and genetic similarities or 
differences between late onset and child-onset cases? With respect to clinical practice, the findings 
discussed above suggest that clinicians should not discard the possibility of an ADHD diagnosis in adults 
just because they were not able to track ADHD symptoms in their childhood. However, a careful 
assessment of pervasiveness and impairment and of any other potential causes explaining/mimicking the 
ADHD symptoms in adulthood is strongly recommended. In sum, a careful assessment using all DSM-5 
ADHD criteria except age-of-onset is fundamental when evaluating adults. In cases where comorbidities 
such as general anxiety disorder, depression or cannabis use might better explain adult-onset symptoms, 
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that are excluded by each criterion. Note that adolescent and adult-onset groups overlap because 
case who were excluded in adolescence were given a second chance to be evaluated for adult-
onset ADHD. There were 31 cases that were evaluated as potential late-onset cases in both age 
periods.  
b. As discussed below, the MTA applied a second criterion to define ADHD as late-onset besides 
lack of categorical diagnosis of DSM ADHD, which was absence of symptom criterion in SNAP 
rating scales before age 12 according to both parents and teachers. The cohorts did not apply 
this additional criterion. 
c. A final methodological refinement proposed in the MTA to exclude any clinically relevant ADHD 
phenotypic trace in childhood for adult-onset cases. 
d. Although performed in some epidemiological samples, we are assuming that assessment was not 
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A) remission or desistence of symptoms; B) initial normalization of the symptomatic profile, 
but later symptomatic reemergence; C) persistence of symptoms since childhood.; D) late 
onset of symptoms; E) transient symptoms; F) late onset and persistent symptoms; G) 








































Figure 2: The Restricted Phenotype Model of ADHD 
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The neurodevelopmental course of ADHD encloses challenging and complex unanswered 
questions. This is a field where several important paramount findings by previous investigations 
had slowly built a sound framework upon which new evidence can be appraised, debated, 
possibly improving or updating an already solid knowledge. Therefore, we both extensively 
reviewed the literature and produced new evidence in this thesis.  
 
Our contributions can be summarized as follows: We provided one of the first longitudinal 
evidences of the existence and validity of late-onset ADHD (Article #1). We had also contributed 
to a clinical independent study that found results that were, to a certain extent, contradictory 
to ours (Appendix #1). We have then joined the principal investigators of this last study to 
review the entire literature so far available on late-onset ADHD and to provide possible 
rationales for the discrepant findings (Article #6).  
 
In the quest for relevant predictors of ADHD persistence and an individualized perspective of 
risk determination, we had systematically reviewed the literature and meta-analyzed 
summarized effects of association between a series of predictors and the persistence of ADHD 
for the first time in the literature (Article #2). Furthermore, we had reviewed what are the 
challenges of conducting long-term longitudinal studies about ADHD, and how methodological 
decisions influence observed findings (Article #5). Leveraging from the knowledge of these two 
studies, we were able to develop a multivariable risk model to predict adult ADHD joining three 
large birth cohorts and one large clinical sample. This risk model was generated and 
independently validated within these samples, and an open-source free risk calculator for 
clinical use was made available on-line (Article #3). 
 
Similarly, when we focused on clarifying the issue of relative immaturity and its effect on ADHD 
diagnosis, our approach was two-fold. We conducted a systematic review, meta-analysis and 
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meta-regression of the available literature on the effect estimates of relative immaturity on 
ADHD. Confirming the lack of a longitudinal population-based and actively assessed design, we 
analyzed data of three population-based cohorts in Brazil, providing new sound evidence on the 
matter. Both these studies, the original studies and the review, are included in Article #4.  
 
How can we join the findings of this thesis into one developmental framework? First, by 
considering that the expression of ADHD symptoms is not a static dichotomy, but instead lies 
on a dynamic continuum that arises from the interplay of environmental and neurobiological 
pressures. These can change with time. When children enter school, their environmental 
demand suddenly increases, and ADHD will be expressed according to their underlying 
neurobiology. We demonstrated that children who are relatively immature because of their 
younger age in class will express more ADHD symptoms determined by their 
neurodevelopmental stage and their environmental demands. Moving forward in our 
framework, neurodevelopment occurs rapidly in adolescence and tends to complete by young 
adulthood. Accordingly, childhood-onset ADHD symptoms tend to reduce, but this is not true 
for all individuals. We investigated predictors of this failure to remit – as would be expected – 
and developed a tool that parses out these individuals in advance, for clinical and research 
purposes. Going even further, by young adulthood, again environmental pressures usually 
increase, and interact with otherwise hidden neurobiological factors. For instance, many young 
adults move away from their parents – sometimes losing positive environmental factors – and 
start college in high-demand, competitive academic environments. We, along with others, 
provided evidence that many young adults with a clinical presentation of ADHD had their age at 
onset after childhood, while their impairment and adverse outcomes associated with the 
disorder were the same as the childhood-onset cases. 
 
We conclude this thesis by acknowledging both our small but significant contributions to the 
field of research of the neurodevelopmental course of ADHD, and the several open questions 
that are left to be answered. The validity and existence of the late-onset trajectory still needs to 
be further explored in independent samples with even more scrutiny than the studies had so 
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far provided. For instance, current studies mostly consider only two time-points in their 
definition of late-onset ADHD, leaving either adolescence or young adulthood uncovered by 
their designs113. An ideal approach is to use thorough repeated assessments with long-term 
follow-ups in large scale studies, estimating precise age-at-onset instead of categorical 
definitions such as “adolescent-onset” or “adult-onset”. Nevertheless, the combination of these 
features in one single study is yet unavailable. Another challenge is to disentangle the role of 
heterotypic continuity on the emergence of ADHD after childhood. Most reports identified 
higher rates of childhood psychopathology among individuals with late onset ADHD 15,86,91. 
Sophisticated mediation and moderation analyses in samples with repeated dimensional 
measures could explore to what extent this psychopathology drives later onset of ADHD 
symptoms. The consideration of neurobiological features, for instance, with genetic and 
neuroimaging approaches, could further clarify the nature of this novel syndrome. Three 
investigations already reported lower genetic risk scores for ADHD in late onset ADHD 
individuals84,87,92. However, these polygenic risk scores were derived with traditional childhood-
onset ADHD samples – therefore, these findings might mean that late onset ADHD is driven by 
other causal pathways, instead of a smaller biological load. 
 
The development of more sophisticated risk models could aid research and care of ADHD, and 
other areas in mental health. The inclusion of other types of data could improve accuracy of the 
model proposed in this thesis – for instance, family history, polygenic risk scores, neuroimaging 
and complex neurocognitive measures. Prematurity, which is an established risk factor for 
ADHD116, should also be considered in further studies. An ideal design would convey several 
kinds of data measured in baseline, with long-term follow-up assessments including repeated 
measures of thorough evaluations of the outcome – a categorical and dimensional diagnosis of 
ADHD. Independent replication in diverse settings remains a challenge, and should always be 
pursued in such efforts. A complex matrix of predictors would then require advanced methods 
of statistical prediction, such as deep learning methods with automated selection of prediction 
variables. However, the informative power of complex and sophisticated predictors, such as 
neuroimaging data, should be weighed against the loss of clinical usefulness in settings with 
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fewer resources. In previous predictive models, phenotypic data outperformed complex 
functional and structural neuroimaging data in predicting the diagnosis of ADHD112.  
 
Not only technical, but also ethical considerations should be considered when developing 
predictive models in Psychiatry. The first and foremost issue relates to the uncertainties that 
are inherent to this kind of approach. Even when our model is accurate, it often goes wrong for 
certain individuals. For those, there are undeniable consequences of predicting an outcome 
that will never occur – and all the clinical management that might come with this forecast. 
Likewise, underestimating someone’s risk might have serious consequences, especially if any 
effective preventive intervention would have been available. A sensible way of reducing the 
harm is to provide information on risk on a continuum – for instance, an 80% risk - rather than 
binary, and with confidence intervals, instead of a clear-cut number. Either way, these 
uncertainties should be thoroughly discussed with the patient by the attending physician, who 
should be aware of the limitations of the method. Another issue relates to the utility of 
prognosis when no specific intervention is available. Taking the case of our own prognostic 
model for ADHD, no preventive intervention ever tested has been effective so far for reducing 
the risk of future ADHD. Therefore, taking into consideration the potential harms of informing 
the prognosis of any individual, will the actual benefits surpass these harms? These questions 
could be further clarified on randomized clinical trials where preventive interventions are 
tested on at-risk individuals. 
 
The identification of a consistent effect of relative immaturity should be followed by 
evaluations of the functional outcomes of the younger children along development. 
Importantly, not only data, but also a deeper theoretical discussion, is lacking in the case of 
relative immaturity and ADHD. Conceptual questions remain open: Who are these children that 
present an ADHD phenotype when facing educational demands higher than they can handle, 
real ADHD or ADHD phenocopies? Are the ADHD symptoms causally related to their relative 
immaturity or associated to other causes associated to the immaturity and not yet identified? 
Should they be considered valid cases of ADHD, and therefore referred and treated? Or should 
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their difficulties be addressed on their own school environment? These questions actually cross 
the field of mental health care through the boundaries of the organization of the educational 
system. If it is the case that these children and their parents are actually reporting impairing 
symptoms due to the insensible way the educational demands are tailored in the first years of 
schooling, it might be the case that educational reforms are needed to properly address this 
issue. Nevertheless, just delaying school entry might not be sufficient or recommendable. An 
observational study found no academic benefits for children with ADHD whose entry was 
deliberately delayed when they were followed up years later117. This study was, however, 
biased by the higher likelihood of the severe cases to be red-shirted compared to more mild 
ADHD cases. The failure to neutralize the issue of relative immaturity with common sense 
interventions only reinforces the need for more research that is informed by the data from the 
mental health and educational fields. Furthermore, the issue of relative immaturity seems to 
transcend the academic environment. Researchers have found that birth month was unevenly 
distributed in high performance environments such as national sports competitions and among 
leading politicians: those relative older were found to be overrepresented in such selected 
populations118-120. In this sense, more research is needed to more comprehensively understand 
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ADHD is not only a child-onset neurodevelopmental disorder 
We thank Dr. Solanto for her interest in our paper and for providing some thoughtful ideas on 
how to understand these intriguing similar findings from three population samples based in 
different continents that challenge the notion of attention-deficit/hyperactivity disorder 
(ADHD) as only a child-onset neurodevelopmental disorder.1,2,3 Dr. Solanto suggests that our 
study might have missed a substantial proportion of cases of ADHD predominantly inattentive 
type (ADHD-PI) in childhood, consequently decreasing the rate of adult ADHD with roots in 
childhood. She based this hypothesis on the idea that we had collected data on ADHD 
symptoms in childhood before DSM-IV criteria. 
In fact, the 1993 Pelotas Birth Cohort collected data on childhood ADHD in 2004, a decade after 
DSM-IV was launched. However, as mentioned in the paper, we assessed childhood ADHD with 
a screening instrument that emphasizes hyperactive-impulsive symptoms. Considering the 
potential lower performance of the instrument for ADHD-PI subtype, Dr. Solanto`s hypothesis 
makes a lot of sense and warrants proper testing. 
In 2004, a subsample of 288 participants at age 11 was also assessed with the Development and 
Well-Being Assessment (DAWBA), a semi-structured interview that generates DSM-IV diagnoses 
– including ADHD-PI. In this subsample, 24% of the ADHD cases were of ADHD-PI, 40% of which 
were not detected by the screening instrument. Therefore, we can conclude that 10% (40% of 
24%) of the childhood ADHD cases were not included in the childhood ADHD group. 
Extrapolating for the entire sample at 11 years of age, the scenario suggests that the 393 cases 
in childhood represent 90% of the real ADHD cases and the ADHD-PI that were not diagnosed 
by the instrument would count up 44 new cases. It is important to note that this mathematical 
reasoning addresses only the issue related to ADHD-PI. It does not take in to account the 
performance of the screening for other subtypes of ADHD.  
Although the ADHD combined type seems to be the most persistent subtype,4 let us assume 
conservatively that all these ADHD-PI cases in childhood would continue to present ADHD in 
young adulthood. This assumption would increase the proportion of young adults with ADHD 
with childhood history of ADHD symptoms from 13% (reported in the manuscript) to 21%.  
Thus, we cannot throw the baby out with the bath water! We were also surprised with our 
findings and explored our data from diverse angles to assess potential flaws. Others did the 
same.5 The main message continues to be that the great majority of young adults with the 
ADHD phenotype do not have a childhood history of significant ADHD symptoms. 
Finally, we are in complete agreement with Dr. Solanto’s proposal that the translation of data 
from population-based to clinical studies is challenging and that more studies are needed to 
understand the reasons for this surprising rate of adult-onset ADHD cases in population 
samples. Indeed, a group of researchers interested in this controversial issue has begun to work 
on numerous data-driven hypotheses.6 
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Attention Deficit Hyperactivity Disorder, Diagnosis And Classification 
Objective: Adolescents and young adults without childhood attention deficit hyperactivity 
disorder (ADHD) often present to clinics seeking stimulant medication for late-onset ADHD 
symptoms. Recent birth-cohort studies support the notion of late-onset ADHD, but these 
investigations are limited by relying on screening instruments to assess ADHD, not considering 
alternative causes of symptoms, or failing to obtain complete psychiatric histories. The authors 
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address these limitations by examining psychiatric assessments administered longitudinally to 
the local normative comparison group of the Multimodal Treatment Study of ADHD. 
Method: Individuals without childhood ADHD (N=239) were administered eight assessments 
from comparison baseline (mean age=9.89 years) to young adulthood (mean age=24.40 years). 
Diagnostic procedures utilized parent, teacher, and self-reports of ADHD symptoms, 
impairment, substance use, and other mental disorders, with consideration of symptom context 
and timing. 
Results: Approximately 95% of individuals who initially screened positive on symptom 
checklists were excluded from late-onset ADHD diagnosis. Among individuals with impairing 
late-onset ADHD symptoms, the most common reason for diagnostic exclusion was symptoms 
or impairment occurring exclusively in the context of heavy substance use. Most late-onset cases 
displayed onset in adolescence and an adolescence-limited presentation. There was no evidence 
for adult-onset ADHD independent of a complex psychiatric history. 
Conclusions: Individuals seeking treatment for late-onset ADHD may be valid cases; however, 
more commonly, symptoms represent nonimpairing cognitive fluctuations, a comorbid disorder, 
or the cognitive effects of substance use. False positive late-onset ADHD cases are common 
without careful assessment. Clinicians should carefully assess impairment, psychiatric history, 
and substance use before treating potential late-onset cases. 
In recent years, an influx of adolescents and young adults without documented childhood 
attention deficit hyperactivity disorder (ADHD) have presented to clinics with complaints of 
inattention and/or hyperactivity/impulsivity symptoms, often inquiring about stimulant 
medication (1–3). It remains unclear whether this trend is driven by typically developing 
individuals seeking stimulant medication for cognitive enhancement or by individuals with late-
onset ADHD that warrants medical treatment. Recent birth cohort studies support the 
phenomenon of late-onset ADHD, reporting a 2.5% 10.7% prevalence for a form of ADHD that 
first emerges in adolescence or adulthood (4–7). These studies claim that most adult ADHD 
cases (67.5% 90.0%) do not involve the experience of symptom onset in childhood. This claim 
is contrary to decades of research characterizing ADHD as a chronic neurodevelopmental 
disorder with symptoms that appear before age 12 (8–11). The authors speculate that late-onset 
ADHD may appear spontaneously, but critics suggest that these cases may also represent 
individuals with undetected childhood symptoms (i.e., late-identified rather than late-onset) (12–
14). 
Critics also suggest that late-onset ADHD prevalence may be inflated by methodological 
artifacts, such as reliance on ADHD screening instruments, inability to detect symptoms that 
emerged in long gaps between assessments, a false-positive paradox, and failure to consider 
other mental disorders, health problems, or substance abuse as the source of symptoms (12–14). 
If many late-onset cases are false positives, this may misinform the field’s understanding of 
ADHD as a chronic disorder and overstate its prevalence. On the other hand, true late-onset 
ADHD may partially explain the uptick in adolescents and young adults seeking first-time 
treatment for newly reported difficulties (4–7). 
The present study investigates late-onset ADHD in the local normative comparison group of 
the Multimodal Treatment Study of ADHD, which was designed to carefully assess ADHD 
symptoms over time (15, 16). For 14 years from childhood to adulthood, comparison participants 
underwent comprehensive psychiatric evaluations with multi-informant assessment of ADHD 
symptoms and impairments (17, 18). Due to the frequency (eight time points) and 
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comprehensiveness of these assessments, ADHD symptom onset, other mental disorders, 
impairments, and substance use can be isolated temporally and considered when determining the 
history and nature of potential late-onset cases. Through careful review of multi-informant, 
longitudinal psychiatric data using a stepped diagnostic procedure that pinpoints symptom 
origins, we aimed to 1) understand what proportion of individuals with reported late-onset 
ADHD symptoms represent true cases of the disorder and 2) provide detailed clinical profiles for 
identified late-onset ADHD cases. Our procedure complements the epidemiological population 
studies by exploring the nature of late-onset ADHD after addressing previously noted 
methodological confounds and illustrating how late-onset ADHD might emerge over time (12–
14). 
Method 
The Multimodal Treatment Study of ADHD compared effects of 14 months of pharmacological 
and psychosocial treatments for children (7.0–9.9 years old) with ADHD, combined type (15). 
Two years after baseline, 289 classmates were recruited for the local normative comparison 
group. The Multimodal Treatment Study of ADHD continued with prospective follow-up until 
16 years after baseline (15–18). Informed consent was obtained in childhood and adulthood. 
Participants 
We identified a comparison group subsample (N=239) (Table 1) who did not meet diagnostic 
criteria for ADHD during childhood baseline assessment and who had at least one assessment in 
adolescence (ages 12–17) and adulthood (aged 18 years or older). Of the 289 originally recruited 
comparison participants, we excluded 31 individuals with a baseline Diagnostic Interview 
Schedule for Children diagnosis of ADHD (17–19) and 19 participants with insufficient follow-
up data. This subsample (N=239) was recruited between 8.19 and 13.85 years of age (mean=9.89 
years [SD=1.22]), and the average age at the final adult assessment was 24.40 years (SD=1.36). 
Procedures 
Comparison group recruitment was designed to reflect the local population from which the 
ADHD sample was drawn. Classes in the schools of the ADHD participants were randomly 
selected. After obtaining consent from more than 50% of the classmates in the selected 
classroom, individuals were selected randomly and group-matched for sex. ADHD diagnosis was 
neither inclusionary nor exclusionary for the comparison group. Study assessments were 
administered to comparison participants upon recruitment (comparison baseline; 2 years after 
ADHD baseline) and at 3, 6, 8, 10, 12, 14, and 16 years after initial baseline by Bachelor’s-level 
staff who were trained to be objective. 
Measures 
ADHD symptoms. 
Symptoms in childhood and adolescence were measured using the SNAP [Swanson, Nolan and 
Pelham] Rating Scale completed by parents, teachers, and adolescents (20, 21). Symptoms in 
adulthood were measured using the Conners’ Adult ADHD Rating Scale completed by 
participants and parents (22). The SNAP and Conners’ scales both list DSM-IV-TR ADHD 
symptoms. Respondents indicated the extent to which participants displayed each symptom on a 
scale from 0 “not at all” to 3 “very much.” Scores of 2 and 3 indicated symptom presence, as is 
standard practice when using these scales to detect clinically meaningful ADHD symptoms (23). 
Impairment. 
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In adolescence, impairment was measured using the parent version of the Columbia Impairment 
Scale (24). Because the Columbia Impairment Scale assesses impairment across multiple 
domains, including several that are unrelated to ADHD (e.g., feeling nervous/afraid), we 
examined impairment scores for four central domains of ADHD-related impairment: “getting 
along with kids own age,” “schoolwork,” “behavior at home,” and “behavior at school.” The 
scale utilizes a 0–4 severity range, and a score 3 in at least one of the four domains was 
considered sufficient to meet the impairment threshold (25). In adulthood, parent- and self-
versions of the Impairment Rating Scale were used to measure impairment globally and in 11 
domains of functioning (26). Response options ranged from 0 (“no problem”) to 6 (“extreme 
problem”). The Impairment Rating Scale is a measure of general impairment and has strong 
psychometric properties for identifying ADHD-related impairment. An empirically validated 
cutoff score >3 on any item was used to define clinically significant impairment (26). 
Substance use. 
Heavy substance use was measured using the Diagnostic Interview Schedule for Children and 
Substance Use Questionnaire (19, 27, 28). Substance use disorders reported on the Diagnostic 
Interview Schedule for Children by either the parent or participant were considered when 
determining late-onset ADHD. Self-reported marijuana or other drug use on the Substance Use 
Questionnaire more than twice per week was classified as heavy substance use. 
Mental disorders. 
On the Diagnostic Interview Schedule for Children (19), parent- or self-report that indicated the 
presence of a mental disorder that better accounted for ADHD symptoms was exclusionary for a 
late-onset ADHD diagnosis. All disorders assessed using the Diagnostic Interview Schedule for 
Children were considered (see the data supplement accompanying the online version of this 
article). Eight experienced, licensed clinicians (three psychiatrists, five clinical psychologists) 
reviewed onset and chronicity of all mental symptoms, and each voted whether a case should be 
excluded based on ADHD symptoms or impairment being attributable to another disorder (e.g., 
effects of anxiety symptoms on concentration). A case was excluded if agreed upon by a 
majority. Most decisions were unanimous (see the online data supplement). 
Analytic Plan 
There is a considerable risk for both false negative and false positive ADHD diagnoses in 
adolescents and adults (29). Regarding false negatives, there is established underreporting of 
ADHD symptoms in non-self-referred children, adolescents, and adults, concern that informants 
do not fully observe the functioning of adolescents and adults, and evidence that wording of 
some DSM ADHD symptoms may not be developmentally relevant for adolescents and adults 
(21, 29–32). Regarding false positives, normative variations in attention can be mistaken for 
ADHD symptoms, and ADHD symptoms often overlap with features of other disorders (33). To 
optimize sensitivity and specificity, our strategy to assess adolescent- and adult-onset ADHD 
took the stepped approach outlined by Sibley et al. (34), which first casts an intentionally wide 
net for ADHD symptoms to protect against false negatives (using a version of an “or rule” that 
allows all reported symptoms to be considered). The second step protects against false positives 
by carefully assessing and requiring meaningful impairment, establishing symptoms across 




At each assessment, ratings on the SNAP (parent, teacher, and adolescent) or Conners’ (parent 
and adult) scale were combined at the item-level using an “or rule,” such that if a symptom was 
endorsed by any rater, it was deemed present. Symptom count was determined separately for 
inattention and hyperactivity/impulsivity. After calculating combined symptom count, DSM-5 
symptom thresholds were applied considering current age (six symptoms for participants ages 
12–16; five symptoms for participants aged 17 and over) for either inattention or 
hyperactivity/impulsivity (35). 
Impairment. 
Next, parent- and self-ratings from the Impairment Rating Scale were combined at the item level 
using an “or” rule to designate clinically significant impairment. If a participant who met 
symptom threshold for ADHD also had clinically significant impairment according to the parent 
Columbia Impairment Scale (adolescents) or combined Impairment Rating Scale (adults), he or 
she was retained as a potential case of late-onset ADHD. 
Onset. 
We examined SNAP symptom data at all assessments for those cases with symptoms and 
impairment in adolescence (ages 12–17) or adulthood (aged 18 or older). If a case subject was 
younger than 12 years old when symptom criteria for ADHD were first met, the individual was 
not considered to be late-onset. 
Substance use. 
All retained cases were examined to determine whether heavy substance use was a probable 
source of ADHD symptoms. If ADHD symptoms occurred exclusively in the context of heavy 
substance use, we designated substance use to be the source of ADHD symptoms. 
Other mental disorders. 
Next, retained cases were examined to determine whether ADHD symptoms or impairments 
were better explained by another mental disorder. Cases with comorbidities were retained as 
potential cases of late-onset ADHD if there was low likelihood that the comorbid disorder could 
account for ADHD symptoms or impairments. 
Cross-situational symptoms. 
DSM-5 ADHD diagnosis requires several symptoms to be present in two or more settings (35). 
Therefore, cross-situational symptoms were required at the time DSM-5 symptom thresholds 
were met. Cross-situational symptoms were defined as 1) at least two symptoms reported, each 
by the parent and teacher, or 2) at least two symptoms endorsed, each by the case subject (self-
report) and another informant. Because symptoms endorsed on self-reports might occur in the 
same setting as parent or teacher reports, we consulted interview questions about symptom 
setting to ensure self-reported symptoms represented a second context. 
Onset and chronicity. 
Among case subjects who met criteria for late-onset ADHD, we calculated the average age at 
onset and examined chronicity by plotting ADHD symptoms by rater at each assessment point. 
To consider whether included case subjects were late-onset compared with late-identified, we 
compared childhood ADHD symptom severity for included cases to sample (N=239) means at 




An outline of the multistep assessment process and display of the proportion of case subjects 
included in each step are provided in Table 2. 
Symptom criteria. 
Of the 239 comparison case subjects without ADHD at baseline, 96 (40.2%) met DSM-5 
symptom threshold for ADHD based on combined parent, teacher, and self-reports using an item 
level “or rule” during at least one adolescent follow-up assessment. (If a stricter “or rule” was 
applied requiring a single rater to endorse symptoms above the DSM-5 threshold, 93 adolescents 
met DSM-5 ADHD symptom count.) 
Impairment. 
Of the 96 case subjects who met symptom criteria for ADHD in adolescence, 32 (33.3%) 
experienced clinically significant impairment at the time they met the DSM-5 symptom count. In 
total, 13.4% of the 239 comparison case subjects without ADHD at baseline met both symptom 
and impairment criteria for ADHD at an adolescent follow-up assessment. 
Adolescent-onset. 
Among these 32 cases, 11 were under age 12 when they first met DSM ADHD symptom count 
according to at least one source and were considered childhood-onset cases. Thus, only 21 case 
subjects actually had onset during adolescence. 
Ruling out substance use. 
Among the 21 case subjects who showed adolescent-onset ADHD symptoms and impairment, 
three had a marijuana use disorder that better accounted for the ADHD symptoms. In total, 18 
cases of adolescent-onset ADHD with significant impairment were not attributable to heavy 
substance use. 
Ruling out other disorders. 
Of these 18 case subjects, nine had a history of pre-existing or concurrent mental disorders and 
were reviewed by the clinical panel. The panel voted to exclude five based on evidence that 
symptoms better reflected another mental disorder (see the online data supplement). Thus, 13 
case subjects appeared to have onset of elevated ADHD symptoms and impairment in 
adolescence that was not attributable to other mental disorders. 
Cross-situational symptoms. 
Of the 13 case subjects who had onset of elevated ADHD symptoms and impairment in 
adolescence, six had symptoms that were only reported by a teacher. One had symptoms that 
were reported by the teacher and the participant (self-report), but self-reported symptoms 
occurred only in the classroom. Thus, six case subjects (2.5% of the comparison subjects without 
ADHD at baseline) appeared to have an onset of elevated ADHD symptoms and impairment in 
adolescence that were present in more than one setting (see Table 2). 
Onset and chronicity. 
The average age at onset among the six adolescent-onset cases of ADHD was 14.22 years 
(SD=1.50; range: 12.09–16.08). The chronicity of ADHD across assessment points for all 
adolescent-onset ADHD cases is shown in Figures 1 and 2. Four of these six met symptom 
criteria only during the teenage years. These four remitting case subjects did not receive any 
medication or behavioral treatments for ADHD during the follow-up period. Two had symptoms 
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that persisted into their 20s. Five of the six adolescent-onset case subjects (83.3%) had childhood 
ADHD symptoms that exceeded sample baseline means (see Table 1 and Figures 1 and 2). The 
average number of childhood symptoms among the six included case subjects was 2.5 for 
inattention (range=0–5; SD=2.26; Cohen’s d=0.31) and 1.67 for hyperactivity/impulsivity 
(range=0–3; SD=1.21; Cohen’s d=0.33). 
Adult-Onset ADHD 
Symptom criteria. 
Of 239 comparison case subjects without ADHD at baseline, 19.7% (N=47) met DSM-5 
symptom criteria for ADHD during at least one adult assessment based on combined parent and 
self-report using an item-level “or rule.” (If a stricter “or rule” was applied requiring a single 
rater to endorse symptoms above the DSM-5 threshold, 43 adults met DSM-5 ADHD symptom 
criteria.) 
Impairment. 
Among 47 case subjects who met symptom criteria, 40 (85.1%) experienced clinically significant 
impairment. In total, 16.7% of the 239 comparison cases without ADHD at baseline met both 
symptom and impairment criteria for ADHD during at least one adult assessment. 
Adult onset. 
Of the 40 case subjects with both ADHD symptoms and impairment in adulthood, 12 showed 
symptom onset during childhood, 18 during adolescence, and 10 during adulthood. Four were 
previously deemed adolescent-onset cases. Thus, 24 of 239 case subjects first met impairment 
criteria for ADHD in adulthood, although 14 had initial symptom onset in adolescence and 10 
had initial symptom onset in adulthood. 
Ruling out substance use. 
Of the 24 case subjects meeting symptom and impairment criteria, 14 had impairing symptoms 
exclusively in the context of heavy substance use (see the online data supplement). In total, 10 
adult-onset ADHD cases were not attributable to heavy substance use. 
Ruling out other mental disorders. 
Of the 10 remaining case subjects, five were excluded because symptoms or impairment were 
attributable to another mental health disorder. Two did not possess Diagnostic Interview 
Schedule for Children data for adulthood, and these cases were deemed inconclusive. Thus, three 
case subjects appeared to have onset of elevated ADHD symptoms and impairment in 
adolescence that was not attributable to other mental disorders. One of the included adult case 
subjects was excluded in adolescence due to anxiety and mania but included in adulthood 
because comorbid disorders had remitted when ADHD symptoms returned (see Figure 3). 
Cross-situational symptoms. 
One of the three remaining adult-onset ADHD case subjects possessed symptoms in only one 
setting. Thus, of 239 comparison case subjects without ADHD at baseline, only two (0.8%) 
showed evidence of adult-onset ADHD (see Table 2). 
Onset and chronicity. 
The adult-onset case subjects reported onset at ages 21.05 and 27.45, respectively. Both met 
criteria for ADHD at only one adult assessment. One subject’s childhood symptoms (inattention, 
 37 
N=0; hyperactivity/impulsivity, N=1) were below the baseline sample average. The other was 
first assessed at age 12, reporting one inattention symptom and two hyperactivity/impulsivity 
symptoms at that time (see Figure 3). 
Characteristics of case subjects with late-onset ADHD symptoms and impairment who were 
excluded from diagnosis are summarized in the online data supplement. 
Discussion 
The local normative comparison group of the Multimodal Treatment Study of ADHD provided a 
unique opportunity to study detailed fluctuations in ADHD symptoms over time in adolescents 
and young adults without a childhood history of ADHD. After using a stepped diagnostic 
procedure that carefully considered multi-informant data, longitudinal symptom patterns from 
childhood to adulthood, impairment, co-occurring mental disorders, and substance use, 
approximately 95% of case subjects who initially screened positive for late-onset ADHD were 
excluded from diagnosis (Table 2). These data indicate that when assessing adolescents and 
young adults for first-time ADHD diagnoses, clinicians should obtain a thorough psychiatric 
history and assessment of current functioning. Furthermore, 53% of adolescents and 83% of 
adults who met all symptom, impairment, and late-onset criteria for ADHD were excluded 
because symptoms or impairment were better explained by heavy substance use or another 
mental disorder (Table 2) (also see the online data supplement). Therefore, previously reported 
late-onset ADHD prevalence rates (2.5% 10.7%) may be overestimated due to limited ability to 
consult multi-informant data, track symptoms in extended gaps between assessment points, and 
review detailed patterns of substance use and comorbidity over time when determining diagnosis 
(4–7). 
Six adolescent-onset ADHD case subjects appeared in the comparison group. One form of 
adolescent-onset ADHD (N=4) was adolescence-limited (Figure 1) and characterized by above-
average childhood symptoms, borderline to average intelligence, and symptom remission by age 
19. In all four of these cases, the preponderance of symptoms was reported by teachers, although 
corroborated by parents and the adolescents. One explanation for this pattern is developmental 
misfit that mimics or facilitates inattention symptoms. Mounting environmental demands in 
adolescence may temporarily exacerbate above-average but subthreshold childhood ADHD 
symptoms (Figure 1) or create cognitive overload for adolescents with slower developing 
prefrontal regions (36, 37). In absence of mature executive functions, some adolescents may also 
display deficient self-control in socially or emotionally salient contexts, leading to adolescence-
limited behavior problems that may be perceived as hyperactive/impulsive symptoms by raters 
(38). Further work is needed to better understand this adolescence-limited presentation and the 
influence of cognitive development on ADHD-like symptoms in adolescents without childhood 
ADHD. 
A second adolescent-onset ADHD presentation was characterized by above-average 
childhood ADHD symptoms and superior intellect (Figure 2). Two male subjects with superior 
IQs exhibited a persistent form of late-onset ADHD with slowly escalating symptoms from 
childhood through young adulthood. This profile echoes previous findings that childhood ADHD 
symptoms may be masked in individuals with cognitive strengths, delaying initial ADHD 
diagnosis (1). Since symptoms were likely present but mitigated in childhood, these individuals 
might better be characterized as late-identified, rather than late-onset, ADHD cases (39). 
The Multimodal Treatment Study of ADHD comparison group did not support adult-onset 
ADHD independent of a complex psychiatric history. The two case subjects identified as adult-
onset both possessed a variety of past or current mental health symptoms (Figure 3). In both 
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cases, it was difficult to disentangle the etiology of these individuals’ symptoms, and thus the 
panel conservatively voted to retain the cases. In line with the false-positive paradox (8), the vast 
majority of case subjects who initially met late-onset symptom and impairment criteria were 
excluded from diagnosis because of clear evidence that heavy substance use or another mental 
disorder better accounted for symptoms or impairment (Table 2). In fact, the majority of 
impairing late-onset ADHD symptoms in young adulthood could be traced to heavy substance 
use (Table 2) (also see the online data supplement). There are still other potential causes of late-
onset symptoms, such as brain injury, illness, or trauma, that should also be considered in future 
investigations. Without clear exclusionary guidelines for ADHD in adolescents and adults, there 
is risk that ADHD may become a catchall diagnosis for executive dysfunction stemming from 
any source. It is unclear whether ADHD-like presentations stemming from nontraditional sources 
should be differentiated from a chronic form of ADHD with developmental origins, although 
treatment may be similar (40). Despite many strengths to birth-cohort samples, they are limited 
because they do not possess the detailed and frequent data collection required to carefully follow 
psychiatric functioning over time. One of the studies also did not perform full childhood 
diagnostic assessments, which may have led to missed childhood symptoms in some cases (5). 
Of course, the average age at comparison baseline was approximately 10 years old, limiting our 
study’s ability to consider detailed symptom records before this assessment. 
The comparison group was drawn from the same local school, sex, and age/grade pool as the 
ADHD sample, which may over-represent certain characteristics, such as male sex or slightly 
above-average family income. During adolescence, impairment ratings were only available from 
parents. Some case subjects may have met impairment criteria in adolescence if teacher or self-
ratings had been available. We assessed case subjects only to the mid-to-late 20s. New late-onset 
cases might appear later in development. We also did not collect comprehensive data on physical 
health or personality disorders with impulsive features that may better explain late-onset cases. 
Because only eight late-onset cases were detected, we were insufficiently powered to conduct 
analyses comparing late-onset cases with other subgroups. 
Conclusions 
Some adolescents and young adults who present for first-time ADHD diagnoses may represent 
valid late-onset cases. However, the most common source of impairing late-onset ADHD 
symptoms in adolescence and young adulthood was substance use. Prior to diagnosing or treating 
ADHD in late-onset cases, clinicians should carefully assess and treat substance use and 
comorbid mental health disorders as a potential source of symptoms. The majority of adolescent-
onset cases possessed transient symptoms. Thus, it may be appropriate to give provisional first-
time ADHD diagnoses in adolescence and to monitor symptoms over time, as remission may 
occur within a few years. Further research is needed to understand how cognitive immaturity or 
adolescent neurocognitive changes might mimic or facilitate emerging ADHD symptoms. 
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TABLE 1. Baseline Characteristics of the Comparison Subsample (N=239)a 
Characteristic  
 N % 
Male sex 191 79.9 
Race/ethnicity 239  
 White 159 66.5 
 Black 27 11.3 
 Hispanic 31 12.9 
 Other 22 9.3 
 Mean SD 
Age at baseline (years) 9.89 1.22 
Intelligence scoreb 109.82 18.65 
SNAP Rating Scale scorec   
 Baseline inattention symptoms count 1.70 2.61 
 Baseline hyperactivity/impulsivity symptom count 1.03 1.92 
a The median household income of the comparison subsample was $55,000. 
b Determined using the WISC-III. 
c SNAP=Swanson, Nolan and Pelham Rating Scale. 
 
TABLE 2. Results of Stepped Procedure for Evaluating the Validity of Late-Onset ADHD 
Casesa 
Result Adolescent-Onset Adult-Onset 
 N % N % 
Meets DSM-5 ADHD symptom criteria 96 40.2 47 19.7 
 Clinically significant impairment 32 13.4 40 16.7 
  Late-onset 21 8.8 24 10.0 
   Not due to substance abuse 18 7.5 10 4.1 
    Not attributable to other mental disorder 13 5.4 3 1.3 
     Cross-situational symptoms 6 2.5 2 0.8 
Absence of subthreshold childhood symptoms (less than 3 1.3 2b 0.8 
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three childhood symptoms of inattention and 
hyperactivity/impulsivity) 
a Symptom criteria were counted using an “or rule” that considered information from all 
available informants (e.g., parent, self, teacher); the designated period was either adolescence or 
adulthood; cross-situationality was inferred from multiple raters and consulting interview 
questions about context as needed. 
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Attention-deficit/hyperactivity disorder (ADHD) is a common and impairing disorder affecting 
children, adolescents and adults. Several treatment strategies are available that can 
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successfully ameliorate symptoms, ranging from pharmacological to dietary interventions. Due 
to the increasing range of available options, an informed selection or prioritization of 
treatments is becoming harder for clinicians. This review aims to provide an evidence-based 
appraisal of the literature on ADHD treatment, supplemented by expert opinion on plausibility. 
We outline proposed mechanisms of action of established pharmacologic and non-
pharmacologic treatments, and we review targets of novel treatments. The most relevant 
evidence supporting efficacy and safety of each treatment strategy is discussed. We review the 
individualized features of the patient that should guide the selection of treatments in a shared 
decision-making continuum. We provide guidance for optimizing initiation of treatment and 




Attention-deficit/hyperactivity disorder (ADHD) is characterized by pervasive and impairing 
symptoms of inattention, hyperactivity, and impulsivity1. The disorder affects around 5% of 
children and adolescents2 and 2.5% of adults3 worldwide. Decades of research consistently 
report strong links between ADHD and adverse life outcomes4-6. Children with ADHD show an 
increased risk of accidental injuries7, poor relationship with peers8 and parents9, worse quality 
of life10, and impaired school performance11. Adolescents with ADHD show more school refusal 
and grade retention11, earlier and more frequent use of marijuana, tobacco and other drugs12, 
13, earlier sexual engagement14 and more frequent teenage pregnancy15, 16. Prospective studies 
of adults with child-onset show that individuals with persistent ADHD (but not remitting ADHD) 
have lower education attainment, reduced job performance, and increased emotional 
problems17-19, and studies of adult onset ADHD show increased risk of traffic accidents20, 
criminality21, unemployment22 and substance abuse23. A common denominator throughout the 
life cycle is increased mortality by external and accidental causes24. Overall, the estimated 
incremental economic burden imposed by ADHD ranges from $143 to $266 billion dollars in the 
United States alone, most of which is a consequence of lost productivity 25.  
 
The evidence documenting the individual and social impact of ADHD is the most important 
justification for treatment. Accordingly, there is agreement between clinical guidelines from 
Pediatrics, Psychiatry, and Primary care bodies that health professionals should be identifying, 
diagnosing and treating individuals with ADHD26-30. Furthermore, numerous meta-analyses 
published in the last few years have assessed the efficacy of pharmacological, non-
pharmacological and combined treatment for managing ADHD31-42. Evidence clearly supports 
short-term efficacy of pharmacological treatments, but evidence for long-term efficacy is less 
clear. Non-pharmacological interventions such as cognitive training and neurofeedback are 
probably not efficacious, and more research is needed to support or refute the role of 
behavioral therapies on ADHD treatment. Interestingly, health professionals are often given 
differing and sometimes contradictory advice about how to best interpret this evidence and 
prioritize the various treatment approaches for their patients. In this review, we examine the 
evidence of efficacy, safety, and tolerance of available interventions, and propose a balanced 





Pharmacological treatment remains the mainstay of ADHD treatment in most clinical settings 
and guidelines26-30. In some settings, around 90% of children with ADHD eventually receive 
medication as treatment43. The most widely used medications are two psychostimulants, 
methylphenidate (MPH) and the Amphetamines (AMP). Second-line medications include 
atomoxetine (ATX), guanfacine (GFC) and clonidine (CLO), usually prescribed after lack of 
response, intolerance or contraindication to the psychostimulants. Other unlicensed 
medication options include bupropion, modafinil, and tricyclic antidepressants.  
 
 
MECHANISMS OF ACTION OF MEDICATIONS FOR ADHD TREATMENT 
 
A comprehensive discussion on mechanism of action of all drugs used for ADHD treatment is 
beyond the scope of this paper; however most medications for ADHD are thought to act 
primarily on catecholamine pathways44 (Figure 1). At the synaptic level, these drugs seem to be 
catecholamine agonists, increasing availability of dopamine or norepinephrine (e.g., by blocking 
reuptake). However, there is controversy about the density of dopamine transporters in 
individuals with ADHD and the impact of this on catecholamine levels. Some studies suggest 
increased transporter density with rapid recycling of synaptic dopamine resulting in a dopamine 
deficit45-47. Others48, 49 suggest a dopamine deficit associated with low dopamine release, which 
in untreated cases is associated with low transporter density. Recent PET imaging studies 
indicate that transporter density increases and becomes high after chronic treatment with 
stimulants50, 51.  
 
There are differences in the specific mechanism of action for each medication. The 
psychostimulants (MPH and AMP) inhibit dopamine and norepinephrine transporters. They 
work as reuptake inhibitors increasing neurotransmission, primarily in the striatum and 
prefrontal cortex 52. Atomoxetine inhibits the norepinephrine transporter 1 (NET 1). It prevents 
the reuptake and therefore increases neurotransmission of norepinephrine in all regions of the 
brain53 and of dopamine specifically in the prefrontal cortex, where there are very few 
dopamine transporters53. The alpha-2 receptor agonists (clonidine and guanfacine) stimulate 
alpha-2 noradrenaline receptors in the central nervous system. The mechanism of action in 
ADHD symptoms is mediated by the increased noradrenergic tone in the prefrontal cortex and 
an indirect input of noradrenaline from the locus coeruleus54. Bupropion is converted into two 
main metabolites (hydroxybupropion and threohydrobupropion) that are potent 
norepinephrine enhancers by transporter inhibition55. Tricyclic antidepressants (TCAs) primarily 
act by blockade of the serotonin and norepinephrine transporters, which enhances 
neurotransmission56. There is little effect on dopamine transporters52. Modafinil has been 
shown to induce an atypical conformational change in the DAT compared to traditional 
psychostimulants57.  
 
The simplified mechanisms of action described are useful for an initial discussion of the 
expected therapeutic and adverse effects of these medications. Nonetheless, we acknowledge 
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that this is a reductionist and incomplete perspective. For example, although these medications 
may have different mechanisms of action, the ultimate effects may be similar, since they all 
appear to increase the availability of dopamine and/or noradrenaline. This in turn modulates 
neurotransmission of a wide range of brain circuits (primarily GABAergic and glutamatergic) 
that control a range of cognitive functions including executive functioning, response to reward, 
memory and timing58-61 (Figure 1 – inferior left panel). These immediate effects on 
dopaminergic and noradrenergic neurotransmission do not fully explain other aspects of 
treatment, such as differences in the latency for onset and offset in efficacy, which are short 
(hours to days) for stimulants and longer (weeks to months) for non-stimulants 62-65. One 
plausible albeit speculative hypothesis is that some ADHD medications may promote long-term 
alterations in the brain through the regulation of genes and proteins involved in neurite 
outgrowth and configuration of receptors and transporters of neurotransmitters66-68 (Figure 1 – 
inferior right panel). If this hypothesis is correct, long-term stimulant treatment could even 
normalize the trajectory of cortical development and other structural brain changes 69. 
However, these changes are also consistent with the development of long-term tolerance 
through up-regulation of monoamine transporters70.  
 
 
PHARMACOGENOMICS OF MEDICATION FOR ADHD 
 
Although pharmacological treatment with psychostimulants for ADHD are among the most 
effective interventions available in Psychiatry71, a considerable proportion of patients - roughly 
a third - do not respond adequately to and/or tolerate stimulant treatment72, 73. This 
heterogeneity in individual response and adverse events could be due to genetic factors, which 
has been investigated in dozens of ADHD pharmacogenomic studies in the last decades, with 
most studies focusing on methylphenidate74. 
 
Most reports describe candidate-gene approaches with catecholamine receptor genes. A recent 
meta-analysis reviewed all pharmacogenomic studies with methylphenidate and suggested 
associations of single nucleotide polymorphisms (SNPs) at ADRA2A, COMT, SLC6A2 and variable 
number of tandem repeats (VNTRs) in DRD4 and SLC6A375 with response to treatment. Authors 
suggested that future studies might propose a multivariable approach to combine small effects 
of individual genes into one valuable clinical tool, but current clinical use is not yet 
recommended. 
 
Another promising field of research in ADHD pharmacogenomics relates to genes involved in 
the metabolism of the medications. Studies investigating the role of the human 
carboxylesterase 1 gene (CES1), that encodes an enzyme that metabolizes MPH76, have shown 
that CES1 variants are associated with the total dose needed and the effect side profile in 
children medicated with MPH77, 78. Likewise, different alleles of the cytochrome p450 2D6 
(CYP2D6) gene confer to individuals the feature of poor to extensive metabolizers of 
Atomoxetine, which has been shown to significantly affect clinical response and effect side 
profile79, 80.  
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Lately, more sophisticated designs have been applied to the study of ADHD pharmacogenomics. 
Two genome-wide studies have been conducted, failing to find specific genetic variants 
associated with response to treatment or adverse effects81, 82. A study which combined GWAS, 
functional annotation, pathway enrichment analyses and expression quantitative trait loci 
strategies, provided promising evidence for potential gene candidates that mediate 
methylphenidate response in adult patients. A meta-analysis conducted within this study 
identified 15 positive signals. The phosphatidyelathanolamine binding protein 4 (PEBP4), which 
is involved in cell proliferation and survival, was the top hit (Pagerols et. al, final review). The 
underlying mechanisms that mediate these findings through clinical effects are yet to be 
clarified. 
  
Several companies offer extensive genetic testing with a promise of optimizing pharmacological 
selection for ADHD83-85. We reviewed the information on the websites, which we find to be 
insufficient for the claims made. We and others do not believe that routinely use of these 
genetic tests to guide ADHD treatment is currently supported by evidence and that they should 
not be recommended74, 86. However, special cases, such as patients with clear indication to 
atomoxetine but refractory to treatment, might benefit from dose adjustments based on their 
classification between slow and fast metabolizers through CYP2D6 genotyping.  
 




Psychostimulants are the most studied medications used for ADHD. Hundreds of randomized 
clinical trials have been conducted to study short-term efficacy and safety of psychostimulants 
for the treatment of ADHD in children, adolescents, and adults and have been summarized in 
many meta-analyses32, 33, 38, 39, 87-105. The overall conclusion is that psychostimulants are the 
most effective available treatment for ADHD, at least in the short-term87, 89, 106, with clear acute 
benefits (typically within an hour after an adequate dose) that continue until the drug is 
metabolized (which depends on pharmacokinetic properties of the drug and method of drug 
delivery used). If medication is continued, these acute benefits persist for at least a year 
(although dose increases may be necessary to maintain full efficacy). The evidence also 
suggests that stimulants are safe and well-tolerated37, 107.  
 
A recent Cochrane review and meta-analysis questioned the quality of available data on the 
efficacy of methylphenidate 33. Authors confirmed the previously observed substantial effect 
sizes for symptom reduction and the absence of major adverse effects in randomized clinical 
trials of methylphenidate for children and adolescents with ADHD. However, they classified all 
185 included trials as being at high risk of bias. This review has been criticized by experts in the 
field due to methodological choices of bias assessment108-110. For instance, randomized clinical 
trials funded by government or independent funding agencies were labeled as biased if any one 
of multiple authors had disclosed a financial connection to the pharmaceutical industry.  
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A network meta-analysis including 190 randomized clinical trials of ADHD treatments supported 
psychostimulants as the most efficacious treatment available for ADHD considering 
pharmacological and nonpharmacological options32. This review also found no differences in 
acceptability between psychostimulants and other pharmacological options. Summarized 
estimates of efficacy and tolerability reported in this meta-analysis are presented in Table 1. 
However, the overall quality of the studies ranged from low to very low according to the GRADE 
system. A second network meta-analysis of pharmacological treatments including 73 studies 
and 15,025 participants used a ranking strategy to stratify medications according to efficacy and 
tolerability111. Authors concluded that Lisdexamfetamine and Methylphenidate had the best 
overall ranking scores. It is important to note that some methodological aspects in these meta-
analyses like the heterogeneity among studies, the different number of studies included for 
each comparison, and the quality of some studies included provide results that need to be 




Atomoxetine is considered an important pharmacological treatment for ADHD in clinical 
guidelines26-30, particularly when psychostimulants are contraindicated or not tolerated. In 
addition, it might be considered in some special situations e.g. when ADHD is comorbid with 
Bipolar Disorder and the risk of mood destabilization is high with stimulants, substance 
abuse/dependence or Tourette Syndrome26-30. 
 
Randomized clinical trials and several meta-analyses have consistently suggested that 
atomoxetine has acceptable efficacy and tolerability, but the observed effect size is smaller 
than that for psychostimulants32, 38, 87. Importantly, clinical trials have been conducted in 
children and adults with common comorbidities, like Anxiety disorders. In these patients, 
atomoxetine was effective in reducing ADHD symptoms while not exacerbating and in some 




The effectiveness of immediate release clonidine was demonstrated in several early 
randomized clinical trials116. An early meta-analysis reported a moderate effect size for the 
reduction of ADHD symptoms, particularly hyperactivity117, although not as big as that for 
stimulants. However, due to a short duration of action and adverse  effects such as somnolence 
and hypotension 118-120, it is relatively infrequently prescribed as a standalone treatment. In 
some countries, it is used as an add-on treatment with psychostimulants26-28, 32. An extended-
release formulation of clonidine has been approved for ADHD in some countries.  
 
Guanfacine is a more selective alpha 2 agonist with less sedating and cardiovascular effects. An 
extended-release preparation of guanfacine (GFC) was approved by the FDA for the treatment 
of ADHD in 2010. Seven randomized clinical trials in children and adolescents, support efficacy 
compared to placebo. Meta-analyses suggest that the effect size is lower than for 
psychostimulants and comparable to atomoxetine32, 87, 116. While one small clinical trial in adults 
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reported a large effect121, the actual effect size is still uncertain. There is evidence that 
guanfacine is useful as an adjunctive treatment to psychostimulants, being more effective than 





The effectiveness of bupropion as a treatment for ADHD has been studied in six clinical trials for 
children and adolescents and six clinical trials for adults. Results were summarized recently in 
two systematic reviews both of which concluded that the overall effect is small to moderate 
and quality of the evidence is poor125, 126. Comparative evidence seems to suggest that 
bupropion efficacy is inferior to that of psychostimulants and probably similar or inferior to that 
of atomoxetine127, 128. 
 
Tricyclics, and in particular desipramine, have been studied in six randomized clinical trials for 
children and adolescents including 216 participants summarized in a Cochrane meta-analysis129. 
There are even fewer studies in adults and no meta-analysis is available121, 130, 131. The evidence 
seems to support the efficacy of these medications in reducing ADHD symptoms. However, 
tricyclics are usually considered a third or fourth-line option in the treatment of ADHD26-30, 
because of the small number of studies and the overall low quality of evidence, as well as their 




Evidence describing the efficacy of modafinil for ADHD symptom reduction is still emerging. The 
results of five short-term randomized clinical trials in children and adolescents have been 
summarized in a meta-analysis132. Modafinil appeared to have a moderate effect in reducing 
ADHD symptoms and a dropout rate due to side effects similar to placebo. Prominent adverse 
effects were insomnia and decreased appetite. Studies on adults are less conclusive with 
contradictory results121. Clinical trials and post-surveillance reports have associated Modafinil 
with serious skin reactions, which led to FDA’s request of more data for the approval of the 
drug for ADHD133, 134. 
 
New drugs on the ADHD portfolio 
 
Nearly all of drugs in development for ADHD continue to focus on enhancing dopamine and 
norepinephrine (e.g., HLD200, Dasotraline, Viloxazine, and Mazindol)135-138. These drugs are 
being successfully tested in phase II and III trials and are likely to enter the market soon. 
However, because of the very similar mechanisms of action, their side effect profile and 
counter indications are likely to overlap with the drugs already available.  
 
Nevertheless, clinical trials registers and patent applications indicate that novel targets are 
being considered in preclinical studies. Amiloride is a sodium channel blocker used as an 
adjunctive treatment for high blood pressure. There is one ongoing clinical trial investigating its 
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role in ADHD139. Fasoracetam is a metabotropic glutamate agonist that is approved for stroke 
and vascular dementia. Phase II and III trials have been completed with adolescents, but no 
results have been published so far140. Metadoxine is a GABA modulator approved for acute 
alcohol intoxication. It was being tested for ADHD, but it failed phase III trials and the company 
halted its development141. Molindone, an antipsychotic drug that antagonizes dopamine 
receptors, is being testes as an add-on treatment for aggressive behavior in children and 
adolescents with ADHD142. Vortioxetine is an atypical antidepressant that inhibits the reuptake 
of serotonine, and is being tested in a phase II trial with adults with ADHD 143. While these have 
very different mechanisms of action to current ADHD medications, it should be noted that they 
are likely to be acting on the same brain circuits but downstream of the dopamine and 
noradrenaline modulation.  
 
In summary, the field should not expect significant revolutions in drug resources for ADHD in 
the next few years. Most of the new developments are focused on changing the mechanisms of 





Behavioral and psychosocial treatments 
 
Behavior parent training and social skills training are the primary recommended alternatives to 
medication management of ADHD26-28 They are usually regarded as first-line treatments for 
very young children or those with mild to moderate ADHD26-28. They are also the standard add-
on to medication treatment for severe presentations at any age26-28. In summary, most 
guidelines recommend behavioral interventions for ADHD in any situation, either alone or in 
combination with medication treatment26-28 and these are the most frequently used 
nonpharmacological treatment among children and adolescents43. 
 
However, the evidence is mixed and complex, making a definitive interpretation difficult. A 
seminal study was the Multimodal Treatment study for ADHD (MTA)144. In this 14-month 
randomized clinical trial, children were randomized to receive methylphenidate plus behavioral 
treatment (a combination of previously suggested strategies of parent-training, child-focused 
and school-based behavioral therapies), medication only, behavioral treatment only, or 
referred to usual care within a community setting. The authors and others have noted145 that 
there was no statistical difference between combined treatment and medication alone at the 
end of the treatment-by-protocol (primary analyses). This led to the conclusion that intensive 
behavioral treatment did not add to the efficacy of well-managed treatment with medication. 
 
Subsequent to the MTA, additional studies have provided evidence of efficiency for behavioral 
treatments. For example, (a) Charach and colleagues reviewed the efficacy of behavioral and 
pharmacological treatment for preschool children with ADHD94. For this age group, the 
evidence for benefits of behavioral treatment was strong, but the evidence for pharmacological 
treatment was not, and (b) sequencing of behavioral and pharmacological treatment revealed 
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that starting with behavioral treatment and adding medication resulted in better outcome (at a 
lower dose) than starting with medication and adding behavioral treatment146.  
 
Current appraisals of the available evidence do not agree on whether the balance of evidence 
supports or refutes the efficacy of psychosocial treatments for ADHD. One meta-analysis 
concluded that behavioral treatments were highly effective for ADHD147, and a review for the 
Agency for Health Care Research and Quality concluded that the evidence for positive effects of 
behavioral treatment on preschool children was strong enough to guide clinical practice94. 
However, a Cochrane systematic review and meta-analysis of randomized trials concluded that 
while BPT may have a positive effect on the behavior of children and adolescents with ADHD, 
the evidence is not strong enough to guide clinical practice41. A separate Cochrane meta-
analysis concluded that the evidence was insufficient to support social skills training for 
adolescents42. Several clinical guidelines have recommended both BPT and social skills as 
behavioral treatments26-28. Some of these discrepancies may be explained by the type of rater 
considered by reviews. Two recent meta-analyses identified a moderate and statistically 
significant pooled effect size for behavioral therapies on ADHD symptoms when all probably 
unblinded raters were included but that this effect was not maintained when considering only 
probably blinded raters.36, 148. The same group did however confirm that behavioral therapies 
were effective in improving positive parenting and conduct problems of children with ADHD, 
even on blinded ratings. 
 
The evidence for psychological therapies in adults is also conflicting. A carefully conducted 
randomized clinical trial compared the effect of adding a highly structured cognitive behavioral 
therapy (CBT) or relaxation with educational support to standard medication treatment. The 
main finding was a greater improvement in ADHD symptoms in the CBT group149. Another 
important study compared group CBT with individual clinical management either in 
combination with MPH or placebo, finding no difference in core symptom reduction but better 
outcomes in the Clinical Global Impression Scale150. Meta-analyses conclude that the overall 
effect of cognitive-behavioral therapies is small to moderate compared to active control groups 
for adults with ADHD151, 152.  
 
In summary, the evidence for behavioral interventions is difficult to integrate and summarize. 
Several different protocols are available and it is likely that not all patients are suitable for 
receiving each of the behavioral interventions. This may explain some of the controversial 
findings in the literature. Meanwhile, behavioral interventions are supposedly free from 
adverse effects and are strongly preferred over medication by some patients and caregivers153-
155. Considering the evidence from blinded studies, we conclude that we need more high-
quality studies before we can support the effectiveness of behavioral interventions on core 
ADHD symptoms. For now, well controlled studies suggest that they are effective at improving 
parenting, parent child relationships and oppositional behaviors that are common in children 
with ADHD and their families. Positive effects are more likely to be seen in favorable clinical 
settings where patient and/or caregiver are willing to engage in therapy, and a suitable protocol 
is readily available. Also, the combination of behavioral intervention with medication may result 
in a clinical dose that is lower than for treatment with medication alone. However, more 
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studies are needed to unequivocally prove or refute the effectiveness of behavioral 





Cognitive training strategies aim to reduce ADHD symptoms by improving performance in 
specific neuropsychological functions associated with ADHD (e.g.: attention, inhibitory control 
and working memory)31, 156. Cognitive training programs are usually delivered through 
electronic interfaces such as computers or mobile phones, and are designed to be appealing to 
the user (i.e. resembling videogames). Performance is continually reassessed so that training is 
adaptive157-159.  
 
A recent meta-analysis evaluated the effects, across sixteen randomized clinical trials, for 
probably blinded and potentially un-blinded raters separately 35. The conclusions match those 
of previous meta-analyses40, 148, indicating moderate efficacy in improving the 
neuropsychological functions targeted by the intervention but a less clear effect on symptoms. 
The effect size for total ADHD symptoms and inattentive symptoms was moderate and 
significant when rated by a potentially un-blinded rater. The estimates decreased when 
outcomes were rated by a probably blinded rater. Of note, the effect size was much larger for 
programs that included multiple process training (i.e., targeting more than one executive 
functioning) compared to those that focused on just on cognitive process. However, for the 
multiple process studies only potentially unblinded ratings were available. In summary evidence 
so far available suggests that cognitive training has no effect on core ADHD symptoms or other 




In neurofeedback, the patient is trained to improve self-control over brain activity patterns, 
which is most often monitored through simultaneously collected electroencephalogram (EEG) 
data160, 161. Its use in ADHD stems from the knowledge that patients with ADHD exhibit distinct 
EEG patterns compared to their non-affected peers162, 163. Current neurofeedback protocols 
focus predominantly on decreasing theta waves (low-frequency waves related to decreased 
vigilance) and/or increasing beta waves (high-frequency waves related to concentration and 
neuronal excitability). This is achieved by measuring EEG activity while the patient is engaged in 
a task, often a simple computer game, and modulates performance and reward according to 
specific changes in EEG pattern. It is estimated that in the United States around 10% of children 
and adolescents with ADHD have received neurofeedback interventions 43. 
 
While preliminary evidence from open-label trials suggested moderate to large effect for ADHD 
symptoms,164, 165 the latest meta-analyses concluded that the effects are moderate to large 
when proximal, potentially unblinded, raters were considered, but reduced by half and lost 
statistical significance when pooling estimates from probably blinded raters34, 148. However, the 
aggregated measures included both trials with standard and non-standard protocols. An 
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exploratory analysis revealed that, considering only 3 trials with both probably blinded raters 
and a standard protocol, the effect was moderate and significant, albeit with a large confidence 
interval. 
 
Although neurofeedback may have few adverse effects, it is a specialized intervention which 
usually requires 20 to 40 sessions, and as a consequence it is often expensive for the end user. 
Future research may identify more effective methods for using neurofeedback in ADHD. For 
instance, new protocols are using simultaneous functional magnetic resonance imaging as the 
therapy target of the intervention (i.e., the parameter that patients are induced to improve)166, 
167. On the other hand, feasibility also requires less expensive and complex equipment 
requirements. The evidence available indicates that neurofeedback is not effective for core 
ADHD symptoms and more high-quality studies should be performed before we can support 
the effectiveness of neurofeedback on core ADHD symptoms. Future trials should focus on 




The hypothesis that dietary factors might play a role in the etiology of ADHD was first proposed 
over forty years ago, and it remains a controversial topic until the present day. The main 
restrictive strategies are to remove artificial food colors from diet continuously (AFC) or to 
restrict several foods in a rapid course of 9 to 28 days – the ‘few foods approach’ (FFD). 
Supplementation with poly-unsaturated fatty acids (PUFAs) is also a commonly proposed 
strategy, based on the possible neuroprotective effect of those substances. 
 
The observed effect of dietary modification strategies for ADHD varies considerably depending 
on methodological aspects, including whether assessments are made by blinded or unblinded 
raters. A recent systematic reviewed data from 6 out of 14 available meta-analyses on this 
subject  and concluded that the estimated effect size of PUFAs for ADHD is too small to be 
considered a tangible contribution. The estimated effect of AFC exceeds that of PUFAs, but, 
while it is not so small to dismiss, neither is it large enough nor secure enough to make 
conclusive recommendations for implementation. The effect sizes for FFD were medium to 
large, and authors consider that the results might justify its administration in children with 
ADHD. However, they also note that the complete implementation of this treatment, which 
encompasses several courses of intense food restriction to identify the individual ideal scheme,  
might be unfeasible in many cases. Authors of the trials with the largest effect sizes have not 
made the protocols for their interventions public and it is therefore not yet possible to 
implement these outside of the original research setting. An overall appraisal of the evidence 
seems to suggest that the FFD and AFC diets have significant, although clinically small, effects 
on ADHD symptoms while having few adverse effects. 
 
Other promising nonpharmacological therapies  
 
New nonpharmacological options and strategies are being developed and tested for ADHD. 
Coaching programs designed to help an individual cope with the demands of the environment 
 54 
usually focus on improving executive functions such as time management, prioritization and 
effort sustainment over time. Initial empirical studies have shown promising results168, 169, but 
these trials are small naturalistic studies that need to be confirmed by randomized clinical trials. 
The Supporting Teens’ Autonomy Daily (STAND) program targets adolescents with ADHD and 
uses motivational interviewing to enhance adherence. A randomized clinical trial showed 
promising acute and long-term (six months after treatment ceased) effects on ADHD symptoms, 
parental stress and executive functioning skills170. Mindfulness is the act of self-regulating 
attention towards the current moment and the self. Mindful-based therapies are rooted in 
ancient Buddhist practices, and have recently gained popularity in western cultures to promote 
general well being and treat psychiatric disorders171. Some investigators suggest that 
mindfulness therapies are especially well suited to address the deficits associated with ADHD, 
as it involves intensive training of attentional and emotional regulation. A recent systematic 
suggested that the observed effect is moderate to large for children with ADHD, but the overall 
quality of the studies is very low172. The only randomized clinical trial reported negative results, 
as did two out of only three trials that had a control group. At the moment, more well-designed 
studies are needed.  
 
IMPACT OF TREATMENT IN REAL-LIFE OUTCOMES 
 
The extent to which reduction of ADHD symptoms leads to better real-life outcomes is studied. 
A systematic review of long-term clinical studies suggested that patients with ADHD who 
received treatment (by any modality) had better long-term outcomes than their non-treated 
counterparts across most studied domains, and the effect was higher for combined 
pharmacological and nonpharmacological treatment than for either of those alone173. Evidence 
from randomized clinical trials supports the conclusion that treatment for ADHD improves the 
quality of life of patients174-177.  
 
Medical registries from large-scale observational studies have been used to investigate 
outcomes within the same individuals by comparing periods on and off medication. Those 
studies showed that medication periods were associated with improved performance on higher 
education test exams178, reduced vehicle motor crashes179, reduced criminality21, reduced 
emergency room admission related to substance abuse23 and reduced risk of trauma and brain 
injuries180-182. Some limitations of these studies need to be highlighted. The within-subject 
design controls for between-subject and time independent within subject factors but not for 
time dependent factors that might influence on patient´s decision to start or stop medication. 
Furthermore, the nature of this design (based on frequent starting and stopping of medication) 
evaluates effects over short periods of time, limiting the evaluation of long-term effects of 
medication. 
 
In line with this reasoning, prospective follow-up studies of childhood-onset ADHD have 
documented clear beneficial effects of starting medication, but have not detected long-term 
benefits in adulthood associated with typical long-term patterns of treatment (either residual 
effects of inconsistent treatment associated with stopping medication in childhood or 
adolescence or consistent treatment into adulthood that occurs in less than 10% of the 
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cases)183-185. An important complicating factor might be the age-related decrease in symptom-
severity and remission of ADHD in many affected children, which is associated with improved 
real-life outcomes, regardless of treatment.  
 
Overall, the evidence suggests that treating ADHD can improve several important functional 
outcomes. Likewise, cost-effectiveness studies consistently show that treatment benefits 
significantly outweigh its costs186-188. The critical question for clinicians is how to prioritize 
among available treatments for individual patients. 
 
SELECTION OF TREATMENT 
 
Among the available efficacious treatments for ADHD, the main differences relate to modality 
(i.e., pharmacological and nonpharmacological), age of the patient, financial cost, patient and 
caregiver time demand, expected effectiveness on symptom reduction, adverse effects, safety 
and tolerability. Selection should be a shared decision-making process with input from the 
clinician and the patient and their caregivers. To engage in this process, patients and their 
families need to be adequately and accurately informed about the evidence and the choices189. 
The first major decision will be to consider whether pharmacological and/or non-
pharmacological interventions will be used, and if both how they will be sequenced.  
 
The Clinician Input  
 
The clinician’s input is a technical appraisal of the patient's characteristics that takes evidence 
into account to favor some treatment options above others. Major considerations include: 1) 
age of the patient; 2) severity of the disorder; 3) comorbidities (Table 2).  
 
Age is a major factor in the recommendations of ADHD clinical guidelines. For instance, most 
guidelines do not usually recommend pharmacological therapy for preschool children (under 
age 6)26-28. Although this partially relates to the fact that these medications are generally not 
licensed for use in those under six years of age, it is also true that  the efficacy and safety of 
medication treatments is much less studied in this age range.190 When studied, the benefits are 
smaller and the side effects are greater than in older children191. Behavioral therapy has more 
evidence of efficacy than medication for preschoolers94. Furthermore, the targets of  treatment 
may be different since the academic demands are less for preschool than school-aged children. 
With increasing patient's age, there will be a tendency to favor medication due to increased 
evidence for efficacy and safety and as increasing academic and social demands are less likely 
to be met with nonpharmacological interventions alone. For school-aged children, 
pharmacological treatment is usually the first choice. Likewise, the technical appraisal of 
evidence is balanced towards pharmacological treatment for adult patients, as effectiveness is 
less clear for nonpharmacological interventions192. In adulthood, findings on the effectiveness 
of combined treatments (i.e., CBT interventions + stimulants)149, 150 are more controversial. 
 
The severity is another important clinical consideration. As addressed here and elsewhere32, 87, 
106, the effectiveness of ADHD treatments are on a continuum beginning with 
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nonpharmacological treatment showing small to moderate effect sizes; non-stimulant 
pharmacological treatment with moderate to large effect sizes; and stimulant treatment with 
large to very large effect sizes. Combined treatments (medication plus cognitive behavioral 
therapy or stimulant plus non-stimulant) has often been assumed to be the most effective 
strategy, although the evidence supporting superiority to psychostimulants alone remains 
controversial. We recommend that severity should be matched with the expected effectiveness 
of the treatment: (a) for low severity, nonpharmacological interventions; (b) for moderate 
severity, pharmacological interventions; (c) for high severity, combined intervention. 
 
Simple and uncomplicated ADHD is not common. In most cases ADHD co-occurs with other 
psychiatric and developmental disorders, and these comorbidities also have implications for the 
treatment required (see Table 2). For example, Oppositional Defiant Disorder and Conduct 
Disorder are the most common co-occurring disorders, and only pharmacological treatment has 
been shown to reduce these comorbid symptoms with large effect sizes39. Tics or tic disorders 
also co-occur with ADHD, and although psychostimulants might not exacerbate these comorbid 
symptoms in general193, tic worsening might occur in some patients194. Co-occurrence with 
Substance Use Disorders (SUDs) is also common in adolescence and adulthood. In patients who 
have both ADHD and SUDs195, the evidence suggests that psychostimulants are effective in 
reducing ADHD symptoms, but not in improving substance abstinence. Also, many clinicians are 
apprehensive to prescribe these medications for these comorbid cases because of their 
potential for abuse, although available evidence does not fully support this view196. Thus, non-
stimulants like atomoxetine and the alpha 2 agonists, which have a much lower liability of 
abuse than the stimulants, or nonpharmacological treatment might be preferred for treatment 
of some ADHD patients with comorbid SUDs197. If stimulants are recommended, 
methylphenidate and extended-release formulations (which may have less abuse potential) 
should be preferred over amphetamine derivatives and immediate-release formulations198. It 
was usually believed that Atomoxetine was the preferred option when ADHD was comorbid 
with Anxiety Disorders, due to its positive effect in Anxiety symptoms, while psychostimulants 
might have a negative effect114, 199.  Particular co-occurring disorders might cause or exacerbate 
ADHD symptoms while being hierarchically prioritized in the treatment decision. These include 
mood disorders such as depression and bipolar disorder, and psychotic disorders in the 
schizophrenia spectrum. Even if the clinician judges that the criterion E of the DSM is met (i.e., 
symptoms are not explained by the co-occurring disorder), we recommend prioritizing 
treatment of the comorbid disorder. The clinical assessment of ADHD to select treatment 
should focus on symptoms that remain after stabilization of a major mood or psychotic 
disorder.  
 
The Patient/Caregiver Input  
 
The patient/caregiver input involves an analysis of personal aspects that, considering the 
clinician's recommendations, will give more or less weight to a given set of suggested treatment 
options. This is highly variable and depends on complex sociocultural aspects and their 
interactions. The most important aspects are: 1) preferences around treatment modality; 2) 
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expectations of efficacy; 3) feasibility considering financial and time demands; 4) age of the 
patient.  
 
Among the most important individual aspect to consider is the acceptance of the proposed 
treatment by the patient/caregiver. Studies suggest that the likelihood of preferring medication 
treatment as a first-line approach for ADHD is somewhat idiosyncratic but highly dependent on 
social and cultural characteristics153, 154. For instance, parents with higher education more 
frequently conceptualize ADHD as a biomedical illness, which in turn increases their likelihood 
of accepting medication183, 200. However, these preconceived conceptualizations should not be 
considered a closed topic and an adequate understanding of the disorder by patients and 
parents should be one of the goals of the therapeutic process. Furthermore, discrepancies 
between child and parent preferences are common. A trial on medication is usually sought by 
the parent, and children are frequently reluctant to or refuse to take medication due to 
complex factors such as social stigma, side effects or simply not appreciating the benefits of 
treatment201, 202. In those cases, particular characteristics of the family such as the extent of 
autonomy that parents give to the child play an important role in treatment choice. In 
summary, patient and caregivers usually exhibit preconceived treatment preferences closely 
related to their sociocultural context. 
 
They also have different expectations about treatment effectiveness. These expectations 
should be carefully assessed by the clinician, as they should be matched with actual treatment 
efficacy/safety. Unrealistic expectations should be discussed and patients properly informed. A 
young adult attending college with severe ADHD causing failure to thrive academically probably 
expects more from the treatment than another young adult with less attentional demand and a 
milder disorder. The former would have his/her expectations frustrated by treatments with 
small to moderate effect sizes; the latter may not find the benefit to risk and cost ratios of the 
most effective treatments favorable. Accordingly, the degree of symptom control was the most 
important factor taken into account by parents who selected stimulant treatment in a study of 
six European countries154.  
 
Finally, the gap between the ideal world and clinical practice also impacts the final decision on 
treatment selection for ADHD. Effective nonpharmacological strategies such as behavioral 
therapies, neurofeedback or cognitive training are more expensive, time-consuming, and less 
available outside central urban areas of developed countries than pharmacological alternatives. 
There are also differences in the cost of medications that need to be considered in countries 
where patients pay with out of the pocket money.  
 
 
SELECTION OF THE FIRST MEDICATION  
 
Many cases that present to clinical practice will require and ADHD medication. Several factors 
need to be considered for the selection of the first medication, mainly to decide between 
stimulants versus non-stimulants. These are summarized in Table 3.  
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MONITORING, FOLLOW UP AND CONTINUED CARE 
 
There is evidence that monitoring patient improvement through the use of rating symptom 
scales in each visit increases positive clinical outcomes and chance of remission in Psychiatry203. 
There is also now emerging evidence that implementing a carefully constructed medication 
protocol with routine measure of standardized outcomes can result in significant improvements 
in clinical outcomes and that these can be sustained over long periods of time204. We 
recommend assessing the intensity of ADHD symptoms before and after treatment at each 
appointment using validated rating scales205, 206 and adjusting treatment in order to optimize 
outcomes (see the MTA medication algorithm207 and Dundee ADHD Clinical Care Pathway 
protocol204 for possible strategies). Alongside with symptom monitoring, clinicians should also 
assess real-life measurable parameters of functional benefits accompanying from symptom 
control. They need to combine their subjective impressions with such objective measures to 
guide dosage adjustments, treatment switch or add-on therapy. Likewise, adverse effects 
should be actively asked about in a "review of systems" manner and in the physical exam, 
focusing on the most likely adverse effects of each medication. After stabilization of symptoms, 
clinicians should reassess treatment response and adherence, vital signs and adverse effects at 
least once a year26.  
 
The question ‘how long should a patient be treated?’ is an incompletely answered question. 
ADHD is regarded as a chronic disorder: in long-term clinical follow up studies (i.e., six years or 
more), about 50% of the child-onset cases are reported to have persisting ADHD impairing 
symptoms208, 209. Adverse outcomes also continue to occur more frequently in those with ADHD 
for many years after the initial diagnosis, even for those who symptoms remit210. Although 
some meta-analyses suggest that treatment improves the majority of long-term ADHD 
outcomes and combined treatment seems to be associated with larger effects sizes for these 
improvements173, long-term benefits of ADHD treatment is yet a controversial area. After 
treatment cessation, the associated benefits tend to reduce until they are no longer 
discernable. 
 
This suggests that in routine clinical practice patients and caregivers should be informed about 
the heterogeneous course of ADHD symptoms throughout life, and that desistence is seen in 
many of childhood-onset cases. Several childhood factors increase the risk of long-term 
syndrome persistence. These include increase ADHD severity and comorbidity with disruptive 
disorders and major depression211. Also, self-selection will result in stopping medication in 
many cases from whom ADHD is recognized and treatment is initiated in childhood. In some 
cases, shared treatment decisions will result in carefully medication tapering (or to reduce the 
intensity of non-pharmacological treatments gradually) over time as an individual matures. This 
may be used to evaluate syndrome remission, preferable in a period of stable relatively lower 
demands from the environment. Alternatively, in some cases, the symptoms may emerge when 
some individuals encounter higher demands in adolescence or adulthood212, and previously 
treated cases may require re-starting medication (or previous unrecognized and untreated 





Patients with ADHD benefit from a wide variety of available efficacious treatments that target 
and alleviate the disorder symptoms, impairment and poor functioning. They encompass 
different classes of medication, several protocols of therapy, computerized training, dietary 
modification, and their combinations. New strategies, such as coaching and mindfulness, are 
being developed and tested. Facing this wealth of options, the clinician may find it hard to 
hierarchize treatments in an effective, evidence-based manner. 
 
We conclude that all ADHD medications, while differing in their synaptic mechanisms, 
eventually act on broader neuro-cognitive networks in the short-term. Psychostimulants are 
highly effective, when compared to other psychiatric medications. Non-stimulants while less 
effective options should be considered in special situations. Psychosocial interventions are 
especially useful for very young children or mild disorders, or as an add-on treatment to 
medication to improve efficacy or reduce required dosage. Treatment selection should rely on a 
shared decision-making process between the clinician and his or her patient. The main aspects 
to be considered by the clinician are age of the patient, severity of the disorder and 
comorbidities. Patients should be routinely followed to assess response to treatment and 
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Table 1. Efficacy and tolerability of treatments approved for ADHD  
 
 
 Efficacy Tolerability 
 Magnitude # trials Magnitude # trials 
Methylphenidate ++++ 40 +++ 55 
Amphetamine derivatives ++++ 9 ++++ 8 
Atomoxetine +++ 27 ++++ 37 
Clonidine +++ 4 ++ 6 
Guanfacine +++ 10 ++++ 9 
Modafinil ++++ 5 +++ 6 
Bupropion ++ 1 +++ 3 
Behavioral therapies +++ 15 +++ 25 
Cognitive training +/- 2 ++++ 10 
Neurofeedback ++/- 4 +++ 10 
Poly-unsaturated fatty acids ++/- 3 ++++ 9 
Stimulants + behavioral ++++ 8 +++ 13 
Non-stimulants + behavioral ++++ 4 ++++ 3 
Stimulants + non-stimulants ++++ 4 +++ 7 
 
Efficacy and tolerability estimates were extracted from a recent network meta-analysis 32. Odds Ratio against placebo were 
converted to Cohen’d effect sizes. The higher the number of +, higher are efficacy and tolerability. Tolerability expressed as number 
of patients discontinuing the protocol.  
+ = up to 0.2 | ++ = 0.2 to 0.5 | +++ = 0.5 to 0.8 | ++++ = more than 0.8 | /- = non significant 
 
Please note that the strength of the evidence is not considered (there is large heterogeneity in the overall number of trials available 
for each intervention). # trials represents the number of high-quality trials (as judged by the authors of the meta-analysis) used to 
compute the effect estimates. 
 







Table 2. Major clinical aspects implicated in the selection of treatment strategies for ADHD 
Aspect Recommendation Rationale 
Patient's age - Start with behavioral treatment 
when possible in preschool children  
 
 
- Prefer pharmacological treatment in 
adults 
- Less evidence supporting safety 
and efficacy and lower benefit : risk 
ratio for medication in preschool 
children.  
- Lower efficacy of 
nonpharmacological interventions 
ADHD severity - Monotherapy with 
nonpharmacological treatment for 
mild disorder 
 
- Combination treatment for severe 
disorder 
- Expected efficacy of treatment lies 
within a continuum: 
nonpharmacological < non 
stimulants < stimulants < 
combination therapy 
Comorbidities - Tic disorders: non-stimulants might 
be an option in cases where 
methylphenidate increases tics 
 
- Disruptive disorders: prefer 
stimulants 
 
- Substance use disorders: non-
stimulants might be an option 
 
- Mood and psychotic disorders: 
prioritize comorbidity treatment 
- Psychostimulants might 
exacerbate symptoms of tic 
disorders in some cases 
 
- Psychostimulants reduce ODD/CD 
symptoms with large effect sizes 
 
- Theoretical potential for abuse of 
this class of medication 
 
- Comorbid conditions may cause 
or exacerbate ADHD symptoms; 
their core features are not likely 


















Table 3. Factors implied in the selection of the first medication treatment for ADHD 
Factor Evidence Recommendation 
Effectiveness Stimulants are the most effective 
class 
Prefer stimulants for moderate to 
severe cases 
Adverse effects Non-stimulants (especially ATX and 
GFC) have different profile of 
adverse effects 
Prefer non-stimulants in case of 
intolerance to stimulants or when 
specific adverse effects are a special 
concern 
Duration of action Extended release formulations of 
stimulants last for around 12h; ATX 
and extended release GFC last for 
the entire day  
Prefer these when the effect is desired 
for more than one segment of the day 
Abuse potential Stimulants have theoretical abuse 
liability 
Non-stimulants might be an option 
when abuse is a relevant concern 
Time to onset of effect Stimulants have immediate 
onset/offset of action 
Prefer stimulants when immediate 
onset/predicted offset is needed 
Patient and parental 
preferences 
Patients and parents might have 
personal opinions on existing 
options 
Consider patient and parent 

































Figure 1. Proposed mechanisms of action for the medications commonly used to treat ADHD 
 
Pharmacodynamics (superior panel): Amphetamines (blue square) have at least three mechanisms of action: 1) they are transported by the 
monoamine transporters DAT and NET, thus competing with those neurotransmitters and decreasing their reuptake in the synapse; 2) They also 
cause Trace amine-associated receptor 1 (TAAR1) to phosphorylate DAT. The Phosphorylated DAT is either internalized into the presynaptic 
neuron and ceases transport or inverses the efflux of dopamine; 3) they enter the presynaptic  monoamine vesicle and cause efflux of 
neurotransmitters off the vesicle, which in turn augments the efflux towards the synapse. These mechanisms are more studied and established 
for dopamine neurotransmission, but are thought to occur similarly for norepinephrine. Atomoxetine (gray square) binds to NET, inhibiting the 
reuptake of norepinephrine. In the prefrontal cortex, where there is much less expression of DAT, dopamine reuptake by NET is also inhibited by 
the action of Atomoxetine. Methylphenidate binds to NET and DAT, inhibiting the reuptake of norepinephrine and dopamine. Clonidine binds to 
and activates alpha-2 adrenergic receptors. Guanfacine binds to and activates specifically alpha-2A adrenergic receptors. Bupropion inhibits 
DAT and NET weakly. Imipramine inhibits NET and SET. Modafinil inhibits DAT to a weaker extent than other psychostimulants.  
Brain network activation (left inferior panel): Pharmacological treatment acutely enhances activation and normalize brain networks involved in 
attention, cognitive control and working memory in children with ADHD.  
Neurodevelopmental signal (right inferior panel): ADHD medications regulate the expression of genes involved in neurite outgrowth. In the 
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To the editor: A recently published report by the Bipolar Disorder Working Group of the 
ENIGMA Consortium has analyzed neuroimaging data on 6503 individuals, providing compelling 
evidence for the existence of a cumulative degenerative effect of Bipolar Disoder (BD) on the 
cortex of affected patients1. Their conclusion, that patients have decreased cortical thickness 
than unaffected individuals and that this effect is moderated by duration of disease, endorses 
several previous studies that identified that the disorder is characterized by evident clinical 
neuroprogression2.  
 
Nevertheless, the analyses on treatment effects yielded interesting results. Among patients with 
BD, those on lithium had increased cortical thickness compared to patients not taking lithium, 
with effect sizes comparable to those observed between patients and controls. On the other 
hand, antiepileptic treatment was associated with decreased cortical thickness and atypical 
antipsychotic treatment was associated with decreased surface area among BD patients. The 
findings of the ENIGMA study concur with previous findings from non-randomized studies that 
already pointed out that the use lithium is associated with increased or preserved gray matter in 
bipolar patients, while anticonvulsants and antipsychotics are not3.  
 6 
 
Clinical guidelines usually consider some antiepiIeptics and atypical antipsychotics together with 
lithium as first-line treatments for acute phase or maintenance of BD4. The National Institute For 
Health and Clinical Excellence, on the other hand, is one of the only main guidelines to suggest 
lithium as preferred maintenance treatment, while considering other alternatives as second-line 
options5. Lithium prescriptions have been reducing worldwide, while prescription of antiepileptics 
and atypical antipsychotics have been rising6. Therefore, the evidence of a positive effect of 
lithium against a negative effect of other therapeutic options on neuroimaging markers of 
cognitive functioning should be given uttermost and careful attention as it could influence clinical 
practice.  
 
Although we welcome with enthusiasm such interesting findings of the differential effects of BD 
treatments on cortical thickness and surface area, we suspect that important factors might be 
confounding the results and should be controlled for. First, there is the case of the distinctive 
subtype of excellent lithium responders. There is now substantial evidence that about a third of 
individuals with BD have excellent response to lithium6. These patients cluster in families and 
have a specific genetic signature7. More important, they have a significantly better long-term 
prognosis8. As a matter of fact, these singular features have led some authors to understand this 
subgroup of patients as a separate diagnostic subtype of Bipolar Disorder9. Second, there is 
evidence for an inverse correlation of psychotic symptoms and both cortical thickness and gray 
matter volume in bipolar patients10.  
 
In a cross-sectional analysis such as the ENIGMA sample, it is unlikely that excellent lithium 
responders and their special neurobiological signature are distributed equally among treatment 
comparisons. It is reasonable to assume that excellent responders to lithium are more frequently 
taking lithium than other medications. Likewise, patients with psychotic features are more likely 
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receiving antipsychotics than other patients. Therefore, the differences of cortical thickness and 
surface found between treatments might have been overestimated by the measure of patient 
effects, rather than medication effects. We would like to emphasize that controlling for 
medication use, which was carefully conducted by the authors, does not address this bias 
entirely. If results hold unchanged even taking into consideration the excellent responder group 
and the presence of psychotic symptoms, the field will be even more convinced of the existence 
of a causal relationship between choice of treatment and cortical neurodegeneration. Future 
longitudinal studies, and especially randomized trials, could help to clarify the issue even further 
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Revisiting the Werther Effect in the 21st Century: Bullying and 
Suicidality Among Adolescents Who Watched 13 Reasons Why  
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Cavalcante Passos, MD PhD; Christian Kieling, MD PhD. 
To the Editor: 
 
Unlike most leading causes of death in the US, suicide rates have not declined 
during the past 50 years.1 Among young people the situation is even more dramatic, as 
suicide rates are rising,2 and suicide is now the second cause of death in 15 to 29-year-
olds globally.3 It has been suggested that descriptions of suicide in the media might 
impact behavior, and the young may be more vulnerable to this effect.4  
In the late eighteenth century, the novel The Sorrows of Young Werther by 
Johann Wolfgang von Goethe was blamed for unleashing a suicide epidemic among 
young men in Europe. There are now real social and scientific concerns on the possible 
contagion effect of descriptions of suicides in both fictional or nonfictional works.5,6 The 
premise that exposure to accounts of suicides may cause predisposed individuals to 
make attempts is supported by a number of ecological studies;7,8 however, most research 
on the topic is outdated, as the relationship between teenagers and the media is rapidly 
changing.9 Moreover, ethical and methodological aspects frequently hamper the 
empirical investigation of this issue.  
The success of the Netflix show 13 Reasons Why10 was followed by a heated 
debate on how it approaches the story of an adolescent who commits suicide after being 
bullied at school.11 Several experts argued that the show could result in an increase in 
suicidal thoughts and behaviors,12,13 which was reinforced by a recently-published article 
that presented an association between the show release date and suicide-related 
Google searches.14 However, to our knowledge, direct evidence on whether the show 
influences adolescent thinking and behavior is lacking. To address this issue, we 
assessed adolescents who watched 13 Reasons Why by asking their perceptions on 




The study was approved by the Research Ethics Committee of the Hospital de 
Clínicas de Porto Alegre, Brazil. We created online surveys in English and in Portuguese 
with questions related to bullying, depression and suicide prior and after watching 13 
Reasons Why.  
We asked respondents whether they had ever been bullied or had bullied 
someone else before watching the show; for those who answered affirmatively to any of 
these two questions, we used a 5-points likert scale to assess how much they believed 
watching the series had changed the way they felt or behaved regarding bullying. For 
those who had not engaged in bullying before the show, we asked whether they had 
bullied anyone afterwards. 
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To measure depressive symptoms, the survey included the Patient Health 
Questionnaire-2 (PHQ-2),15 which consists of two questions related to symptoms of 
depression over the prior two weeks. Scores on the PHQ-2 range from 0-6, in which 0 
indicates no cardinal depressive symptoms and 6 indicates feeling depressed and 
anhedonic practically every day. For this study, the questionnaire asked about the two 
weeks prior to watching the show. A score equal to or greater than 3 in the PHQ-2 is 
considered a positive screening for depression. 
The last two questions in the survey referred to suicidal ideation. Participants 
were asked whether, before watching the show, they had ever thought about taking their 
own life (dichotomic) and how watching the show changed the way they felt about it (5-
point likert scale). Answers to this last question were operationalized as decreased (1 
and 2), unchanged (3) and increased (4 and 5) suicidal ideation. For the group with no 
prior suicidal ideation, answers 1 to 3 were merged and considered as no increase in 
suicidal thoughts (see supplementary material for details). 
For the primary analysis, we used Facebook advertising to reach adolescents 
living in the United States or Brazil who liked pages related to the TV series. Participants 
included in this analysis were 12 to 19-year-olds, living in the aforementioned countries, 
who reported having watched all 13 episodes and completed the questionnaire. To 
address the potential of selection bias by including only participants who liked Facebook 
pages related to 13 Reasons Why and may therefore have a more favorable view of the 
show, we recruited a control group who had liked pages related to Netflix on Facebook 
but not 13 Reasons Why. We performed chi-squared tests to compare results between 





 A total of 280,973 people viewed the survey links and 26,103 responded. After 
excluding 2,382 people who did not complete the questionnaire, 2,214 who did not 
watch all episodes of the show and 445 who were not aged between 12 and 19 years, 
21,062 people were included in our sample. Most participants were female, Brazilian 
residents, and aged 15-17 years (Table 1). Most respondents screened positive for 
depression (PHQ-2 ≥ 3) in the two weeks before watching 13 Reasons Why (65.6%), 
and 64.5% reported a lifetime history of suicidal ideation.  
Among this latter group, 16.5% expressed more and 59.2% reported less suicidal 
ideation after watching the show – 24.2% indicated no change. In the group of 
participants with no prior history of suicidal ideation, 6.4% reported increase in suicidal 
thoughts after watching the show. Figure 1 displays the changes in suicidal thinking after 
watching the show among participants with low (0) and high (6) PHQ-2 scores. 
A total of 78.7% of the participants said they had suffered bullying, and, 40.5% of 
them reported feeling better about it after the show. and A total of 41.3% of the 
participants stated that they had engaged in bullying before watching the show. A; 
among those who had not, 97.3% reported unchanged behavior. Among those who had 
engaged in bullying, 95.5% reported they rethought such behavior after watching the 
show, and 90.1% of these who reconsidered their attitudes said they began bullying less 
afterward. mong those who engaged in bullying, 95.5% reported they rethought such 
behavior after watching the show, and 90.1% of these who reconsidered their attitudes 
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said they began bullying less afterward. There was no difference in regard to changes in 
bullying behavior or feelings related to bullying  according to PHQ-2 score or history of 
suicidal ideation in participants who reported bullying or suffering bullying before 
watching the show (see supplementary Figure S1 for details).  
A total of 2,323 people met inclusion criteria for the control group (adolescents 
who liked Netflix-related pages, but not 13 Reasons Why). No significant difference was 
found between results in the primary sample vs. control group regarding decrease in 




Our data demonstrate that watching 13 Reasons Why was associated with 
decreased rates of self-reported bullying-related attitudes and suicidal ideation among 
adolescents who took part in our survey. Results related to bullying were well-distributed 
in the sample, while reductions in suicidal thinking were more pronounced in individuals 
with no depressive symptoms prior to watching the show.  
Regardless of the overall positive effect in this population, it is important to note 
that a more vulnerable subgroup – participants with depression and/or with prior suicidal 
ideation – may be more negatively affected by watching the show. These results 
suggest that while the series has the potential to have positive effects for most of its 
viewers, it may have negative effects on high-risk individuals. For this reason, the 
decision on whether to watch the show should be individualized and decided jointly by 
adolescents, parents and medical authorities,16 taking into consideration each 
adolescent’s individual characteristics and the impacts of the show observed in this 
study. Also, although higher rates of suicidal ideation after watching the series were 
more pronounced in the group with preexisting psychopathology, the rates among those 
with no depressive symptomatology nor suicidal ideation were non-negligible. It is 
concerning that 4.7% of adolescents with no prior suicidal thoughts or symptoms of 
depression (PHQ-2=0) reported they thought more about taking their own life after 
watching the series. 
Despite the advantages of targeting adolescents using social media, there are 
intrinsic limitations to the method in terms of selection bias, so results here presented 
might not be generalizable to all teenagers. First, only people who use Facebook were 
invited to the survey, and only 7.5% of those approached to participate provided valid 
responses, which may not represent the show’s general audience. The respondent 
sample had a very high prevalence of bullying, depression, and suicidal thoughts. 
Second, even though a control group showed no differences in the responses compared 
with the original sample, the survey was primarily targeted at adolescents who had liked 
pages related to 13 Reasons Why and, therefore, had a potentially favorable bias 
towards the show. Third, although it is a common and accepted method of measuring 
this behavior, self-reporting of bullying might be associated with potential reliability 
issues. Another important limitation refers to the fact that suicidal thoughts before and 
after watching the show were both assessed retrospectively. As our survey did not 
include a question addressing how adolescents perceived specifically the suicide scene, 
we were not able to assess this controversial issue. It is also noteworthy that, although 
analyses in this study were focused on bullying, depression and suicide, there may be 
other potentially relevant unmeasured effects related to watching the show (e.g., related 
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to the portrayal of help seeking in the series). Finally, because of the retrospective 
design and lack of a contemporaneous control group that watched a different show that 
did not address bullying or suicide, it was not possible to identify spontaneous 
fluctuations or to establish a causal link between watching 13 Reasons Why and the 
changes in thinking and behavior we observed. 
Public affairs involving emotional issues – such as suicidal behavior induced by a 
TV show – frequently provoke the spread of emotional opinions and reactions. The 
present report provides empirical evidence on the potential benefits and risks of the 
Netflix series 13 Reasons Why on adolescents’ behavior, suggesting a predominant 
decrease in bullying and suicidality, while also indicating an increased probability of 
harmful effects to a subgroup of vulnerable youths. Suicide among adolescents is a 
major public health issue, but one for which preventive strategies are currently 
available.17 We hope that further understanding such a complex phenomenon can 
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Figure 1. Suicidal Ideation After Watching 13 Reasons Why 
 
The Patient Health Questionnaire-2 depression scale ranges from 0-6, in which 0 signals 
no depressive symptoms in the two weeks prior to watching the show and 6 indicates 
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To the editor: 
 
A recent study published on the Lancet Psychiatry found, once again, a prospective association between traumatic 
brain injuries (TBI) and an increased risk of dementia and Alzheimer's disease1. Authors leveraged data from the 
Danish registries, with hundreds of thousands of cases, allowing interesting analyses, providing a strong case for the 
association between TBI and Alzheimer’s disease. However, previous data has shown that the effect is inconsistent2 
and markedly attenuated by controlling for confounders3. What does these data tell us about causality?  
 
One alternative possibility for the study findings is that TBI might occur more frequently in individuals with low 
cognitive functioning4, and, therefore, this event might be a risk marker for dementia, but with no causal role. This 
hypothesis is reinforced by considering the extent to which the association found in the study by Fenn and colleagues 
is stronger in the first months after the trauma. To address this potential source of bias, authors conducted two sets of 
supplemental analyses that reinforce TBI’s causal role, for which we provide here some new discussion. 
First, the study shows that TBI increased the risk of dementia even when it occurred before age 30. Considering the 
traditional model of Alzheimer's disease, by which affected individuals show normal cognitive functioning during 
development and early adulthood, reverse causality could be rejected because these young adults performed just like 
their peers before TBI occurred. However, recent evidence showed that, even in childhood and adolescence, genetic 
risk for Alzheimer's disease correlates with worse memory performance and lower hippocampal volumes5. Therefore, 
even before the disease becomes self-evident, correlated genetic risk between dementia and TBI might still affect the 
likelihood of exposure to TBI in subjects with high genetic risk for Alzheimer’s disease.   
 
Second, authors argue that the risk of dementia in people with TBI versus those without was almost identical to the 
risk in people with TBI versus those with non-TBI fractures. However, they do not report if there was an association 
between non-TBI fractures and dementia. To make this evidence stronger, the authors could provide analyses similar 
to the ones conducted for TBI considering non-TBI fractures of similar magnitude.  
 
We argue that available data still cannot exclude the hypothesis of reverse causality for the association between TBI 
and dementia and genetically-informed designs are needed to rule out the role of genetically mediated exposure to 
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